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EXPRESSION, REGULATION AND FUNCTION OF DRUG TRANSPORTERS IN 
TISSUES AND CELLS RELEVANT TO HIV-1 SEXUAL TRANSMISSION 
 
Tian Zhou, MS 
University of Pittsburgh, 2014 
 
Although some clinical trials have shown the promise of antiretroviral-based topical and oral 
pre-exposure prophylaxis (PrEP) products in the prevention of HIV-1 sexual transmission, other 
studies have achieved inconsistent results. Drug exposure in the cervicovaginal tissues, 
colorectal tissue, and immune cells positively correlates with PrEP effectiveness, and there is an 
urgent need to identify critical physiologic determinants of drug exposure in these relevant 
tissues and cells, to inform product optimization. Drug transporters are important regulators of 
antiretroviral pharmacokinetics. This dissertation aims to examine the expression, regulation, and 
function of drug transporters in human cervicovaginal and colorectal tissues, as well as in the 
animal models and cell lines utilized in PrEP product testing. 
 
Multiple efflux and uptake transporters, including P-gp, BCRP, MRP4, 5, 7 and ENT1, were 
found to be positively expressed in the cervicovaginal and colorectal tissues of humans, 
macaques, rabbits, and mice. A smaller panel of transporters were positively detected in three 
epithelial cell lines (End1/E6E7, Ect1/E6E7, VK2/E6E7) derived from human endocervix, 
ectocervix, vagina, and a T cell line (PM1). Menstrual cycle, exogenous hormones, 
contraceptives, and proinflammatory cytokines were found to impact transporter expression in 
mice and/or cell lines. The protein expression of P-gp, BCRP, and MRP4 was demonstrated 
v 
 
using immunohistochemical staining, in the cervicovaginal and colorectal tissues of humans, 
macaques and mice. The transporters were found to localize at multiple cell types along the 
cervicovaginal tract, and the protein abundance and localization of transporters were affected by 
menstrual cycle and hormone/contraceptive use in a mouse model. In a Depo-Provera 
synchronized mouse model, the co-administration of MRP4 inhibitor MK571 with TFV vaginal 
gel or intraperitoneal TFV solution significantly increased TFV concentration, in tissues and 
fluids relevant to HIV transmission. However, MK571 exerted differential effects on the 
distribution of vaginally administered TFV, when MK571 was given via different routes. 
Collectively, these studies have shown that antiretroviral drug-related transporters are positively 
expressed in tissues and cells relevant to HIV-1 sexual transmission, and their expression can be 
regulated by hormones and cytokines. Further, the studies have provided proof of concept on 
Mrp4 function in TFV exposure in cervicovaginal and colorectal tissues.  
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1 INTRODUCTION 
 
 
1.1 HIV global pandemic calls for novel strategies to prevent HIV sexual transmission 
1.1.1 Preventing HIV new infections to curtail its global pandemic  
Human immunodeficiency virus (HIV) pandemic continues to be a worldwide public health 
problem, and it is necessary to prevent new infections in order to curtail its pandemic.
1
 HIV 
infection causes acquired immunodeficiency syndrome (AIDS) if not properly treated. AIDS is 
featured by progressive failure of immune system, which ultimately allows the development of 
life-threatening opportunistic infections and cancers.
2
 HIV has two subtypes: HIV-1 and HIV-2. 
HIV-1 is the cause of the majority of HIV infections globally. HIV-2 is much weaker than HIV-1 
in virulence and infectivity, and is largely confined in West Africa.
3
 In 2012 alone, 1.6 million 
people died of AIDS globally, and the number of people living with HIV was estimated to be 
35.3 (32.2-38.8) million in 2012.
1
 Since more and more people are receiving the life-saving 
antiretroviral therapy, the annual AIDS-related deaths have been significantly reduced in the past 
decade.
1
 However, although current therapies can suppress the AIDS symptoms, slow down the 
disease progression, and reduce the transmission rate to uninfected individuals, they are not able 
to eradicate the virus in HIV-positive patients.
4
 In addition, more than 2 million people are newly 
infected each year.
1
 Taken together, these resulted in a steady increase in the number of people 
living with HIV worldwide.
1
 In order to further reduce AIDS-related deaths, control the number 
of HIV-positive patients, and ultimately achieve an AIDS-free world, efforts must be made to 
develop strategies to eradicate HIV from infected patients, and to prevent or significantly reduce 
the acquisition of HIV in healthy population.
1
 While the promise of HIV-eradicating medications 
2 
 
is still unclear,
4
 prevention of new infections has been considered as a very important and 
practical means to curtail HIV pandemic.
1
  
 
1.1.2 Preventing HIV sexual transmission through vaginal and anal intercourse  
Currently a great emphasis has been placed on the prevention of HIV sexual transmission. The 
causes of new infections differ among regions,
1
 but sexual transmission is the cause of a vast 
majority of new HIV infections in sub-Saharan Africa, where 70% of global new infections occur. 
HIV sexual transmission can occur via the vaginal as well as anal intercourse. Anal intercourse 
can be practiced by heterosexual couples, or by homosexual men who have sex with men (MSM). 
The subpopulations with high risk of HIV infection are more likely to practice anal sex, 
including sex workers, injection drug users, and serodiscordant heterosexual couples (one partner 
is HIV-positive while the other partner is negative).
5
 Although the prevalence of anal intercourse 
is much lower compared to vaginal sex, the transmission rate through this route is estimated to 
be 20 times higher, due to a number of anatomical and physiological reasons.
6,7
 Therefore, HIV 
prevention efforts should target the transmissions via both vaginal and anal routes. 
 
Multiple approaches have been demonstrated to be effective in reducing the acquisition rate of 
sexually transmitted HIV, but novel strategies are needed for HIV prevention. Existing 
approaches include the use of condoms, male circumcision, reduction in the number of sex 
partners, and enhancement of the diagnosis and treatment of sexually transmitted infections 
(STIs).
1,8,9
 However, even with the knowledge of these approaches, HIV continues to spread 
rapidly in developing countries, due to a number of reasons. People’s willingness to use condoms 
is associated with religious, social, and economic factors.
1
 Women sometimes cannot negotiate 
3 
 
condom use with male partners, and the condom use is even lower in anal intercourse compared 
to vaginal sex.
1
 The behavior changes, such as the reduction of sex partners, face complex 
cultural and social challenges and take long time to exert effect. In addition, the facilities and 
medical professionals required for the diagnosis and treatment of STIs are not readily accessible 
in many developing countries where the rate of HIV sexual transmission is alarmingly high. 
Women especially young women (15-24 years) are disproportionally affected in HIV sexual 
transmission.
1
 In sub-Saharan Africa, women constitute about 60% of all the people living with 
HIV, and the HIV prevalence in young women is more than twice as high as among young men 
in the same region.
1
 Compared to the male partners, women are anatomically more susceptible to 
HIV sexual transmission.
1
 Homosexual men are another group that needs special considerations. 
In many developing countries, homosexual men are living with social and legal disadvantages, 
which worsen their ability to access the necessary medical products and services, and increase 
their vulnerability to sexually transmitted HIV.
1
 Based on these considerations, novel convenient 
strategies that can be controlled by heterosexual women and homosexual men to protect 
themselves are urgently needed. Such strategies will have high potential to reduce new HIV 
infections especially in the sub-Saharan countries where the incidence of sexual transmission has 
been alarmingly high.
1
 
 
1.2 Understanding critical determinants of drug exposure in transmission-related tissues 
and cells to enhance the effectiveness of pre-exposure prophylaxis (PrEP) 
1.2.1 Topical and oral PrEP are promising strategies for the prevention of HIV sexual 
transmission, but clinical trials yielded inconsistent efficacy results 
Pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs to prevent HIV infection in 
4 
 
uninfected population, and has shown promise in some clinical studies. Currently, most PrEP 
products are at different stages of development, and these products may be administered orally or 
topically (vaginally or rectally). The drugs used in PrEP and treatment-for-prevention studies 
include entry inhibitors (EIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and integrase 
inhibitors (II), which target different steps of HIV life cycle.
6,10-12
 The oral and topical PrEP have 
been considered promising in the prevention of HIV sexual transmission. Many drug candidates 
undergoing PrEP testing are marketed drugs approved by the U.S. Food and Drug Administration 
(FDA) for AIDS treatment, or at least have shown good efficacy and safety in preclinical tests.
12-
15
 Therefore, the use of these drug products, especially via topical administration, has the 
potential to result in sufficient drug exposure in the tissues relevant to HIV sexual transmission 
without causing significant toxicities. In addition, the receptive partners don’t have to negotiate 
the use of these drug products. Rather, these products can be used without the cooperation, 
consent or even knowledge of the insertive partners. An oral product Truvada, which is a tablet 
containing two reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil 
fumarate (TDF), has been approved by the U.S. FDA for HIV prevention in high-risk uninfected 
individuals, such as MSM. The PrEP Initiative study (iPrEX) is a key study demonstrating 
clinical effectiveness and safety toward approval of this product. In this study, the daily Truvada 
use significantly reduced HIV acquisition in 2499 homosexual men.
16
 The vaginally and rectally 
applied antiretroviral drug products (microbicides) are undergoing development and there is no 
approved microbicide product to date. Microbicides can be formulated into various dosage forms 
including gels, films, rings, suppositories and tablets, to meet the diverse needs of different user 
groups. Compared to the oral route, vaginal and rectal administration could theoretically result in 
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better accumulation of administered drugs in the cervicovaginal tissues, colorectal tissue, and 
immune cells associated with these tissues, which are the primary sites of HIV transmission at 
initial stage. In addition, topical administration results in lower systemic blood drug levels 
compared to oral administration, and is unlikely to cause systemic side effects. The effectiveness 
and safety of topical microbicides have been demonstrated in CAPRISA 004 study. In this Phase 
2b trial, the 1% vaginal gel of tenofovir (TFV) reduced HIV acquisition by 39% in uninfected 
women compared to the placebo.
13
   
 
However, PrEP clinical trials have yielded inconsistent effectiveness results, especially for 
studies that involved TFV. For example, in the topical microbicide trials, the 1% TFV vaginal gel 
showed 39% reduction in HIV incidence rate in the CAPRISA 004 trial,
13
 however the TFV gel 
arm was discontinued in the VOICE trial due to futility.
17
 Among the oral PrEP trials, the iPrEX 
study which involved daily oral use of Truvada reduced the HIV acquisition in men who had sex 
with men (MSM).
18
 The same oral regimen showed efficacy in serodiscordant couples in the 
Partners PrEP and TDF2 studies.
14,19
 On the contrary, the same FTC/TDF oral regimen failed to 
prevent HIV-negative women from HIV transmission in the FEM-PrEP and VOICE trials.
15,20
 
Even for the oral PrEP trials that showed statistically significant efficacy compared to placebo, 
the determination of effectiveness was not definitive due to the wide confidence intervals.
12
  
 
1.2.2 Tissue drug exposure positively correlates with PrEP efficacy 
While many reasons may account for the suboptimal efficacy, several clinical pharmacokinetic 
studies have revealed the importance of cervicovaginal or colorectal tissue drug exposure in the 
effectiveness of PrEP. In CAPRISA 004 trial, the TFV concentration in vaginal fluid was 
6 
 
measured in 353 healthy premenopausal women 24 hours after the vaginal administration of 1% 
TFV gel. A clear trend was observed that the higher TFV concentration in the vaginal fluid, the 
lower the HIV acquisition rate in participants.
21
 HIV acquisition rate in the low exposure group 
(vaginal fluid tenofovir concentration < 1000 ng/mL) was similar to that in the placebo group, 
whereas the rate was 3 times lower in high exposure group (> 1000 ng/mL).
21
 In the MTN-006 
trial, UC781-exposed human colorectal biopsies were cultured ex vivo and challenged with HIV. 
UC781 efficacy positively correlated with its concentration in tissue, as reflected by a high 
EC90:EC50 ratio.
22
 These results suggest that the more drug accumulation in cervicovaginal and 
colorectal tissues, the higher efficacy in HIV prevention.  
 
The importance of tissue drug exposure can be explained by mechanisms of PrEP drug action, 
HIV transmission, and mucosal tissue physiology. The majority of PrEP drug candidates must 
reach and/or enter submucosal immune cells to take effect. These drugs prevent the contact 
between virus and host immune cells (entry inhibitors), or prevent the viral DNA production 
(reverse transcriptase inhibitors) and integration (integrase inhibitors) after the viruses enter a 
tiny amount of host immune cells. For example, both tenofovir and UC781 are reverse 
transcriptase inhibitors. To effectively prevent HIV infection, these drugs must reach and/or enter 
the immune cells before significant infection occurs, and stay above effective concentration for 
the entire time window of viral exposure.  
 
Susceptible HIV target immune cells include those in the female genital tract and colorectal 
tissue, and in tissue-associated lymph nodes, as well as immune cells circulating in the systemic 
compartment. The circulating immune cells may migrate to lymph nodes/tissues during the early 
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stage of infection. The immune cells being initially infected during sexual transmission are those 
residing in female genital tract or colorectal tissues (Figure 1.1). Studies suggest the prevention 
strategies should intervene at very early stage of HIV infection. During sexual intercourse, the 
ejaculated viral particles can cross the mucosal epithelial barrier and infect a small group of 
target cells (T cells, macrophages, dentritic cells with positive expression of CD4 receptor on cell 
surface) within or underneath the epithelial layer, in a few hours.
23,24
 This “founder population” 
then undergoes local expansion in the first following week to accumulate sufficient viral particles 
for systemic dissemination. From the second week the viruses start to disseminate throughout the 
body and establish a highly active infection which becomes difficult to eradicate.
23,24
 Therefore, 
the prevention modalities should be able to prevent the formation and local expansion of the 
“founder population” at initial stage of viral exposure. This requires rapid and deep penetration 
of a sufficient amount of antiretroviral drug molecules into the tissue. This tissue level must be 
retained until the viral invasion risk is diminished, so that tissue-associated immune cells can be 
fully protected. Since the in vivo effective drug concentration for each drug in mucosal tissues 
has yet to be determined, it has been suggested that one of the goals of future clinical trials is to 
achieve the highest tolerable drug exposure in the tissues relevant to HIV sexual transmission.
21
  
 
1.2.3 Sufficient tissue drug exposure is difficult to achieve 
However, it is challenging to achieve sufficient drug exposure in the tissues, due to behavioral 
and physiological reasons. Poor patient adherence observed in the clinical trials of once-daily 
oral and topical PrEP products renders the drug level insufficient to counteract the virus.
12
 In 
CAPRISA 004 trial which tested the effectiveness and safety of 1% tenofovir vaginal gel, 76% 
of the 335 participants were categorized into the low-exposure group, and had a 3-fold higher 
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infection rate compared to the high-exposure group. Poor adherence has been revealed to be 
associated with low drug exposure in this study.
21
 In the VOICE trial which tested both TFV 
vaginal gel and oral tablets containing TFV, most participants did not use the product once daily 
as instructed.
25
 The PK analysis in the blood samples collected from the VOICE trial participants 
showed that TFV level was detectable in only 23% of the participants in the TFV gel arm.
26
 This 
indicated that three out of four participants did not use the gel product properly.
26
 Similarly, in 
the FEM-PrEP study which tested the oral Truvada tablet, the drug analysis in blood indicated 
that no more than 30% of women took the tablet as instructed.
27
 To address this adherence issue, 
sustained release and long-acting dosage forms have been actively pursued, and several products 
have entered clinical phases of evaluation.
28 
For topical microbicides, intravaginal rings have 
been shown to release the antiretroviral drugs in a sustained manner, are generally safe to be 
used in the female genital tract, and are well accepted by African women.
12,26,28-31
 For oral PrEP, 
a long-acting injectable product containing raltegravir (integrase inhibitor) has shown good 
safety and effectiveness results in a non-human primate model.
32
 
 
However, even with the emergence of sustained-release and long-acting products, challenges 
remain toward achieving sufficient tissue drug exposure in a safe and effective manner. Multiple 
physiological barriers exist and limit drug penetration into the tissues, for both topically and 
orally administered drugs. The female genital tract and colorectal tissue are covered with a 
mucus layer which can entrap topically administered drugs and reduce their contact with 
epithelial cells. In female genital tract, the vagina and ectocervix are lined with multi-layer 
squamous epithelial cells (up to 40 layers), which serves as a permeation barrier to topical drug 
administration (Figure 1.1).
33
 The endocervix, uterus, and colorectum are lined with single-layer 
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columnar epithelial cells (Figure 1.1), but the tight junction expression is more intense in these 
epithelial layers compared to the ectocervical and vaginal epithelia.
34
 Moreover, these single-
layer tissue regions are at especially high risk of HIV infection and may require different levels 
of drug exposure than other tissues, because the single layer epithelium is easily breached during 
sexual intercourse, and the submucosal compartments of these single-layer regions possess more 
abundant immune cells susceptible to HIV infection.
7
 Therefore, achieving sufficient drug 
exposure in the tissues with single-layer epithelium is not necessarily easier compared to the 
tissues with multiple epithelial layers. During the sexual transmission, the viral particles can 
quickly penetrate into mucosal tissues and reach the immune cells residing in the deep stromal 
sites within a few hours.
24
 Since these immune cells are distributed at different depths throughout 
the female genital and colorectal tracts, the administered drugs must penetrate deeply and 
accumulate sufficient concentration in the niches surrounding the tissue-associated immune cells. 
This is difficult to achieve for both topically and orally administered drugs. 
 
For topically administered PrEP drug candidates, the absorption could be problematic, due to the 
permeation barriers posed by the mucus layer and the epithelium (tight junctional proteins) of the 
cervicovaginal and colorectal tracts,
33
 as well as the blood and lymphatic drainage systems which 
serve to extract the drug from the tissue (Figure 1.1). This is especially true for hydrophilic drugs 
that have low binding affinity to tissue proteins. These drugs generally cannot efficiently 
penetrate the plasma membrane, and they mainly utilize the intercellular space to permeate. A 
recent Phase I trial (MTN-013/IPM 026) evaluating ring products containing dapivirine (non-
nucleoside reverse transcriptase inhibitor, hydrophobic) and maraviroc (entry inhibitor, 
hydrophilic) revealed that maraviroc was not absorbed well and did not exert protective effect 
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compared to dapivirine.
35
 In this study, three antiretroviral vaginal rings were tested: a ring 
containing 25 mg of dapivirine, a ring containing 100 mg of maraviroc, and a combination ring 
containing 25 mg of dapivirine and 100 mg of maraviroc. The fourth ring, a placebo, contained 
no active drug. The rings were inserted into the vaginal lumen of healthy women for 28 days. 
The vaginal fluid, cervical tissue, and blood samples were collected at different time points 
during the 28-day period for the analyses of drug concentration and HIV-preventive efficacy in 
an ex vivo challenge model. Dapivirine was detected in all three types of samples. Although 
maraviroc dose was 4 times higher, and can be released efficiently from the ring products into 
vaginal fluid, it was not detected in blood, and the cervical tissue maraviroc concentration can 
only be detected in 4 of 24 women using either the maraviroc-only ring or the combination ring. 
In line with the PK findings, the cervical biopsies taken from women using the dapivirine-only 
ring and the combination ring were able to counteract HIV infection following the ex vivo HIV 
challenge. However, cervical biopsies from the women using the maraviroc-only ring failed to 
counteract HIV infection.
35,36
 Novel strategies that can increase the tissue penetration of 
hydrophilic drugs will benefit the development of topical microbicides.  
 
For hydrophobic PrEP drug candidates to be applied topically, such as dapivirine, the challenges 
toward achieving sufficient in vivo concentration still exist. Although the hydrophobic drugs can 
be absorbed more efficiently compared to the hydrophilic drugs, their distribution within the 
tissues can be potentially problematic. A recent study using excised human ectocervical tissue 
showed that film-released dapivirine mostly accumulated around the basal layers of 
cervicovaginal epithelium infiltrating the upper part of the stroma.
37
 The amount of drug 
reaching the deep stroma was very little.
37
 This observation posed questions to the design of 
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microbicide pharmacokinetic/pharmacodynamics (PK/PD) studies and interpretation of the 
results, especially at the stages of non-human primate (NHP) testing and early phase clinical 
trials. In these studies, the effectiveness of microbicide products is primarily examined in the ex 
vivo challenge model. In this model, the cervical or vaginal tissue biopsies are taken from the 
product-exposed participants (NHPs or humans), and cultured ex vivo for several days, followed 
by the challenge of HIV, and measurement of viral proteins as an indicator of HIV replication. 
The tissue biopsies taken from placebo-exposed NHP or human subjects are used as negative 
controls.
35,38,39
 Since the biopsies are small pieces of tissue, the drug concentration measured in 
these samples mainly reflect the drug concentration in the epithelial layers and upper part of the 
stroma. It does not necessarily reflect the drug concentration in the deeper part of the stroma. In 
the case of dapivirine, the PK/PD results obtained using the tissue biopsies tend to overestimate 
the drug’s capability of penetrating the tissue and preventing HIV infection in vivo. This may be 
true for other hydrophobic drugs as well, which extensively bind to tissue proteins and don’t 
penetrate efficiently into deep stroma. Therefore, strategies that can increase the tissue 
penetration of hydrophobic compounds will likely improve their in vivo PK/PD in HIV 
prevention. 
 
The tissue distribution of some orally administered antiretroviral drugs also needs to be enhanced 
for improved effectiveness. PK studies have demonstrated that antiretroviral drugs differ 
markedly in their ability to penetrate into mucosal tissues and fluids, after oral dosing.
40-43
 In the 
studies focusing on female genital tract, a general trend can be observed that highly protein 
bound drugs have lower tissue-to-plasma ratios (tissue penetrating ratio, TPR, usually calculated 
by dividing the area under the concentration-time curve (AUC) of cervicovaginal tissues or 
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vaginal fluid to the AUC of plasma), because only the free drug portion not associated with 
plasma albumin or α1-acid glycoprotein can move into tissues. Protease inhibitors (PIs) have the 
greatest protein binding affinity (95-99% bound to plasma proteins) and generally possess TPRs 
less than 0.5.
41
 Although a number of nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs) are less bound to plasma proteins (<49% bound) and possess TPRs higher than 2,
40
 
some exceptions exist. The TPRs of several NRTIs, including abacavir, stavudine, and 
didanosine were found to be 0.08 (0.08-0.13), 0.05 (0-0.12) and 0.21 (0.01-0.4), at steady state 
after oral dosing.
43
 The non-nucleoside reverse transcriptase inhibitors (NNRTIs) have drug-
specific penetration profile. Efavirenz is an example with low TPR (0.004) in this class.
43
 For 
integrase inhibitors (II), currently tested raltegravir and dolutegravir possess very different TPRs, 
probably due to the difference in plasma protein binding.
40
 Although raltegravir has 
cervicovaginal tissue and fluid levels several fold higher than plasma level, dolutegravir has 
relatively high plasma protein binding (>99%) and its TPR was found to be around 0.07.
40,44
 
Large inter-individual variability has been observed in the female genital tract drug concentration, 
for drugs within the same class and across different classes.
42
 In addition, the variability in drug 
exposure in female genital tract is generally greater than that observed in plasma.
41,42
 Apparently, 
a better understanding of the causes underlying the low tissue penetration and inter-individual 
variability will facilitate the achievement of sufficient drug exposure after oral dosing. 
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Figure 1.1 Anatomy of the female genital tract.  
The female genital tract that can be infected by sexually transmitted HIV include uterus, 
endocervix, ectocervix, and vagina. A mucus layer covers the epithelia of all these tissue 
segments, serving as a physical barrier to vaginally administered drugs. Stratified, squamous 
epithelial layers line the vagina and ectocervix, and a single-layer of columnar epithelial cells 
lines the endocervix and uterus. The epithelial layers and stroma are separated by the collagen-
rich laminar propria. The CD4+ T cells, dentritic cells and macrophages are HIV target cells, and 
they are distributed in epithelial layers, stroma, and draining lymph nodes. The invading HIV-1 
particles can infect these immune cells and establish local tissue infection, expansion, and 
progress to systemic dissemination. Blood vessels (veins, arteries) and lymphatic vessels mediate 
the distribution of drug between the tissues and systemic compartments (circulating blood and 
lymph). LCs, Langerhan’s cells, which are the dentritic cells residing in peripheral tissues. EC, 
epithelial cells. The picture was drawn using CorelDRAW software. 
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1.2.4 Understanding critical determinants of tissue drug exposure to enhance PrEP drug 
exposure and efficacy 
Currently, the effective in vivo drug concentration remains unknown for many microbicide drug 
candidates being evaluated.
21
 Current consensus on PrEP drug delivery is to achieve the 
maximally tolerated drug concentration in the tissues and cells relevant to HIV sexual 
transmission.
21
 For the antiretroviral drugs with poor ability to penetrate tissues, an easy way of 
increasing the cervicovaginal tissue drug exposure is to increase the dose. However, high topical 
dose of some drugs is associated with altered vaginal microbiome and/or genital tract irritation,
45
 
and poses challenges to the manufacturability and applicability of microbicide products given 
limited drug loading capacity of topical products. For the oral PrEP, high doses of antiretroviral 
drugs may cause a variety of toxicities to liver, kidney, and cardiovascular system.
46
  
 
The necessity and challenges of achieving high drug exposure in a safe and effective manner call 
for a need to better understand critical determinants of antiretroviral drug exposure in the tissues 
and cells relevant to HIV-1 sexual transmission. An enhanced understanding of tissue exposure 
determinants could benefit PrEP optimization, in several aspects. First, the new knowledge will 
enable better understanding of the causes of intra-individual and inter-individual variability in 
antiretroviral drug PK/PD, and will inform clinical trial design and data interpretation toward 
individualized regimens. Secondly, the new knowledge will facilitate the development of novel 
strategies that enhance tissue drug exposure. This will not only benefit drug candidates tested 
toward PrEP application, but will also help antiretroviral drugs used in AIDS treatment. Since the 
increased drug exposure in the cervicovaginal tissues and fluids presumably will result in lower 
viral load in these compartments of HIV-infected women, the improvement of tissue exposure of 
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antiretroviral drugs will likely reduce the risk of female-to-male sexual transmission, and will 
ultimately facilitate PrEP in both receptive and insertive partners, and help reduce the number of 
HIV-positive patients. The enhanced tissue exposure of drugs used in PrEP and treatment will in 
turn enlarge the pool of drug candidates that can be selected for PrEP testing, and will reduce the 
drug dose to be administered and minimize the risk of toxicity associated with high dose. To 
summarize, further understanding of critical determinants of tissue drug exposure is necessary 
for PrEP product optimization. 
 
1.3 Drug transporters play an important role in antiretroviral drug pharmacokinetics 
1.3.1 Classification and transport mechanisms of efflux and uptake transporters  
Drug transporters are transmembrane proteins that control the movement of substrates in and out 
of the cell, and they localize on plasma membrane or the membrane of intracellular organelles 
such as mitochondria.
47
 Numerous studies have established the role of transporters in controlling 
drug accumulation, and in maintaining the homeostasis of endogenous substances in multiple 
tissues/organs including brain, liver and kidney,
47-56
 and in various types of cells including 
epithelial cells, endothelial cells and immune cells. ATP-binding cassette (ABC) and solute 
carrier (SLC) superfamilies are transporters that are most relevant to antiretroviral drugs. ABC 
transporters are mainly for efflux function. They contain a transmembrane domain which allows 
the flow-through of substrates, and an ATP binding cassette which binds the intracellular ATP 
molecules and facilitates their hydrolysis (Figure 1.2A). Using the energy released from ATP 
hydrolysis, the transmembrane domain undergoes conformational change and pumps the 
intracellular substrates to the extracellular space (Figure 1.2A).  
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SLC transporters are mainly for uptake. They are localized on plasma membrane or the 
membrane of intracellular organelles such as mitochondria. The transport mechanisms of SLC 
transporters include facilitative transport and secondary active transport. The facilitative 
transport allows the substrates to flow with concentration gradients (Figure 1.2B). The secondary 
active transport allows the substrate to flow against the electrochemical gradient, and couple this 
process to the transport of another substance with its gradient, so that favorable overall free 
energy change can still be achieved (Figure 1.2C).  
 
 
Figure 1.2 Transport mechanisms of ABC and SLC transporters.   
A, ABC transporters. NBD, nucleotide binding domain, TMD, transmembrane domain. B, 
SLC transporter (facilitative transport). C, SLC transporter (secondary active transport). 
Purple particles, first substrate. Yellow particles, secondary substrate. Pictures were drawn 
using CorelDRAW software. 
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1.3.2 ABC transporters in the pharmacokinetics of antiretroviral drugs 
In humans, 49 genes have been identified so far in the ABC transporter superfamily. These 
transporters are further categorized into 7 families, from ABCA to ABCG.
57,58
 In this chapter, 
emphasis is given to ABCB1 (P-glycoprotein) from the ABCB subfamily, ABCC1 to 7 
(multidrug resistance associated protein 1 to 7) from the ABCC subfamily, and ABCG2 (breast 
cancer resistance protein) from the ABCG subfamily, since they comprise the major efflux 
pumps for antiretroviral drugs. 
 
ABC transporters affect the intracellular accumulation of all classes of antiretroviral drugs, such 
as maraviroc (EI), saquinavir (PI), tenofovir (NRTI), efavirenz (NNRTI), and raltegravir (II). In 
addition to xenobiotics, ABC transporters also could affect the homeostasis of endogenous 
substances, and participate in physiologic processes, such as the immune response. Apart from 
being the substrates, xenobiotic and endogenous substances could also inhibit the transporter 
activity by competitively binding to the critical domains for transporter activity. For example, the 
protease inhibitors (e.g. ritonavir) are potent P-gp inhibitors, which exert the inhibitory effect 
through competitive binding to the extracellular domain of P-gp.
47,49
 Besides marketed drugs, 
some generally-regarded-as-safe (GRAS) excipients have been shown to potently inhibit ABC 
transporters, by temporarily depleting intracellular ATP availability and/or reversibly modifying 
plasma membrane fluidity.
47,59
  
 
In tissues with high expression and/or critical localization of transporters, differential tissue 
distribution patterns of the substrates vs. non-substrates have been observed. In addition, genetic 
polymorphisms of a number of transporters are associated with inter-individual variability in 
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antiretroviral drug pharmacokinetics (PK). Up-regulation or down-regulation of transporter 
expression/activity could alter antiretroviral drug PK profile and efficacy. Co-administration of 
efflux transporter inhibitors, including antiretroviral drugs and pharmaceutical excipients, has 
been shown to be an effective approach to enhance drug exposure in tissues with high level of 
transporter expression. Since transporter expression and activity can be modulated by many 
drugs, a significant portion of drug-drug interactions is mediated by transporters. More detailed 
information on this topic can be found in published reviews.
47,48,60
 
 
1.3.2.1 ABCB1 (P-gp) 
Many antiretroviral drugs are substrates of P-gp.
49
 All protease inhibitors (PIs) are high-affinity 
substrates of P-gp.
61-66
 In addition, the entry inhibitor maraviroc, the NRTIs such as tenofovir 
disoproxil fumarate (TDF) and abacavir, and some integrase inhibitors such as raltegravir, can be 
transported by P-gp. P-gp belongs to the B family (ABCB1) of ABC superfamily. P-gp is the first 
characterized ABC transporter, and is probably the most extensively studied efflux transporter. It 
is widely distributed in a variety of tissues including liver, kidney, intestine, brain and immune 
system. At cellular level, P-gp is localized in epithelial cells, vascular endothelial cells, as well as 
the immune system cells. Therefore, this transporter could affect drug transport across 
physiologic barriers that are constructed by epithelial cells (e.g. small intestinal enterocytes) and 
endothelial cells (blood-brain barrier), and in the immune cells. P-gp has been shown to possess 
up to five binding sites,
67
 which confer broad substrate specificity. P-gp substrates possess 
diverse structures, but most substrates are hydrophobic, with a molecular weight ranging from 
200-300 Da.
68
 Due to the wide tissue distribution and broad substrate specificity, P-gp has been 
recognized as the major efflux pump responsible for cellular resistance to antiviral and anticancer 
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drugs. The most significant increase of drug accumulation after P-gp inhibition was observed in 
the brain, as demonstrated in the cell cultures derived from blood-brain barrier, and in mice 
lacking the P-gp gene or treated with chemical inhibitors against P-gp. Among antiretroviral 
drugs, some PIs and NNRTIs can inhibit P-gp.
69-74
 Moreover, a select panel of pharmaceutical 
excipients are potent P-gp inhibitors, such as pluronic P85, Vitamin E TPGS, and polysorbate 
80.
59
 The plasma AUC after oral administration of MVC (P-gp substrate) was 3 times higher in 
P-gp knockout mice compared to the wild type mice.
75
 In humans, the concomitant use of P-gp 
inhibitors atazanavir, ritonavir, saquinavir and ketoconazole have been shown to significantly 
increase the Cmax and AUC of orally administered MVC up to 5 fold.
76
 Therefore, P-gp is one of 
the most important transporters in antiretroviral drug PK/PD. When investigating transporters in 
HIV transmission-related tissues and cells toward enhancement of drug exposure and 
effectiveness, P-gp should appear on the priority list.  
 
1.3.2.2 ABCCs (MRPs)  
MRPs belong to the C family (ABCCs) of ABC superfamily, and transport a diverse array of 
antiretroviral drugs.
49
 MRP transporters are also widely distributed in various tissues. Similar to 
P-gp, MRPs also exhibit multiple binding sites for different substrates, and thus are able to 
transport a wide variety of intact substances, as well as their organic anion conjugates.
59
 The 
MRP members most relevant to antiretroviral drugs are MRP1, 2, 4 and 5. MRP1 and MRP2 are 
shown to transport several PIs, including ritonavir, lopinavir, atazanavir, saquinavir, and 
indinavir.
77-81
 MRP1, 2 and 4 also mediate the efflux of many NRTIs. For example, MRP1 
mediates emtricitabine efflux from lymphocytes. MRP2, 4 and 5 transport tenofovir.
82-85
 
Administration of TFV to Mrp4 knockout mice resulted in more than 2-fold higher TFV 
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concentration in the kidney after intravenous administration of TFV.
84
 In humans, genetic 
ABCC4 3463G variants lead to TFV-DP concentrations in peripheral blood mononuclear cells 
(PBMCs) which was significantly higher than that of wild type.
86
 MRP5 has been shown to 
transport stavudine in vitro.
83
 NNRTIs and NRTIs including delavirdine, efavirenz, and 
emtricitabine inhibit several MRPs at clinically relevant concentrations, as revealed in cell 
culture experiments.
87
 In addition, NSAIDs such as indomethacin and ibuprofen are reported to 
be potent inhibitors of MRP4,
88-91
 and have been demonstrated to enhance the antiviral efficacy 
of NRTIs in HIV-1-infected T-lymphocytes.
89
 Moreover, some excipients are reported to inhibit 
MRPs, such as pluronic P85, polyethylene glycol (PEG) 300, and cyclodextrins (CDs).
59
 Due to 
the role of MRP transporters in antiretroviral PK/PD, these transporters are important 
considerations for the enhancement of drug exposure and efficacy in the tissues and cells 
relevant to HIV sexual transmission. 
 
1.3.2.3 ABCG2 (BCRP) 
BCRP belongs to the G family (ABCG2) of the ABC superfamily, and transports a number of 
antiretroviral drugs from different classes.
49
 This transporter was initially characterized in breast 
cancer cells as an efflux pump contributing to the resistance to chemotherapy. It is also widely 
distributed in normal tissues. As demonstrated in lymphocytes and BCRP-overexpressed cell 
cultures, this transporter confers resistance to many NRTIs, including abacavir, zidovudine, 
lamivudine, didanosine, and stavudine.
92-95
 In Bcrp-knockout mice, the brain accumulation of 
abacavir was significantly increased.
92
 BCRP genetic polymorphisms exerted an impact on 
BCRP activity in vitro, however no in vivo correlation was observed between BCRP 
polymorphisms and the concentrations of zidovudine- and lamivudine-triphosphates.
96
 Although 
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PIs and NNRTIs are not BCRP substrates,
97
 they have been demonstrated to be potent inhibitors 
of BCRP. In an in vitro assay using human embryonic kidney (HEK) cells stably expressing 
human BCRP protein, the inhibitory effect of ritonavir, saquinavir, and nelfinavir was studied 
using mitoxantrone as the substrate, and their IC50 values were determined to be 19.5 ± 0.8 µM, 
19.5 ± 7.6 µM, and 12.5 ± 4.1 µM, respectively.
97
 Weiss et al. tested the inhibitory effect of PIs 
and NNRTIs on human BCRP, using MDCKII cells with or without human BCRP 
overexpression. The rank order of the estimated IC50 values was lopinavir (7.66 µM) > nelfinavir 
(13.5 µM) > delavirdine (18.7 µM)  > efavirenz (20.6 µM) > saquinavir (27.4 µM) > atazanavir 
(69.1 µM) > amprenavir (181 µM).
98
 It should be noticed that the in vivo free plasma 
concentration of PIs and NNRTIs are usually at nanomolar or micromolar range, thus the in vivo 
effect of these drugs on BCRP-mediated transport will have to be tested in properly designed 
clinical studies.
98
 However, the gastrointestinal tract drug concentration is often much higher 
than the plasma concentration, after oral administration of antiretroviral drugs.
98
 The BCRP-
inhibiting drugs may at least play a role in the absorption process of co-administered drugs that 
are BCRP substrates, such as a number of NRTIs mentioned above.
98
 Therefore, BCRP plays an 
important role in antiretroviral drug PK/PD, and should be considered when studying the 
transporters in transmission-related tissues and cells toward improved HIV prevention and 
treatment.  
 
1.3.3 SLC transporters in the pharmacokinetics of antiretroviral drugs 
SLC transporters are localized on plasma membrane or the membrane of intracellular organelles 
such as mitochondria. SLC transporters are widely distributed in tissues and cells including liver, 
kidney, intestine, and immune system cells. The SLC transporters comprise 52 functionally 
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distinct families with over 300 members. This review focuses on the SLC subfamilies most 
relevant to antiretroviral drugs, which are organic anion and organic cation transporters (OATs 
aand OCTs), concentrative and equilibrative transporters (CNTs and ENTs), and organic anion-
transporting polypeptides (OATPs), as listed below. 
 
1.3.3.1 SLC22A family members (OATs and OCTs) 
OATs and OCTs belong to the SLC22 family. They transport the ionized drugs across plasma 
membranes. In the pharmacokinetics of antiretroviral drugs, the most extensively studied OATs 
are OAT1 (SLC22A6) and OAT3 (SLC22A8), which can transport tenofovir. On the basolateral 
membrane of renal proximal tubular epithelial cells, these two OATs facilitate the uptake of 
tenofovir from blood circulation into the renal epithelial cells, which could be subsequently 
effluxed by MRP4 into urine. The genetic polymorphisms of renal SLC22A6 associated with 
tenofovir-induced kidney toxicity. OCT1 and OCT2 have been shown to transport several NRTIs 
including lamivudine and zalcitabine.
97
 Among antiretroviral drugs, some PIs including indinavir, 
nelfinavir, ritonavir, and saquinavir, can inhibit OCT1 and OCT2 activities in vitro.
98
  
 
1.3.3.2 SLC28 and SLC29 family members (CNTs and ENTs)  
CNTs and ENTs belong to the SLC28 and SLC29 families, respectively. They are known to 
transport nucleoside analogues, including NRTIs. Based on their relative affinities to cellular 
nucleotides, CNTs are considered as high affinity transporters while ENTs are considered as low 
affinity transporters.
99
 They are ubiquitously distributed in various types of tissues and cells. 
Among human CNTs, CNT1 and CNT2 mainly transport pyrimidine- and purine-nucleosides, 
respectively, in a sodium-dependent manner. CNT3 has broad substrate selectivity, and could 
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transport nucleosides in both sodium- and proton-coupled manner.
100
 ENT1 and ENT2 have 
shown broad substrate selectivity for purine and pyrimidine nucleosides. ENT3 also has broad 
selectivity for nucleosides and nucleobases, and functions in the membrane of intracellular 
organelles such as lysosomes.
100
 Among antiretroviral drugs, zidovudine and lamivudine are 
transported by CNT1,
101,102
 and didanosine can be transported by CNT2.
103
 Zidovudine and 
didanosine can be transported by ENT3 but the affinity of this transporter was low.
104
 The 
nucleoside reverse transcriptase inhibitors are well-known substrates of ENTs. For example, 
didanosine can be transported by ENT1 and ENT2, zidovudine can be transported by ENT2,
105
 
and stavudine and zalcitabine can be transported by ENT3.
60
  
 
1.3.3.3 SLCO family members (OATPs) 
The OATPs belong to the SLCO family. OATP1A2 and 1B1 are mostly studied OATPs in 
antiretroviral drug PK. OATP1A2 and OATP1B1 transport PIs and entry inhibitors including 
darunavir, lopinavir, saquinavir and maraviroc in vitro.
17,106,107
 An OATP1B1 polymorphism, 
521T>C, was significantly associated with higher plasma levels of lopinavir and maraviroc in 
patients.
17,107
 In addition to being transported by OATPs, some PIs are potent inhibitors of 
OATP1B1.
108,109
 
 
1.3.4 The effect of antiretroviral drug permeability and solubility on its interaction with 
transporters 
For a given antiretroviral drug, being an in vitro substrate of a transporter does not necessarily 
mean the transporter will play a significant role in the drug’s tissue absorption and disposition in 
vivo. The functional role of transporters is affected by the drug’s permeability and solubility.60,110 
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Biopharmaceutics Classification System (BCS) categorizes different drugs into 4 classes 
according to drug permeability and solubility: Class 1, high permeability, high solubility; Class 2, 
high permeability, low solubility; Class 3, low permeability, high solubility; Class 4, low 
permeability, low solubility.
110,111
 The BCS classification, and the interaction with efflux 
transporters and uptake transporters are summarized for FDA-approved antiretroviral drugs in 
Table 1.1 below.  
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Table 1.1 Summary of the drug transporters that efflux or uptake antiretroviral drugs.  
  
Antiretroviral drug 
class 
Antiretroviral 
drugs 
BCS Class 
ABC 
transporters 
SLC transporters 
Entry inhibitors (EIs) Maraviroc 3 P-gp OATP1B1 
Nucleoside/nucleotide 
reverse transcriptase 
inhibitor (NRTIs) 
Lamivudine 3 BCRP OCT1, OCT2, CNT1 
Emtricitabine 3 MRP1  
Tenofovir DF 3 P-gp  
Tenofovir 3 MRP4, MRP7 OAT1, OAT3 
Abacavir 1 
P-gp, BCRP, 
MRP4 
 
Zidovudine 1 BCRP, MRP4 
OAT1, OAT2, OAT3, 
CNT1, CNT3, ENT2 
Didanosine 3 BCRP 
CNT2, CNT3, ENT1, 
ENT2 
Stavudine 1 BCRP, MRP5 CNT1 
Non-nucleoside reverse 
transcriptase inhibitors 
(NNRTIs) 
Efavirenz 2   
Nevirapine 2 MRP7  
Delavirdine 1   
Etravirine 4   
Protease inhibitors (PIs) 
Atazanavir 2 
P-gp, MRP1, 
MRP2 
 
Ritonavir 2 
P-gp, MRP1, 
MRP2 
 
Fosamprenavir 2   
Amprenavir 2 P-gp  
Lopinavir 2 
P-gp, MRP1, 
MRP2 
OATP1A2, 
OATP1B1 
Saquinavir 2 
P-gp, MRP1, 
MRP2 
OATP1A2, 
OATP1B1 
Darunavir 2 P-gp 
OATP1A2, 
OATP1B1 
Indinavir 2 
P-gp, MRP1, 
MRP2 
 
Tipranavir 2 P-gp  
Nelfinavir 2 P-gp  
Integrase inhibitors (IIs) Raltegravir 2 P-gp  
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This table is adapted from a review by Kis et al.
49
 A number of these drugs are already 
undergoing clinical testing toward the development of PrEP products, including maraviroc, 
emtricitabine, tenofovir, tenofovir DF, and raltegravir. 
 
 
For Class 1 drugs, due to their relatively high permeability, they can enter the tissue without the 
aid of uptake transporters.
60,110
 Three NRTIs, zidovudine, abacavir and stavudine belong to Class 
1 (Table 1.1). These drugs can easily saturate the efflux transporters because they can quickly 
enter cells and accumulate high intracellular concentration. Therefore, the Class 1 drugs, 
including abacavir, zidovudine, stavudine and delavirdine, are not likely to be influenced by efflux 
and uptake transporters even if they are substrates (Table 1.1).
110
 
 
For Class 2 drugs, they are not likely to be affected by uptake transporters due to high 
permeability, but they are prone to be influenced by efflux transporters because their low 
solubility renders them unlikely to saturate efflux transporters as Class 1 drugs can.
60,110
 The 
efflux transporters are able to pump the drug back into the lumen (topical administration) or 
blood stream (oral administration), and the drug can re-enter the tissue and be repeatedly 
exposed to intracellular metabolizing enzymes. Therefore, a feature of Class 2 drugs is that they 
are more likely to be subjected to transporter-enzyme interplay.
110
 As shown in Table 1.1, all the 
PIs, some NNRTIs such as nevirapine, and the integrase inhibitor (II) raltegravir belong to Class 
2. Therefore, these drugs will be affected by efflux transporters. 
 
For Class 3 and Class 4 drugs, due to their low permeability, they will require uptake transporters 
to help them get into tissues.
60,110
 The effect of uptake transporters is especially evident for Class 
3 drugs which have relatively higher solubility.
60
 These two classes also have the potential to be 
27 
 
influenced by efflux transporters, since they are unlikely to achieve high intracellular 
concentrations that could saturate efflux transporters.
60,110
 As shown in Table 1.1, five NRTIs 
including lamivudine, emtricitabine, Tenofovir DF, tenofovir and didanosine belong to Class 3. 
The EI maraviroc also belongs to Class 3. Currently only one antiretroviral drug etravirine 
(NNRTIs) belongs to Class 4. These drugs may be influenced by both efflux and uptake 
transporters. 
 
To summarize, efflux transporters mainly affect drugs from Classes 2, 3, 4, especially Class 2 
drugs. Uptake transporters mainly affect drugs from Classes 3 and 4, especially Class 3 
drugs.
60,110
 The prediction of the in vivo functional role of transporters in tissue drug exposure 
will need to incorporate the information of drug permeability and solubility, i.e. the BCS 
classification of antiretroviral drugs, even if the drugs are proven to be transporter substrates in 
vitro.  
 
1.4 Delineating the role of cervicovaginal and colorectal transporters in antiretroviral 
drug pharmacokinetics  
1.4.1 Preliminary evidence suggests the expression and function of drug transporters in 
transmission-related tissues and cells 
A growing body of evidence has demonstrated that some efflux and uptake transporters are 
expressed in female genital tract, colorectal tissue, and immune cells (summarized below). 
Studies have demonstrated that efflux transporters of blood-derived immune cells limit the 
intracellular accumulation and/or efficacy of antiretroviral drugs.
112,113
 Although there is little 
direct evidence showing the functional role of these transporters in drug PK in the tissue, clinical 
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PK studies comparing drug exposure in different physiologic compartments have implicated the 
presence of active drug transport mechanisms in the female genital tract.
43,114
  
 
Some transporter substrates, including maraviroc, lamivudine, and emtricitabine, are reported to 
be preferentially distributed in cervicovaginal tissues and/or fluids at higher levels than in plasma, 
after oral administration.
43,114
 These differential drug distribution profiles cannot be solely 
explained by the differences in plasma protein binding and passive permeation, as drugs with 
similar plasma protein binding and permeability displayed different capabilities of distributing 
into cervicovaginal tissues.
41,43,114,115
  
 
Thompson et al. summarized published literature of 58 drugs and developed a mathematical 
model to predict a compound’s cervicovaginal tissue penetration ratio (TPR). In this study, the  
area under the concentration-time curve (AUC) or single-time-point concentration in 
cervicovaginal tissues was collected from literature for each drug after oral administration, and 
was divided by the AUC or single-time-point concentration in the plasma to calculate the TPR. 
The importance of physicochemical properties, protein binding, and the in silico predicted 
probability of being transporter substrates have been evaluated in the developed model. The 
analysis showed that the TPR of orally administered drugs was significantly associated with its 
probability of being the substrate of two efflux transporters MRP1 and MRP4.
116
 This analysis 
highlighted the possibility of in vivo functional role of MRP1 and MRP4, in the blood-to-tissue 
distribution of antiretroviral drugs in lower female genital tract. 
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1.4.2 The need for further study of transporters in transmission-related tissues and cells to 
benefit PrEP optimization 
A detailed characterization of transporters in the transmission-related tissues and cells will 
benefit multiple aspects toward PrEP optimization. First, this information is useful in the 
selection and optimization of PrEP drug candidates. If an efflux transporter is demonstrated to 
play a significant role in tissue and cell drug exposure, then non-substrates of this transporter 
may be better candidates than the substrates, if all other attributes of these candidates are similar. 
On the contrary, if an uptake transporter has a prominent functional role in the tissues and cells, 
then its substrates may be better candidates than non-substrates for further development. Since 
the substrate avidity to transporters is determined by chemical structure, the drug candidates 
could be subject to structural modifications to turn them into non-substrates or substrates, for 
further development. Secondly, the transporter information can be utilized for the optimization of 
the microbicide formulation. Chemical modulators, many of which are antiretroviral drugs, could 
be incorporated into the formulation to inhibit transporter efflux and improve drug penetration 
and/or tissue retention and efficacy. Alternatively, some pharmaceutical excipients are known to 
inhibit efflux transporters such as P-gp, BCRP, and MRPs. Finally, transporter information will 
help explaining and predicting the transporter-mediated drug-drug interaction, and inter-
individual variability in antiretroviral PK and PD. An important source for variability is 
pathophysiological factors including age, gender, and disease status, and the effects of these 
factors on antiretroviral PK-PD are mediated partially by transporters. Taken together, there is a 
clear need for more insightful understanding of the transporters in tissues and cells relevant to 
HIV-1 sexual transmission.  
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1.5 Existing literature on the expression, localization and functionality of transporters in 
cervicovaginal tissues, colorectal tract, and immune cells 
 
Table 1.2 Expression and localization of transporters in human tissues and cells relevant to 
HIV-1 sexual transmission.  
 
Compartments 
Tissue/cell 
type 
mRNA/protein 
expression 
Cellular localization Ref. 
Female genital 
tract 
Uterus 
P-gp, BCRP, MRP1, 
MRP4, MRP5, MRP7, 
OCT3, CNT1, ENT1,2 
OATP3A1 
Glandular cells of 
endometrium (P-gp, MRP4, 
CNT1, ENT1,2); endometrial 
capillaries (P-gp) 
117-122
 
Endocervix P-gp, BCRP 
Glandular epithelial cells (P-
gp); vascular endothelium of 
stroma (BCRP) 
120,123
 
Ectocervix 
P-gp, BCRP 
Squamous epithelium and 
stromal tissue (P-gp); 
vascular endothelium of 
stroma (BCRP) 
119,120,123,
124
 
Vagina 
N/A N/A 
 
Colorectal 
tissues 
Colon 
P-gp, BCRP, MRP1, 
MRP2, MRP3, MRP4, 
MRP5, MRP7 
Columnar epithelium (P-gp, 
BCRP, MRP3,4,5); secretory 
epithelial cells (goblet cells) 
(MRP3,4) 
119,122,124-
139
 
Colorectum P-gp, MRP2, MRP4 
Columnar epithelium and 
submucosal immune cells (P-
gp and MRP2) 
136
 
Immune cells 
Within 
cervicovaginal 
and colorectal 
tissues 
N/A N/A N/A  
Blood-derived 
PBMCs: P-gp, BCRP, 
MRP1,2,3,4,6,7, OCT1, 
OAT2, ENT1,2, 
OATP2B1, 3A1 
 
79,86,89,119,
140-154
 
Lymphocytes or CD4+ T 
cells: P-gp, BCRP, 
MRP1,2,  OATP1A2, 
OATP3A1 
 
113,119,149,1
55-173
 
Macrophages: P-gp, 
MRP1,4,5,7 CNT1,2,3, 
 
149,174-176
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ENT1,2, OCT1,3, 
OCTN1,2 
Dentritic cells: P-gp, 
CNT1,2,3, ENT1,2, 
OCT1,3, OCTN1,2 
 
149,177
 
 
1.5.1 Transporters in female genital tract (uterus, endocervix, ectocervix, vagina) 
The transporters summarized in Table 1.2 include P-gp, BCRP, MRPs from ABC superfamily, 
and OATs, OCTs, ENTs, OATPs from SLC superfamily. These transporters have been 
experimentally demonstrated to transport antiretroviral drugs and are most frequently studied 
transporters in antiretroviral pharmacokinetics. As listed in Table 1.2, the ABC transporters most 
relevant to antiretroviral drugs, including P-gp, BCRP, MRP4 are consistently expressed along 
the entire female genital tract. BCRP appeared to the most highly expressed transporter among 
ABC transporters in female genital tract. Using RT-PCR, the uterine BCRP mRNA level was 
found to be the highest in uterus among all types of tissues and organs examined.
122
 Several 
MRP isoforms are also expressed at different segments of female genital tract. Compared to the 
ABC transporters, SLC transporters were generally less studied in female genital tract. The 
detection methods for transporter mRNA and protein expression included microarray, 
conventional RT-PCR, qRT-PCR, and IHC staining. In addition, using IHC and 
immunofluorescence staining, these transporters were found to locate in cell types that may act 
as gatekeepers to the drug movement among mucosal lumen, mucosal tissues, and systemically 
circulating blood and lymph. However, the type of cells that harbour transporter proteins varies 
among different segments of female genital tract (Table 1.2).  
 
There are only a few reports on transporter function in female genital tract. Uterine P-gp and 
MRP4 functionalities have been studied in murine and cell culture models, but there is no study 
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examining transporter function in endocervix, ectocervix, and vagina. Schinkel et al. found the 
Mdr1a/1b double knockout resulted in 2.2-fold increase in digoxin accumulation in mouse uterus 
after intravenous administration.
178
 The MRP4 was demonstrated to be responsible for the 
extracellular PGE2 release from endometrial epithelial cells, and this release could be inhibited 
by LXA4 through attenuation of MRP4 mRNA and protein.
121
 
 
The regulation of transporter expression and localization in female genital tract was also 
reported.
47,113
 The cellular localization, staining intensity, and percentage of P-gp in uterus varied 
with the phase of the menstrual cycle. The staining intensity increased from early proliferative to 
late proliferative endometrial while diminished from early secretory to late secretory phase.
117
 P-
gp expression parallels that of nuclear progesterone receptor expression in the normal human 
endometrial cycle and early gestational endometrium. In addition, P-gp expression corresponds 
to rising plasma and tissue levels of progesterone as well as to morphologic changes in the 
endometrial glandular epithelium associated with the marked development of the secretory 
apparatus.
117
 In addition to P-gp, the MRP4 protein expression was found to undergo cyclic 
change during the estrous cycle in intact bovine endometrial tissues.
179
 In the uteri from 
peritoneal endometriosis patients, Gori et al. reported that MRP4 was expressed in eutopic and 
ectopic endometrium, where it was overexpressed in peritoneal lesions and localized in the 
cytoplasm of glandular epithelial cells. LXA4 attenuated MRP4 mRNA and protein levels in 
endometriotic epithelial cells in a dose-dependent manner. This regulation was found to be 
mediated through estrogen receptor α, as examined using receptor antagonists and small 
interfering RNA.
121
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1.5.2 Transporters in colorectal tissues (Colon, colorectum) 
As shown in Table 1, P-gp, BCRP, MRPs1-7 are positively expressed in human colorectal tissues 
at moderate to high levels, compared to other genes expressed in colorectum,
119,125,133, 110, 
130,136,138
 or compared to the expression level of the same transporter in liver.
122
 The detection 
methods include qRT-PCR, Western blot, and IHC staining. De Rosa et al. compared the 
expression levels of multiple ABC transporters in the sigmoid colon of HIV-uninfected man.
110
 
In this evaluation, the ranking of transporter mRNA level was: MRP2 > MRP4 > MRP1 > P-
gp > BCRP, and the ranking of transporter protein level was: MRP1 > MRP4 = BCRP > 
MRP2 > P-gp.
110 
However, Zimmermann et al. reported that the rank order of the transporter 
mRNA level was: MRP3 >> MDR1 > MRP4 almost equal to MRP5 > MRP1 >> MRP2.
138
 One 
possible cause for this difference is the source of tissue samples. De Rosa et al. used tissues from 
young men with an median age of 39, while Zimmermann et al. used the tissues from both men 
and women with the average age of 62.
138, 110 
Colorectal P-gp, BCRP, MRP2, MRP3, MRP4 
were localized on the plasma membrane of multiple cell types, including specialized epithelial 
cells with secretory/excretory functions, and endothelial cells of capillary blood vessels.
129,134, 97, 
124
 Furthermore, MRP4 was localized in endoplasmic-Golgi complex and basolateral location in 
goblet cells,
134
 MRP3 and MRP5 were localized on the basolateral membrane of glandular 
epithelial cells.
134,180
 The regional distribution of transporters along the intestinal tract has also 
been studied. Blokzijl et al. reported that P-gp mRNA level in colon was 5-fold lower than the 
level in terminal ileum.
125
 Prime-Chapman et al. examined the mRNA expression of MRP1-6 in 
human colon and rectum. All the 6 MRPs were detected in the colon, but MRP2 and MRP6 were 
not detectable in the rectum.
136
 As to the SLC transporters, OAT2, CNT1, ENT1 were found to 
be highly expressed,
119
 while OAT1, OAT3, OCT2, OCT3 and OATP1B1 were negligible in 
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human colorectum.
133
 
 
The functionalities of colorectal P-gp and BCRP have been studied using human tissues and 
preclinical models. Collett et al. studied the permeability of the P-gp substrate UK-338,003 (UK) 
through mouse ileum and colon. The colonic permeability of UK was at least 40 times lower than 
that of ileum, with large asymmetry (basolateral-to-apical permeability was much larger than the 
apical-to-basolateral permeability). The application of P-gp inhibitor markedly increased the 
colonic permeability of UK to the level comparable to that in ileum. Low apical-to-basolateral 
permeability of UK was also observed in the ex vivo human distal intestine, however the increase 
in UK permeability after the co-administration of P-gp inhibitor was significantly lower than the 
increase in mouse colon.
128
 Enokizono et al. used 4-methylum-belliferone (4MU) as substrate to 
examine Bcrp functionality on the everted mouse colon sacs. A marked reduction in the mucosal 
secretion clearance of the 4MU sulfate was observed in the colon of Bcrp knockout mice 
compared to that of the wild-type mice.
131
  
 
The studies examining the regulation of colorectal transporters have focused on several ABC 
transporters. The effect of gender on human colonic transporter expression remains unknown, 
but there is no difference in colonic P-gp mRNA level between male and female mice.
181
 The 
impact of inflammation on transporter expression is different for different transporters. 
Ulcerative colitis (UC), Crohn's disease (CD), collagenous colitis and diverticulitis cause tissue 
inflammation and strongly decreased P-gp mRNA and protein expression in colonic epithelial 
cells and submucosal mononuclear cells. The inflammation also down-regulates BCRP 
expression.
130
 The down-regulation of P-gp is independent of PXR protein level,
125
 while the 
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decrease in BCRP level was negatively correlated with the IL-6 mRNA level.
130
 On the contrary, 
UC and CD significantly increased MRP1 mRNA expression.
125
 HIV-1 infection significantly 
down-regulated P-gp and MRP2 protein levels in male recto-sigmoid colon, while antiretroviral 
treatment up-regulated P-gp and MRP2 protein levels.
139
 The HIV-1 infection and treatment did 
not have obvious effect on the expression of MRP1, MRP4 and BCRP.
139
 In contrast to ABC 
transporters, the regulation of SLC transporters by infection or antiretroviral treatment is not well 
understood. Kleberg et al. reported that neoplasia up-regulated OATP2B1 and OATP4A1 mRNA 
levels in human colorectum.
134
 
 
1.5.3 Transporters in HIV-1 target immune cells 
Due to the scarcity of human cervicovaginal and colorectal tissues, and the difficulty of purifying 
the immune cells from these tissues, there is a lack of characterization of the transporter 
expression and activity of the tissue-associated submucosal immune cells. However, there have 
been abundant reports on PBMCs, PBMC-derived immune cell subsets, and immortalized 
immune cell lines, due to the easiness of obtaining the blood-derived immune cells and the 
experimental convenience of cell manipulation. Numerous studies have revealed the expression 
profile, functionality, and regulating factors of a number of ABC and SLC transporters in 
PBMCs, blood-derived lymphocytes or CD4+ T cells, blood monocyte-derived macrophages 
(MDM), and blood-derived dentritic cells (DCs). The detection methods include RT-PCR, 
Western blot, and flow cytometry. Large inter-individual differences in P-gp level has been 
observed in primary lymphocytes isolated from healthy volunteers.
155
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ABC transporters in human blood-derived immune cells have been demonstrated to efflux 
antiretrovirals and other drugs. In healthy PBMCs, Janneh et al. reported the inhibitors of P-gp, 
MRP1 and MRP2 significantly increased the intracellular accumulation of saquinavir in healthy 
PBMCs.
79
 Janneh et al. demonstrated that the MRP inhibitors tariquidar, MK571, frusemide and 
dipyridamole, as well as protease inhibitors ritonavir, amprenavir and atazanavir significantly 
increased the intracellular concentration of lopinavir.
158
 In lymphocytes, Gupta et al. revealed 
positive efflux activity of P-gp in healthy CD4+ T cells using flow cytometry (Rho123).
157
 
Clemente et al. revealed that the non-steroidal anti-inflammatory drugs (NSAIDs) blocked 
MRP4 efflux, increased the intracellular concentration and anti-viral efficacy of several 
nucleoside reverse transcriptase inhibitors (NRTIs) including AZT, in peripheral blood 
lymphocytes (PBLs).
89
 Liptrott et al. revealed the nevirapine concentration in the healthy CD4+ 
blood cells can be increased by small interfering RNA knockdown of MRP7.
170
 Lee et al. 
detected MRP1 efflux activity in the CD4+ T cells isolated from healthy subjects, using flow 
cytometry.
182
 The lymphocyte transporter has also been studied in mouse. Elliott et al. revealed 
the positive expression and activity of P-gp (Mdr1a/1b), Mrp1, and Bcrp in mouse blood 
lymphocytes, using RT-PCR and flow cytometry.
164
 Schinkel et al. examined P-gp function in 
mice, and found that the lymph node accumulation of IV administered digoxin was significantly 
increased in Mdr1a/1b double knockout mice, compared to the wild type mice.
183
 In human 
monocyte-derived macrophages (MDMs), the P-gp inhibitor PSC833 and the MRP1 inhibitor 
probenecid increased the intracellular accumulation of AZT in HIV-infected MDM, and 
increased the efficacy of AZT and indinavir.
175
 Liptrott et al. reported the functionality of MRP7 
in effluxing nevirapine from MDMs, using small interfering RNA that specifically knocked 
down MRP7.
170
 Due to the observed efflux activity of immune cell transporters, the genetic 
37 
 
polymorphisms of P-gp, MRP1, MRP4, MRP5 transporters have been shown to correlate with 
varying intracellular concentration and/or efficacy of substrate drugs including protease 
inhibitors and nucleotide reverse transcriptase inhibitors, in PBMCs and blood CD4+ T 
cells.
86,89,154,171
 
 
Apart from the role in drug efflux, immune cell transporters, especially P-gp, have been 
suggested to play a role in immune cell physiology and HIV-1 infection process. Since the HIV 
entry into immune cells involves an interaction of the viral gp41 peptide and the target cell 
plasma membrane, and that P-gp could transport hydrophobic drugs and peptides, the observed 
effect of P-gp overexpression on HIV infectivity may be related to its interaction with the critical 
receptors/co-receptors on immune cell surface.
169
 Some researchers reported inverse correlation 
between lymphocyte P-gp level and HIV infectivity. Lee et al. reported P-gp overexpression 
greatly reduced the HIV infectivity, during the fusion of virus and host plasma membranes, and 
at later steps of the HIV life cycle, in CD4+ human T-leukemic cell line (12D7). This observed 
reduction was not due to altered expression of the CD4 receptor or CXCR4 coreceptor on the 
target cell surface.
169
 Speck et al. observed the overexpression of P-gp in CEM cells significantly 
decreased (by at least 70-fold) the HIV protein and infectious virus production, and this effect 
could be partially reversed by P-gp inhibitors.
173
 Hulgan et al. found that P-gp activity in CD4+ 
T cells from 185 HIV-infected patients receiving antiretroviral therapy was inversely correlated 
with plasma HIV-1 RNA level.
167
 Sankatsing et al. found a reduced intracellular HIV load in the 
patients with high cellular P-gp activity, among both therapy-naive and in PI-treated patients.
172
 
However, there have been controversial reports on the role of P-gp in HIV-1 infection and 
disease progression. In addition to the studies that suggested the role P-gp in HIV infectivity, 
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several studies reported no correlation between P-gp level and HIV-1 infection/progression. 
Bleiber et al. revealed that the difference in physiological levels of P-gp did not alter the 
permissiveness of healthy human CD4+ T cell to HIV in vitro. In addition, the P-gp alleles 
(exons 21 and 26) and haplotypes did not exhibit significant impact on the disease progression 
before the initiation of antiviral treatment, in the HIV-infected patients.
162
 Agrati et al. detected 
no difference in P-gp expression in total PBMC and CD4+ T cells from 3 groups of HIV-
infected patients: treatment naïve, responders, and non-responders. This suggested the immune 
cell P-gp was unlikely to be a determinant of patient response to antiretroviral therapy when P-gp 
substrates constitute a significant portion of the regimen.
140
 Similarly, Bossi et al. did not 
observe an association between CD4+ cell P-gp level and the treatment outcome, in the infected 
patients treated with protease inhibitors.
163
 In addition to P-gp, MRP1 overexpression was also 
shown to increase viral production in the CEM cells, and this effect can be partially abrogated by 
MRP inhibitors.
173
 In CD4+ T cells, the exposure to HIV-binding glycoprotein gp120 in vitro 
resulted in rearrangement of P-gp protein localization, suggesting an interaction between viral 
protein and P-gp exists.
147
 In addition, P-gp was preferentially associated with glycolipid-
enriched membrane (GEM) domains, while MRP1 was not. Since the GEM domain may be an 
important site for the binding and egress of HIV, the difference between P-gp and MRP1 in 
GEM association likely resulted in differential effect of the two transporters on the HIV infection 
process.
173
 In addition to the role in HIV-1 infectivity, P-gp was shown to transport a number of 
endogenous immune mediators including monensin, retinol, IL-2 and IFN-γ, 150 promote 
lymphocyte survival,
142
 and facilitate DC migration into lymphatic vessels.
177
  
 
The effects of disease, drug treatment and activation status on immune cell transporter 
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expression and activity have been evaluated. The effect of HIV-1 infection depended on the 
model and cell type selected for examination. In human PBMCs, HIV infection up-regulated 
mRNA levels of P-gp and MRPs1, 4, 5.
154
 In H9 (T cell line) and U937 (monocytic cell line) 
cells, HIV infection increased the expression of P-gp and increased the efflux of P-gp substrates 
AZT and daunorubicin.
165
 In MDMs, HIV infection increased the mRNA levels of MRP1, 4, 
5.
174
 However, Lucia et al. reported that viral load did not affect P-gp expression in the PBMCs 
of treatment-naive and –experienced patients.145 In cynomolgus macaques, HIV infection 
decreased P-gp mRNA level in PBMCs and lymph node mononuclear cells.
143
 Besides HIV 
infection, myasthenia gravis decreased P-gp efflux function of PBMCs,
152
 and increased 
intracellular cholesterol levels markedly up-regulated P-gp activity in PBMCs.
153
 The effect of 
cytokine and antiretroviral/anticancer drug treatment on immune cell transporters appeared to be 
drug-specific. IL-2 and IFN-γ significantly increased the mRNA and protein expression of P-gp, 
MRP1 and MRP2, and reduced accumulation of digoxin and saquinavir, in the PBMCs of 
healthy volunteers.
144
 In MDMs, IFN-γ increased P-gp mRNA abundance, induced polarized 
redistribution of P-gp protein in pseudopodia, and increased the efflux activity of P-gp.
176
 The 
anticancer treatment of Kaposi sarcoma (KS) using the liposomal formulation of anthracycline 
doxorubicin (L-DOX) up-regulated P-gp in the PBMCs of treatment-naive and –experienced 
patients.
145
 AZT increased the MRP4 expression level in HIV-1 infected T lymphocytes.
89
 
Despite these up-regulating effects, Lucia et al. reported HAART did not affect P-gp expression 
in the PBMCs of treatment-naive and -experienced HIV-infected patients.
145
 Agrati et al. 
reported that antiretroviral treatment did not affect P-gp expression in PBMCs of HIV-infected 
patients.
140
 Bossi et al. found that the protease inhibitor treatment had no effect on the P-gp 
expression and activity, and was not linked to the treatment outcome.
163
 Chinn et al. observed no 
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significant effect of saquinavir and atazanavir treatments on P-gp expression (qRT-PCR) and 
activity (Rho123) of lymphocytes isolated from healthy subjects.
155
 In addition, Lucia et al. 
found that treatment with protease inhibitors, including ritonavir, saquinavir, neifinavir and 
indinavir, reduced the efflux of rhodamine 123 in blood lymphocytes from healthy and HIV 
infected patients.
146
 Lee et al. reported that protease inhibitors exerted differential effects. MRP1 
expression and efflux activity in healthy CD4+ T cells were reduced after the treatment of 
darunavir/ritonavir, but not after efavirenz treatment alone.
182
 In HIV infected cynomolgus 
macaques, HAART (zidovudine [AZT], lamivudine [3TC], and indinavir [IDV]) accentuated the 
infection-induced decrease of P-gp mRNA level, in macaque PBMCs and lymph node 
mononuclear cells.
143
 The chemical-induced activation was shown to increase the expression 
and/or activity of P-gp and ENTs in primary lymphocytes.
149,157
 
 
1.5.4 Summary of existing literature 
The positive expression of multiple transporters in the tissues and cells relevant to HIV 
transmission indicates that these transporters may play a role in drug absorption and disposition 
and PrEP effectiveness. Especially, some important transporters (P-gp, BCRP, MRPs) have been 
demonstrated to localize in multiple cell types (epithelial cells, secretory glandular cells, vascular 
endothelial cells) in these tissues, indicating these transporters may affect multiple processes of 
drug handling in the tissues and cells. The uptake transporters were generally less studied 
compared to efflux transporters. OCTs, CNTs, ENTs, and OATPs can be detected in some tissues, 
however the expression profiles of OAT1 and OAT3, which are the major uptake transporters for 
tenofovir, remain unknown in the tissues and immune cells. The positively expressed transporters 
may be able to affect the drug pharmacokinetics in all the three compartments in HIV-1 
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transmission (mucosal fluid, tissue, and blood). The observation that transporters (e.g. P-gp) can 
be regulated by exogenous hormones, disease status, and concomitantly used drugs highlighted 
the possibility that the transporter functionality may be variable under different 
pathophysiological conditions. 
 
Contradictory reports have been observed for transporter expression and activity. This is 
especially evident in immune cells. There is large heterogeneity between different subsets of the 
immune cells, and even for the same subset, for example, CD4
+
 T cells, there have been 
contradictory reports regarding transporter expression.
112
 However, MRP1 appeared to be 
consistently reported to express at high level in human lymphocytes, indicating that this 
transporter may play a consistently significant role in the pharmacokinetics of antiretroviral 
drugs in the immune cells.  
 
The reasons for these conflicting results may include differences in the experimental approaches, 
including different methods of detection, different reagents, and different models. For example, 
for expression analysis, RT-PCR and Western blot may yield different results, as the correlations 
among mRNA level and protein level are not always good. The antibodies used for the WB, IHC 
staining and flow cytometry may differ in the sensitivity and/or specificity, and may render 
different signal intensity for the same sample. When testing the role of transporters in HIV-1 
infection, the selection of infection model may have strong impact on the results and conclusion.  
 
In addition to the differences in experimental approaches, the potential inherent heterogeneity in 
immune cells being tested may also contribute to the observed conflicting results for transporter 
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expression and activity in immune cells. It has been reported that many factors influence 
transporter expression and activity (varying level of sex hormones, age, gender, methods of 
lymphocyte activation) etc.
112
 If the blood is obtained from patients under the influence of these 
factors, then a large heterogeneity in blood cell transporters may be unsurprising. 
 
1.6 Knowledge gaps that preclude direct utilization of existing knowledge on 
cervicovaginal and colorectal transporters in PrEP optimization 
First of all, there is a lack of systematic characterization of the mRNA and protein expression of 
transporters in human lower genital tract, colorectal tissue, and in the animal models and cell 
lines used in PrEP drug candidate screening. This information is important for a comprehensive 
understanding of human tissue transporter expression, and is necessary for the evaluation of the 
validity of the preclinical models used in the PrEP drug candidate screening. In addition, the 
characterization of transporter expression in the preclinical models will provide valuable 
information on the utility of these models in the studies of transporter regulation and function, as 
discussed below. 
 
The effect of PrEP-relevant factors on transporter expression remains largely unknown. These 
factors include varying levels of sex steroid hormones (due to menstrual cycle and menopause), 
exogenously administered hormonal contraceptives, and local tissue inflammation caused by 
bacterial or fungal vaginosis. These factors have been demonstrated to impact transporter 
expression and activity in metabolic organs such as liver, but few studies investigated their effect 
on cervicovaginal and colorectal tissue transporters. A significant number of these regulations are 
mediated by nuclear receptors (NRs), which are transcriptional factors that regulate mRNA 
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expression of downstream genes through binding and activating the promoter region. The 
information generated from these studies will be helpful for the understanding of the dynamics of 
transporter expression in cervicovaginal and colorectal tissues, and will rationalize the study of 
transporter function in these tissues, as discussed below. 
 
The role of the positively expressed transporters in PrEP drug pharmacokinetics remains 
undetermined. It is not clear whether the positive expression of transporters correlate with 
transport activity, in the cervicovaginal and colorectal tissues. The transporter function in female 
genital and colorectal tissues has been occasionally studied, as a barrier to topically administered 
drug intended for systemic absorption. However, for these tissues, it is more important to know 
whether the transporters could affect drug distribution and retention within the tissues, since the 
tissue-associated HIV-1 target immune cells reside within the tissues. As discussed above, these 
functionality studies need to be conducted in a PrEP-relevant setting. The effect of PrEP-relevant 
factors on the function of transporters in genital tract and colorectal tissue warrants further 
studies.  
 
1.7 Hypothesis and Specific Aims 
Based on the summary and discussion above, emerging evidence has suggested that efflux and 
uptake transporters are positively expressed in the female genital tract and colorectal tissues, 
which are the primary sites of HIV-1 sexual transmission. Further study is warranted to 
systematically examine the expression and localization of transporters in these tissues, especially 
in female lower genital tract. In addition, it is necessary to examine the effect of PrEP relevant 
factors (menstrual cycle, exogenous hormones and contraceptives, cytokines implicated in 
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cervicovaginal tissue inflammation) on transporter expression. Finally, it is crucial to test the 
function of select transporters in tissue pharmacokinetics of topically and systemically 
administered antiretroviral drugs. To address these research questions,  
 
 
We hypothesize that multiple efflux and uptake transporters are positively expressed in 
cervicovaginal tissues, colorectal tract, and immune cells, and their expression can be 
regulated by steroid hormones and cytokines. We further hypothesize that positively expressed 
efflux transporters play a role in tissue drug exposure, which can be reversed by transporter 
inhibitors. 
 
This hypothesis will be tested in the following three specific aims: 
 
Aim 1 will examine mRNA expression profiles of antiretroviral-relevant efflux and uptake 
transporters in human cervicovaginal and colorectal tissues. The transporter expression profile in 
animal and cell models used in PrEP testing will also be examined and compared to the 
expression patterns in human tissues. In addition, the effect of a panel of PrEP relevant factors on 
transporter expression will be evaluated using human tissues or preclinical models, including 
menopause, menstrual cycle, exogenous hormones, contraceptives, and proinflammatory 
cytokines. The results from Aim 1 will identify highly expressed transporters for further 
characterization at the levels of protein expression and functionality. 
 
Aim 2 will examine the protein expression of highly expressed transporters in cervicovaginal 
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tissues of human and animal models used in PrEP product testing, under the influence of PrEP 
relevant factors listed in Aim 1. The results generated in Aim 2 will confirm the mRNA results in 
Aim 1, and will provide valuable information for the design and interpretation of transporter 
function studies. 
 
Aim 3 will test the function of a select transporter in substrate distribution in tissues relevant to 
HIV-1 sexual transmission. According to the results generated from Aims 1 and 2, one 
transporter will be selected based on expression level, relevance to PrEP, and availability of 
research models for this particular transporter. The studies in this aim will provide proof of 
concept on transporter function in cervicovaginal and/or colorectal tissues, in a model utilized in 
PrEP product evaluations. 
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2 RNA EXPRESSION OF TRANSPORTERS IN TISSUES AND CELLS 
RELEVANT TO HIV-1 SEXUAL TRANSMISSION 
 
2.1 Introduction 
As discussed in Chapter 1, antiretroviral drug exposure in the tissues and cells relevant to HIV-1 
sexual transmission positively correlates with PrEP efficacy. It has been suggested that one of 
the goals of future PrEP clinical trials is to achieve maximally tolerable drug concentration in the 
female lower genital tract. Toward this goal, it is imperative to understand the expression, 
regulation, and function of drug transporters in cervicovaginal and colorectal tissues, as well as 
in the HIV-1 target immune cells. The knowledge generated from these studies will facilitate 
better understanding of differential drug distribution profiles of different antiretroviral drugs, as 
well as intra-individual and inter-individual variability in mucosal tissue drug pharmacokinetics. 
In addition, researchers could utilize this information to develop novel strategies to improve the 
exposure and efficacy of antiretroviral drugs in the mucosal tissues and immune cells.   
 
However, functional investigation of cervicovaginal transporters is hampered by a lack of 
systematic and detailed characterization of cervicovaginal transporters in both human and 
preclinical models used in PrEP testing. The transporters’ role in antiretroviral pharmacokinetics 
is complex. A lot of efflux and uptake transporters affect the absorption and disposition of 
antiretroviral drugs, and one drug may be the substrate of multiple transporters. For example, 
tenofovir, the most extensively studied drug candidate in topical microbicide development, is the 
substrate of two efflux transporters (MRP4, MRP7) and two uptake transporters (OAT1, OAT3). 
The human female lower genital tract is composed of endocervix, ectocervix and vagina, which 
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are anatomically and physiologically distinct from each other. In addition to female genital tract, 
the colorectal tissue is an even more vulnerable site of HIV-1 transmission, because it has single 
layer epithelium that is easily disrupted during sexual intercourse, and the submucosal immune 
cells are more enriched in colorectal tissue. Therefore, the expression analysis of a 
comprehensive panel of all the transporters relevant to antiretroviral drugs, in a tissue region-
specific manner, is needed prior to the functional characterization of transporter function and 
modulation in tissues.    
 
The aim of the studies described in this chapter was to examine the mRNA expression of efflux 
and uptake transporters in the cervicovaginal and colorectal tissues of human and animal models 
(macaque, rabbit, mouse), as well as in the cell lines derived from human cervicovaginal tissues 
(End1/E6E7, Ect1/E6E7, VK2/E6E7) and immune system (PM1). Since PrEP participants could 
encounter factors including contraceptives and local tissue inflammation, and these factors have 
been reported to affect transporter expression and activity in other tissues, we seek to examine 
the effect of these factors on transporter expression in transmission-related tissues and cells, 
using mouse model and cell lines derived from cervicovaginal tissues and immune system. Since 
nuclear receptors (NRs) are important mediators of transporter regulation, we examined the 
mRNA expression of 23 transporter-related NRs in human, macaque, and mouse tissues, to 
explain the observed effect of hormones/contraceptives/cytokines, to provide clues for the 
prediction of other factors that may regulate cervicovaginal transporters, and to provide a basis 
for multispecies comparison of transporter regulation mechanisms. The information revealed in 
this chapter will identify highly expressed transporters in the mucosal tissues and immune cells 
relevant to HIV-1 sexual transmission, under the conditions that are commonly encountered by 
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PrEP participants. This will in turn inform the prioritization of future functional characterization 
of transporters in these tissues and cells. 
 
2.2 Materials and Methods 
2.2.1 Procurement of human, macaque, and rabbit tissues 
All human tissues (endocervix, ectocervix, vagina, sigmoid colon, liver) were obtained through 
the Tissue Procurement Facility at University of Pittsburgh Medical Center under IRB approved 
protocols. The gender and age range of the tissue donors, and tissue usage information were 
summarized in Appendix. Human ectocervical tissues were obtained from pre- or 
postmenopausal women undergoing hysterectomy for benign conditions. Human vaginal tissues 
were collected from premenopausal women with vaginal prolapse. Female pigtailed macaque 
tissues (endocervix, ectocervix, vagina, colorectum, liver) were obtained from the Washington 
National Primate Research Center at the University of Washington, through the Tissue 
Distribution Program. The animals were maintained in accordance with the Animal Welfare Act 
and the Guide for the Care and Use of Laboratory Animals. The ages of the three macaques used 
in this study were 12.6, 18.7, 17.6 years. The rabbit tissues were obtained from euthanized New 
Zealand White rabbits, which were a kind gift from Dr. Eric Romanowski of the Eye & Ear 
Institute of University of Pittsburgh. The tissue collection was in line with the regulations of the 
Institutional Animal Care and Use Committee (IACUC) of University of Pittsburgh. The rabbits 
were 6-8 weeks old at the time of euthanasia. Before euthanasia, the rabbits were used for the 
testing of topical drug products for the treatment of eye infection. The infection and drug action 
were contained in the cornea, and these procedures exerted no systemic effect on the tissues 
collected for transporter study.  
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2.2.2 Collection of tissues from mice undergoing natural cycling or being synchronized with 
PMSG/Depo-Provera 
All animal procedures were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee (IACUC). Female Swiss Webster mice (6 weeks old, around 23 g body 
weight) were used for all mouse experiments. Tissues including uterus, endocervix, ectocervix, 
vagina, colorectum, and liver were collected under 4 conditions: estrus and diestrus stages in the 
natural estrous cycle, synchronized estrus stage, and synchronized diestrus stage. For the 
collection of tissues from mice undergoing natural estrous cycle, mouse estrous cycle stage was 
examined daily, and tissues were collected from euthanized mice when the estrus or diestrus 
stage was reached. Mouse estrous cycle stage was determined using vaginal cytology as 
described by Caligioni et al.
184
 The mouse vaginal lumen was injected with 20 µL of normal 
saline. The smear was taken out and evenly spread onto a glass slide and observed under a bright 
light microscope. The smear from proestrus stage predominantly consists of small nucleated 
epithelial cells. The smear from estrus stage is featured by the anucleated cornified epithelial 
cells which are much larger and darker than the cells found in the proestrus. The smear from 
metestrus stage consists of three types of cells: leukocytes, cornified, and nucleated epithelial 
cells. The smear from diestrus stage predominantly consisted of leukocytes. For the collection of 
mouse tissues under synchronization, mice were treated with pregnant mare's serum 
gonadotropin (PMSG, Sigma) or Depo-Provera (Pfizer Inc.), for the synchronization into estrus 
or diestrus stages, respectively. For PMSG treatment, mice were intraperitoneally (IP) injected at 
the dose of 5 IU per mouse (around 23 g). For Depo-Provera treatment, mice were 
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subcutaneously (SC) injected twice, on Day 1 and Day 5, at the dose of 3 mg per mouse. 
Synchronized estrus stage was reached 24 hours after PMSG administration, and the 
synchronized diestrus stage was reached 7 days after the first time injection of Depo-Provera. 
The estrous cycle stage of the synchronized mice was confirmed as described above, tissues were 
collected and stored at -80 °C until further analysis. For each of the 4 conditions, tissues were 
collected from at least 3 mice. 
 
2.2.3 Cell culture and treatment of contraceptives and cytokines 
End1/E6E7, Ect1/E6E7, VK2/E6E7, and PM1 cells were cultured as per the protocols 
recommended by American Type Culture Collection (ATCC), at 37 °C under 5% of carbon 
dioxide (CO2). For End1/E6E7, Ect1/E6E7, and VK2/E6E7 cells, the culture medium was 
keratinocyte-serum free medium (GIBCO-BRL 17005-042) with 0.1 ng/mL human recombinant 
EGF, 0.05 mg/mL bovine pituitary extract, an additional 44.1 mg/L calcium chloride (final 
concentration 0.4 mM). Antibiotic combination containing 50 IU/mL penicillin and 50 µg/mL 
streptomycin was also supplemented into the culture medium to prevent microbial contamination. 
For PM1 cells, the culture medium was RPMI 1640 with 10% fetal bovine serum and the 
supplementation of antibiotic combination containing penicillin and streptomycin. The 
End1/E6E7, Ect1/E6E7, and VK2/E6E7 cells were initially grown in culture flasks. After 60-
90% confluence was reached, the cells were detached using trypsin-EDTA, and diluted in the 
culture medium to reach the target density (5×10
5
 cells per well), followed by seeding onto 6-
well plates. The PM1 cells were always cultured in flasks. Cell treatment with contraceptives and 
cytokines was initiated when the End1/E6E7 and VK2/E6E7 reached 60-80% confluency, and 
when the PM1 cell density reached 1×10
6
 cells per mL. The stock solutions for MPA and P4 
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were prepared using EtOH, and the stock solutions for IL1β and IL8 were prepared using culture 
medium. To test the effect of contraceptives, the cells were treated with culture media containing 
MPA (1 µM) or P4 (1 µM) for 48 h. To test the effect of inflammation, the cells were treated 
with culture media containing IL1β (10 ng/mL) or IL8 (10 ng/mL) for 48 h. It has been reported 
that immediately after the dosing of Depo-Provera (containing 150 mg MPA) to patients, the 
initial plasma level was 1.7 ± 0.3 nmol/L. Two weeks later, the level was 6.8 ± 0.8 nmol/L 
(http://www.medicines.org.uk/emc/medicine/11121). These plasma concentrations corresponded 
to 1.7 - 6.8 × 10
-3
 µM, and the concentration of MPA in the preliminary testing reported in this 
chapter was above physiologic concentrations observed in clinical use of Depo-Provera. The 
concentrations of IL1β and IL8 were determined based on the levels of these two cytokines 
observed during bacterial vaginosis (BV) in human female reproductive tissues.
185-187
 Yudin et al. 
reported that the median cervical level of IL1β was 3.04 (0.01-22) ng/mL, and the median 
cervical level of IL8 was 54.72 (5-389) ng/mL, in 111 pregnant women with BV.
187
 Cauci et al. 
reported that median IL1β level in vaginal fluid was 0.77 (0.30-1.96) ng/mL, and the median IL8 
level was 3.37 (2.36-8.20) ng/mL, in 19 BV patients with high neutrophil count in their vaginal 
fluid.
185
 Imseis et al. reported the vaginal level of IL1β to be 3.36 ng/mL in BV patients.186 
Based on these reported levels, the test concentration was set at 10 ng/mL for both cytokines. 
The control cells were treated with vehicles that were used to dissolve the contraceptives or 
cytokines. The cells were then collected for RNA extraction and real-time RT-PCR analysis of 
transporter expression. 
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2.2.4 RNA extraction from tissues and cells and reverse transcription 
RNA of all the tissue and cell samples was extracted using TRIZOL (Invitrogen) as per the 
manufacturer’s instructions. For conventional RT-PCR, RNA was extracted from the epithelium 
and stroma of human ectocervical tissues, which were separated using hand microtome. For real-
time RT-PCR, RNA was extracted from whole tissue pieces which contained both epithelium 
and stroma in the same sample. For endocervix, ectocervix and vagina, 100-200 mg of tissue was 
used for each sample. For liver and colorectal tissue, 50-100 mg of tissue was used for each 
sample. The RNA was dissolved in DEPC-treated H2O, and the RNA quality and quantity were 
determined using NanoDrop with 2 µL of dissolved RNA samples. For conventional RT-PCR, 
the extracted RNA was directly used for reverse transcription using SuperScript III First-strand 
Synthesis Kit (Invitrogen Inc.). For real-time RT-PCR, the extracted RNA was subjected to 
DNase treatment to remove contaminating genomic DNA, using the Turbo DNase kit (Ambion), 
followed by reverse transcription using SuperScript III kit. The prepared complementary DNA 
(cDNA) samples were used immediately in PCR or stored in -20 °C freezer until use. 
 
2.2.5 Conventional RT-PCR of human tissues 
Conventional RT-PCR experiments were performed using cDNA samples from human tissues. 
Each tissue sample was collected from one patient. In RT-PCR of human efflux transporters 
(Figure 2.1), the ectocervix and vagina samples were collected from 7 and 5 patients, 
respectively. The epithelium and stroma of each tissue sample were separated using a hand 
microtome. For ectocervix, the epithelia from 7 patients were mixed to make pooled ectocervical 
epithelium, and the pooled stroma were made in the same manner. Pooled epithelia and stroma 
of ectocervix were then analyzed by RT-PCR, and occupied two lanes in the gel image (Figure 
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2.1). For vagina, the epithelium and stroma of each of the 5 vagina samples were individually 
analyzed by RT-PCR (Figure 2.1). In RT-PCR of human uptake transporters (Figure 2.2), the 
epithelia and stroma of each ectocervix or vagina were separated, and then mixed to make pooled 
ectocervical epithelium, ectocervical stroma, vaginal epithelium, and vaginal stroma, 
respectively (Figure 2.2). To quantitate the mRNA level, serially diluted liver cDNA was used as 
a standard, given the abundant expression of the drug transporters and metabolizing enzymes 
planned for examination in this study in the liver. Human liver tissue samples were obtained 
from 6 donors with mixed gender, and pooled for RNA extraction and RT-PCR. PCR was 
performed using the GoGreen Hot-start mastermix (Promega Inc.). The cDNA transcribed from 
50 ng of total RNA was used for all the cervicovaginal tissue samples, while the cDNA from 1, 5, 
25 ng total RNA were used for liver standards. Human β2-microglobulin served as the internal 
control. The PCR programs consist of a denaturation at 95 °C for 4 min, followed by 28 to 36 
cycles of 95 °C 30 sec, 60 °C 30 sec, and 72 °C 30 s. The cycle number for each gene was shown 
in the Figures 2.1 and 2.2. The final extension was set at 72 °C for 3 min. The PCR products 
were then analyzed using agarose gel electrophoresis, and gel pictures were captured by using 
the ChemiDoc™ MP imaging system (Biorad Inc.). The information of primer sequences used in 
conventional PCR were summarized in Table 2.1. 
 
Table 2.1 Primer information for conventional RT-PCR of human efflux and uptake 
transporters 
 
Common Gene 
name (Official gene 
symbol) 
GeneBank 
accession no. 
Primer sequence 5' to 3' Ref. 
P-gp (ABCB1) NM_000927 
Forward: CCCATCATTGCAATAGCAGG 188
 
Reverse: TGTTCAAACTTCTGCTCCTGA 
BCRP (ABCG2) NM_004827 
Forward: TGGCTGTCATGGCTTCAGTA 189
 
Reverse: GCCACGTGATTCTTCCACAA 
MRP1 (ABCC1) NM_004996 Forward: ATGTCACGTGGAATACCAGC 188 
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Reverse: GAAGACTGAACTCCCTTCCT 
MRP2 (ABCC2) NM_000392 
Forward: ACAGAGGCTGGTGGCAACC 188
 
Reverse: ACCATTACCTTGTCACTGTCCATGA 
MRP3 (ABCC3) NM_003786 
Forward: GGACTTCCAGTGCTCAGAGG 136
 
Reverse: AGCTGTGGCCTCGTCTAAAA 
MRP4 (ABCC4) NM_005845 
Forward: ATTATTGATGAAGCGACGGC 136
 
Reverse: GCAAAACATACGGCTCATCA 
MRP5 (ABCC5) NM_001023587 
Forward: CCTTTTCACTCCCTCCATCA 136
 
Reverse: ACAGGTCTTGGAGCTGGAGA 
MRP6 (ABCC6) NM_001171 
Forward: ATGAGCTTCGCAGTGTTCCT 136
 
Reverse: TAGGTAGGTGGACAGGTGGC 
MRP7 (ABCC10) NM_001198934 
Forward: GCTGGTGGGCTTGTCGCTGT 190 
Reverse: CTGGGGTTCCTGGGGCAGGT 
OAT1 (SLC22A6) NM_153277 
Forward: CCTTGATTGGCTATGTCTACAGC 190 
Reverse: TCCATACTCAATTTGGCTCCTTC 
OAT2 (SLC22A7) NM_006672 
Forward: CCCTTCCAACTGCGGAATGT 190
 
Reverse: CTGGGGATAGGCAAAGCGG 
OAT3 (SLC22A8) NM_004254 
Forward: AGCACCGTCATCTTGAATGTG 190
 
Reverse: AGGTGTAGCAGTACCCGAGTG 
 OCT1 (SLC22A1) NM_003057 
Forward: ACGGTGGCGATCATGTACC 190
 
Reverse: CCCATTCTTTTGAGCGATGTGG 
OCT2 (SLC22A2) NM_003058 
Forward: AGACAGTGTAGGCGCTACGA 190
 
Reverse: GTTAAACTCGGTGACGATGGAC 
OCT3 (SLC22A3) NM_021977 
Forward: ATCGTCAGCGAGTTTGACCTT 190
 
Reverse: ACCTGTCTGCTGCATAGCCTA 
CNT1 (SLC28A1) NM_004213 
Forward: CCTCACCTGTGTGGTCCTCA 190
 
Reverse: AGACCCCTCTTAAACCAGAGC 
ENT1 (SLC29A1) NM_001078176 
Forward: TGAGCGGAACTCTCTCAGTG 190
 
Reverse: TGAGGTAGGTGAATAACAGCAGG 
ENT2 (SLC29A2) NM_001532 
Forward: TCAGTGCAGTCCTACAGGG 190
 
Reverse: GGCGTGATAAAGTACCCCAGG 
ENT3 (SLC29A3) NM_001174098 
Forward: TTGAGAGCTACCTTGCCGTTG 190
 
Reverse: CAGTGCAGTTATCACCATGAAGA 
OATP-B (SLCO2B1) NM_001145211 
Forward: TTTGCCCACAACAGCAACTC 190
 
Reverse: TGGTTAATGTCCACATAAAGGCG 
OATP-D (SLCO3A1) NM_001145044 
Forward: GTTCCTGACCCACCAGTACAA 190
 
Reverse: CACAGGGGTAGCACCGATG 
OATP-E (SLCO4A1) NM_016354 
Forward: CTGCTCGCCCGTCTACATTG 190
 
Reverse: CCGAGGGTAACCAAGGATGG 
Human β2-
microglobulin 
NM_004048 
Forward: CCAGCAGAGAATGGAAAGTC 188
 
Reverse: CATGTCTCGATCCCACTTAAC 
 
P-gp, P-glycoprotein; BCRP, breast cancer resistance protein; MRP, multidrug resistance 
associated protein; OAT, organic anion transporters; OCT, organic cation transporter; CNT, 
concentrative nucleoside transporters; ENT, equilibrative nucleoside transporter; OATP, organic 
anion-transporting polypeptide. 
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2.2.6 Real-time RT-PCR 
Real-time RT-PCR was performed in a CFX Touch 96 instrument (Biorad) using Ssofast 
Evergreen mastermix (Biorad). The PCR program consisted of an initial denaturation of 95°C × 
30 s, and 40 cycles of 95°C × 5 s and 60°C × 5 s, followed by a melt curve analysis heating from 
65°C to 95°C with 0.5 °C increments. The primer information for transporters and internal 
control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) of human, macaque, rabbit, and 
mouse are listed in Tables 2.2 to 2.4. For many primer pairs obtained from online databases 
(Tables 2.2 to 2.4), the product size has been confirmed by other researchers. Some of the 
primers used in real-time PCR of human transporters were previously used in conventional PCR, 
including the primer pairs for ABCB1 (P-gp), ABCC5 (MRP5), ABCC10 (MRP7), SLC22A6 
(OAT1), SLC22A8 (OAT3), SLC22A2 (OCT2) and SLC29A1 (ENT1). The size of the 
amplification products using these primers has also been confirmed in the conventional RT-PCR 
electrophoresis. The primer sequences for nuclear receptors (NRs) of human and mouse are 
listed in Tables 2.5 and 2.6. The primers for human genes were also used to detect macaque 
transporters, NRs, and GAPDH, due to the high sequence similarity between human and 
macaque in these genes. The efficiency of PCR reactions was confirmed using the relative 
standard curve method with serially diluted liver or colon cDNA. The mRNA levels of 
transporters were normalized to that of GAPDH using the 2
-ΔCt 
method, for the comparison of 
transporter levels across different tissues. 
 
Table 2.2 Primer information for real-time RT-PCR of transporters and GAPDH in human 
and macaque tissues. 
Common Gene 
name (Official gene 
symbol) 
GeneBank 
accession no. 
Primer sequence 5' to 3' Ref. 
P-gp (ABCB1) NM_000927 
Forward: CCCATCATTGCAATAGCAGG 188 
Reverse: TGTTCAAACTTCTGCTCCTGA 
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Ref., references. 
 
 
Table 2.3 Primer information for real-time RT-PCR of transporters and Gapdh in rabbit 
tissues. 
Ref., references. 
 
Table 2.4 Primer information for real-time RT-PCR of transporters and Gapdh in mouse 
tissues. 
BCRP (ABCG2) 
 
NM_004827 
Forward: CAGGTCTGTTGGTCAATCTCACA 122
 
Reverse: TCCATATCGTGGAATGCTGAAG 
MRP4 (ABCC4) NM_005845 
Forward: AAGTGAACAACCTCCAGTTCCAG 136
 
Reverse: GGCTCTCCAGAGCACCATCT 
MRP5 (ABCC5) NM_001023587 
Forward: CCTTTTCACTCCCTCCATCA 136
 
Reverse: ACAGGTCTTGGAGCTGGAGA 
MRP7 (ABCC10) NM_001198934 
Forward: GCTGGTGGGCTTGTCGCTGT 190 
Reverse: CTGGGGTTCCTGGGGCAGGT 
OAT1 (SLC22A6) NM_153277 
Forward: CCTTGATTGGCTATGTCTACAGC 190 
Reverse: TCCATACTCAATTTGGCTCCTTC 
OAT3 (SLC22A8) NM_004254 
Forward: AGCACCGTCATCTTGAATGTG 190 
Reverse: AGGTGTAGCAGTACCCGAGTG 
OCT2 (SLC22A2) NM_003058 
Forward: AGACAGTGTAGGCGCTACGA 190 
Reverse: GTTAAACTCGGTGACGATGGAC 
ENT1 (SLC29A1) NM_001078176 
Forward: TGAGCGGAACTCTCTCAGTG 190 
Reverse: TGAGGTAGGTGAATAACAGCAGG 
GAPDH NM_001256799 
Forward: GGAGCGAGATCCCTCCAAAAT 190
 
Reverse: GGCTGTTGTCATACTTCTCATGG 
Common Gene 
name (Official 
gene symbol) 
GeneBank 
accession no. 
Primer sequence 5' to 3' Ref. 
P-gp (Abcb1) AY360144 
Forward: CCGGAACAGTGCTATTGGAT 191
 
Reverse: GATGCTGCAGTCAAACAGGA 
BCRP (Abcg2) XM_002716965 
Forward: GCTCATTACGGATCCTTCCA 191
 
Reverse: GGAATACCGAGGCTGATGAA 
MRP4 (Abcc4) XM_002713003 
Forward: GATCTTCCTGGCAAAATGGA 191
 
Reverse: ACCAATTGTCTCTGCCCAAC 
MRP5 (Abcc5) XM_002716488 
Forward: TGTCTACATCCAGGCTGCTG 191
 
Reverse: TCGAGTCACTGTGCTGTTCC 
MRP7 (Abcc10) XM_002714691 
Forward: CTGAGCCATGGTCTGCTGTA 191
 
Reverse: GGGTCACCTTCCGTAACTCA 
OAT1 (Slc22a6) AJ242871 
Forward: AAGCTTGTGTGCTTCCTCGT 191
 
Reverse: GACAACCCTTTCCCAGAACA 
OAT3 (Slc22a8) AF533644 
Forward: TCTCCCCACTGGTGAAAATC 191
 
Reverse: GGCGACAGTCCCGTAGATAA 
Gapdh NM_001082253 
Forward: ATCACTGCCACCCAGAAGAC 191
 
Reverse: GTGAGTTTCCCGTTCAGCTC 
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Ref., references. 
 
 
Table 2.5 Information of the primers used for the real-time RT-PCR of nuclear receptors 
(NRs) in human and macaque tissues.  
Common Gene 
name (Official 
gene symbol) 
GeneBank 
accession no. 
Primer sequence 5' to 3' Ref. 
P-gp (Abcb1a) NM_011076 
Forward: CCATCAGCCCTGTTCTTGGAC 190
 
Reverse: TCCCCAGCCTTTTAGCTTCTT 
P-gp (Abcb1b) NM_011075 
Forward:  CTGTTGGCGTATTTGGGATGT 190
 
Reverse:  CAGCATCAAGAGGGGAAGTAATG 
Bcrp (Abcg2) 
 
NM_011920 
Forward: AAATGCTGTTCAGGTTATGTGGT 190
 
Reverse: TCCGACCTTAGAATCTGCTACTT 
Mrp4 (Abcc4) NM_001033336 
Forward: GTGCGACAGAGCGCCGAAGT 190
 
Reverse: CTGGGGGTGGGCGCTTCTTG 
Mrp5 (Abcc5) NM_176839 
Forward: AGGGGGAGCTGTTAATGGAG 190
 
Reverse: GTCAGAACTTACTGGTCCACTG 
Mrp7 (Abcc10) NM_170680 
Forward: ATTGCCAGCGAGGTACATTTC 190
 
Reverse: GTGCCAACCAGGCATAGGAA 
Oat1 (Slc22a6) NM_008766 
Forward:  CTGATGGCTTCCCACAACAC 190
 
Reverse:  GTCCTTGCTTGTCCAGGGG 
Oat3 (Slc22a8) NM_031194 
Forward:  ATGACCTTCTCCGAGATTCTGG 190
 
Reverse:  GTGGTTGGCTATTCCGAGGAT 
Gapdh NM_008084 
Forward:  GCCCAGAACATCATCCCTGC 192
 
Reverse:  CCGTTCAGCTCTGGGATGACC 
Common 
Gene 
name 
GeneBank accession 
number 
Primer sequences 5' to 3' Ref. 
PXR NM_022002 
Forward: GGCCACTGGCTATCACTTCAA 193
 
Reverse: TTCATGGCCCTCCTGAAAA 
CAR NM_001077474 
Forward: GATGCTGGCATGAGGAAAGAC 190
 
Reverse: TTGCTCCTTACTCAGTTGCAC 
VDR NM_001017536 
Forward: TCTCCAATCTGGATCTGAGTGAA 190
 
Reverse: GGATGCTGTAACTGACCAGGT 
PPAR-α NM_005036 
Forward: ATGGTGGACACGGAAAGCC 190
 
Reverse: CGATGGATTGCGAAATCTCTTGG 
PPAR-β NM_177435 
Forward: TCACACAGTGGCTTCTGCTC 194
 
Reverse: TGAACGCAGATGGACCTCTA 
PPAR-γ NM_138711 
Forward: AAGGCCATTTTCTCAAACGA 194
 
Reverse: GAGAGATCCACGGAGCTGAT  
ER-α NM_000125  
Forward: ATGATCAACTGGGCGAAGAG 194
 
Reverse: CAGGATCTCTAGCCAGGCAC 
ER-β NM_001214902 Forward: TCCATCGCCAGTTATCACATCT 190 
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PXR: pregnane X receptor; CAR: Constitutive androstane receptor; VDR: Vitamin D receptor; 
PPAR: Peroxisome proliferator-activated receptor; ER: Estrogen receptor; PR: Progesterone 
receptor; AR: Androgen receptor; GR: Glucocorticoid receptor; MR: Mineralocorticoid receptor; 
RAR: Retinoic acid receptor; RXR: Retinoid X receptor; ROR: RAR-related orphan receptor; 
Nrf2: Nuclear factor (erythroid-derived 2)-like 2; AhR: Aryl hydrocarbon receptor. Ref., 
references. 
 
 
Table 2.6 Information of the primers used for the real-time RT-PCR of nuclear receptors 
(NRs) in mouse tissues. 
Reverse: CTGGACCAGTAACAGGGCTG 
PR M15716 
Forward: GTCAGTGGGCAGATGCTGTA 191
 
Reverse: TGCCACATGGTAAGGCATAA 
AR NM_000044 
Forward: TTGTGTCAAAAGCGAAATGG 194
 
Reverse: AGTCAATGGGCAAAACATGG 
GR NM_001204264 
Forward: ACAGCATCCCTTTCTCAACAG 190
 
Reverse: AGATCCTTGGCACCTATTCCAAT 
MR NM_000901 
Forward: GAAGTGATGGGTATCCGGTC 194
 
Reverse: TTTGAAGGTCTTGAAGATCCAG 
RAR-α NM_000964 
Forward: AAGCCCGAGTGCTCTGAGA 190
 
Reverse: TTCGTAGTGTATTTGCCCAGC 
RAR-β NM_000965 
Forward: TCCAGAAGTGCTTTGAAGTGG 194
 
Reverse: CTCTGTGCATTCTTGCTTCG 
RAR-γ NM_000966 
Forward: TTTCGAGATGCTGAGCCCTA 194
 
Reverse: TCTGAGCTGGTGCTCTGTGT 
RXR-α NM_002957 
Forward: GACGGAGCTTGTGTCCAAGAT 190
 
Reverse: AGTCAGGGTTAAAGAGGACGAT 
RXR-β NM_021976  
Forward: ACGGCTATGTGCAATCTGC 190
 
Reverse: CGGATGGTGCGTTTGAAGAA 
RXR-γ NM_006917 
Forward: GGAGAGGAACATGAACTGACG 194
 
Reverse: ATGGATGTAGAGCCAGTGTGG 
ROR-α NM_134261  
Forward: ACTCCTGTCCTCGTCAGAAGA 190
 
Reverse: CATCCCTACGGCAAGGCATTT 
ROR-β NM_006914  
Forward: CTGGGAGCAGCTTCATGACT 194
 
Reverse: ATCCCAGAGGACTTATCGCC 
ROR-γ NM_001001523  
Forward: CTGCTGAGAAGGACAGGGAG 194
 
Reverse: CGACTTGTCCCCACAGATTT 
Nrf2 NM_006164  
Forward: ACACGGTCCACAGCTCATC 194
 
Reverse: TCTTGCCTCCAAAGTATGTCAA 
AhR NM_001621  
Forward: TCAGTTCTTAGGCTCAGCGTC 194
 
Reverse: AGTTATCCTGGCCTCCGTTT 
Common Gene 
name 
GeneBank 
accession 
number 
Primer sequences 5' to 3' Ref. 
Mouse PXR NM_010936 Forward: GATGGAGGTCTTCAAATCTGCC 
190
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Reverse: CAGCCGGACATTGCGTTTC 
Mouse CAR NM_001243062 
Forward: TTCAAGCCTCCGGCCTATCT 190
 
Reverse: TGATCTGTTGCACCATAAACGTG 
Mouse VDR NM_009504 
Forward: ACCCTGGTGACTTTGACCG 190
 
Reverse: GGCAATCTCCATTGAAGGGG 
Mouse PPAR-α NM_011144 
Forward: AGAGCCCCATCTGTCCTCTC 190
 
Reverse: ACTGGTAGTCTGCAAAACCAAA 
Mouse PPAR-β NM_011145 
Forward: TCCATCGTCAACAAAGACGGG 190
 
Reverse: ACTTGGGCTCAATGATGTCAC 
Mouse PPAR-γ NM_001127330 
Forward: GGAAGACCACTCGCATTCCTT 190
 
Reverse: GTAATCAGCAACCATTGGGTCA 
Mouse ER-α NM_007956 
Forward: CCTCCCGCCTTCTACAGGT 190
 
Reverse: CACACGGCACAGTAGCGAG 
Mouse ER-β NM_010157 
Forward: CTGTGATGAACTACAGTGTTCCC 190
 
Reverse: CACATTTGGGCTTGCAGTCTG 
Mouse PR NM_008829 
Forward: CTCCGGGACCGAACAGAGT 190
 
Reverse: ACAACAACCCTTTGGTAGCAG 
Mouse AR NM_013476 
Forward: CTGGGAAGGGTCTACCCAC 190
 
Reverse: GGTGCTATGTTAGCGGCCTC 
Mouse GR NM_008173 
Forward: AGCTCCCCCTGGTAGAGAC 190
 
Reverse: GGTGAAGACGCAGAAACCTTG 
Mouse MR NM_001083906 
Forward: GAAAGGCGCTGGAGTCAAGT 190
 
Reverse: TGTTCGGAGTAGCACCGGAA 
Mouse RAR-α NM_009024 
Forward: TTCTTTCCCCCTATGCTGGGT 190
 
Reverse: GGGAGGGCTGGGTACTATCTC 
Mouse RAR-β NM_011243 
Forward: CTGCTCAATCCATCGAGACAC 190
 
Reverse: CTTGTCCTGGCAAACGAAGC 
Mouse RAR-γ NM_001042727 
Forward: ATGTACGACTGCATGGAATCG 190
 
Reverse: CCAGTGGCTCTGCGTAGTAA 
Mouse RXR-α NM_011305 
Forward: ATGGACACCAAACATTTCCTGC 190
 
Reverse: CCAGTGGAGAGCCGATTCC 
Mouse RXR-β NM_011306 
Forward: CCACCTCTTACCCCTTCAGC 190
 
Reverse: TGGAAGAACTGATGACTGGGA 
Mouse RXR-γ NM_009107 
Forward: CATGAGCCCTTCAGTAGCCTT 190
 
Reverse: CGGAGAGCCAAGAGCATTGAG 
Mouse ROR-α NM_013646 
Forward: GTGGAGACAAATCGTCAGGAAT 190
 
Reverse: TGGTCCGATCAATCAAACAGTTC 
Mouse ROR-β NM_146095 
Forward: GCAGCATTAGCAATGGCCTC 190
 
Reverse: GACGGCTGACCGGAATCTATG 
Mouse ROR-γ NM_011281 
Forward: GACCCACACCTCACAAATTGA 190
 
Reverse: AGTAGGCCACATTACACTGCT 
Mouse Nrf2 NM_010902 
Forward: TAGATGACCATGAGTCGCTTGC 190
 
Reverse: GCCAAACTTGCTCCATGTCC 
Mouse AhR NM_013464 
Forward: AGCCGGTGCAGAAAACAGTAA 190
 
Reverse: AGGCGGTCTAACTCTGTGTTC 
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2.2.7 Statistical methods 
Statistical analyses were conducted using the GraphPad Prism software. One way analysis of 
variance (ANOVA) with Bonferroni post-hoc test was used to compare the mRNA level of a 
given transporter across different tissue types in a species. P < 0.05 was considered as 
statistically significant, and P < 0.01 was considered as very significant. 
 
2.3 Results 
2.3.1 Conventional RT-PCR screening of efflux and uptake transporters in human 
cervicovaginal tissues 
Since the transporter expression profile remains largely unknown for human cervicovaginal 
tissues, conventional RT-PCR was used to quickly screen the transporters most relevant to 
antiretroviral drug pharmacokinetics. Nine of the efflux transporters from the ABC superfamily 
were examined and the results were summarized in Table 2.7. The liver samples had highest 
expression of MRP2, MRP3 and MRP6, followed by P-gp, BCRP, MRP1, MRP5, MRP5 and 
MRP7 with moderate or low expression level. Compared to the liver, P-gp, BCRP, MRP1, 
MRP4, MRP5 and MRP7 were moderately or highly expressed efflux transporters in human 
cervicovaginal tissues. Inter-individual difference in the expression level of P-gp, BCRP, MRP1, 
MRP4 and MRP7 was observed. The expression level of P-gp, BCRP, and MRP4 appeared to be 
different between epithelium and stroma. Ectocervical MRP1 and MRP4 level appeared to be 
higher than those in vagina (Figure 2.1). Thirteen uptake transporters were examined, including 
10 from the SLC superfamily and 3 from the SLCO superfamily.  
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Figure 2.1 Conventional RT-PCR screening of efflux transporters in human cervicovaginal 
tissues. 
Lanes 1 and 2: ectocervical epithelium and stroma pooled from 7 patients. Lanes 3-7: vaginal 
epithelium from 5 individual patients. Lanes 8-12: vaginal stroma from the same 5 patients. Fifty 
ng cDNA for each sample was loaded for PCR. Lanes 13-15: serially diluted standards including 
human liver cDNA transcribed from 1, 5, 25 ng of liver total RNA, which was extracted from 
liver samples pooled from 6 donors. PCR cycle numbers are indicated in the parentheses. β2-
microglobulin (β2mg) was used as internal control to indicate cDNA loading in PCR. 
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Table 2.7 Summary of efflux transporters expression in human cervicovaginal tissues. 
  
Transporter 
Human transporter level  
(% of human liver) 
Human ectocervix Human vagina 
P-gp (ABCB1) ++ ++ 
BCRP (ABCG2) +++ +++ 
MRP1 (ABCC1) ++++ +++ 
MRP2 (ABCC2) - - 
MRP3 (ABCC3) - - 
MRP4 (ABCC4) ++++ +++ 
MRP5 (ABCC5) ++++ ++++ 
MRP6 (ABCC6) - - 
MRP7 (ABCC10) ++++ ++++ 
 
The density of PCR bands generated from ectocervix and vagina cDNA were compared to the 
bands generated from liver cDNA, and the expression levels of efflux transporters relative to 
liver levels were summarized in the table above. -, ≤2% or undetectable; +, means 2-10%, ++, 
10-50%; +++, 50-100%; ++++, >>100%. The corresponding gel images were shown in Figure 
2.1. 
 
 
Among all the tested uptake transporters, SLC22A7 (OAT2), SLC22A2 (OCT2), SLC22A3 
(OCT3), SLC29A1 (ENT1), SLCO3A1 (OATP-D) and SLCO4A1 (OATP-E) were the most 
highly expressed compared to their expression in liver. The discrepancy in the expression level 
was observed for SLC22A7 (OAT2), SLC22A2 (OCT2), SLC22A3 (OCT3), SLC29A1 (ENT1) 
and SLCO3A1 (OATP-D) between epithelium and stroma in ectocervix. The discrepant 
expression was also observed for OCT3 and OATP-E between epithelium and stroma in vagina 
(Figure 2.2). Results were summarized in Table 2.8. 
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Figure 2.2 Conventional RT-PCR screening of uptake transporters in human 
cervicovaginal tissues 
Lanes 1 and 2: ectocervical epithelium and stroma pooled from 7 patients. Lanes 3 and 4: vaginal 
epithelium and stroma pooled from 5 patients. Lanes 5-7: serially diluted pooled human liver 
cDNA transcribed from 1, 5, 25 ng of total RNA. The cDNA loading is 50 ng for cervicovaginal 
tissue samples (Lanes 1-4), and 1, 5, 25 ng for liver standards (Lanes 5-7). PCR cycle numbers 
are indicated in the parentheses. 
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Table 2.8 Summary of uptake transporters expression in human cervicovaginal tissues.  
 
Transporter 
Human transporter level  
(% of human liver) 
 Human ectocervix Human vagina 
OAT1 (SLC22A6) - - 
OAT2 (SLC22A7) ++ ++ 
OAT3 (SLC22A8) - - 
OCT1 (SLC22A1) - - 
OCT2 (SLC22A2) ++++ ++++ 
OCT3 (SLC22A3) ++ + 
ENT1 (SLC29A1) +++ +++ 
ENT2 (SLC29A2) - - 
ENT3 (SLC29A3) - - 
CNT1 (SLC28A1) - - 
OATP-B (SLCO2B1) - - 
OATP-D (SLCO3A1) ++++ ++++ 
OATP-E (SLCO4A1) ++ ++ 
 
The density of PCR bands generated from ectocervix and vagina cDNA were compared to the 
bands generated from liver cDNA, and the expression levels of efflux transporters relative to 
liver levels were summarized in the table above. -,  ≤2% or undetectable; +, means 2-10%, ++, 
10-50%; +++, 50-100%; ++++, >>100%. The corresponding gel images were shown in Figure 
2.2. 
 
 
2.3.2 Real-time RT-PCR examination of mRNA levels of a select panel of transporters in 
human cervicovaginal and colorectal tissues 
To confirm the conventional RT-PCR results, and quantitatively compare transporter expression 
across different tissues, real-time PCR was conducted to examine mRNA levels of the most 
highly expressed and most relevant transporters identified in conventional PCR (P-gp, BCRP, 
MRP4, 5, 7, OAT1, 3, OCT2, ENT1). The general tendency of transporter expression found in 
human lower genital tract and colorectal tissue was that P-gp, BCRP, MRP4, 5, 7 and ENT1 
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were moderately to highly expressed compared to GAPDH in cervicovaginal and colorectal 
tissues (between 1/1000 and 1/10 of GAPDH level), and compared to the transporter levels in the 
positive control tissue human liver (Figure 2.3). On the contrary, OAT1, OAT3 and OCT2 were 
not detectable (data not shown). These results were generally in line with the conventional PCR 
results except OCT2.  
 
 
Figure 2.3 Real-time RT-PCR analysis of a select panel of transporters in human 
cervicovaginal and colorectal tissues 
The expression in endocervix, ectocervix, vagina, sigmoid colon and liver were examined in 
tissues from 4-6 human donors (Endocervix, 4 donors; ectocervix, 6 donors; vagina, 5 donors; 
sigmoid colon, 5 donors; liver, 6 donors). Only one tissue sample was obtained from each donor, 
and a small piece (50-200 mg) cut from each tissue sample was used for RNA extraction and RT-
PCR analysis. The threshold cycle numbers (Ct) of transporters and GAPDH of each sample 
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were measured in triplicate, and the average Ct was used to reflect the Ct of a tested transporter 
or GAPDH in this sample. The GAPDH-normalized transporter levels (generated using 2
-ΔCt
 
method) in different tissues were plotted in the figure shown above. the GAPDH-normalized 
transporter expression levels in genital tract and colorectal tissues relative to the GAPDH-
normalized transporter expression levels in human liver were summarized in the table. The data 
shown represent mean ± standard deviation of all samples in a given group. 
 
 
Statistical analyses were conducted to compare the expression of each transporter across 
different types of human tissues. Each of the genital tract tissues (endocervix, ectocervix, vagina) 
displayed several fold lower (statistically significant) expression level in P-gp compared to the 
sigmoid colon, but there was no difference between genital tract tissues and liver in P-gp 
expression (Figure 2.3). Sigmoid colon displayed several fold higher P-gp level compared to 
liver (p < 0.01). Within human lower genital tract, P-gp expression was highest in ectocervix, 
followed by endocervix and vagina, but there was no significant difference among these three 
tissue types (Figure 2.3).  
 
For BCRP, there was no difference between genital tract tissues and colorectal/liver tissues. The 
colorectal BCRP level was significantly higher than the liver level (p < 0.05). Within the genital 
tract, human BCRP expression was highest in endocervix, followed by ectocervix and vagina, 
and there was a significant difference between endocervix and vagina (p < 0.01) (Figure 2.3).  
 
For MRP4, the mRNA levels in human endocervix and ectocervix were found to be significantly 
higher than human liver level (p < 0.001 and p < 0.01, respectively). However, no difference 
existed between genital tract and colon. Within the genital tract, the human MRP4 expression in 
endocervix and ectocervix were similar, while vaginal MRP4 level was significantly lower than 
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the endocervical level (p < 0.001). The colorectal MRP4 level was significantly higher than the 
liver level (p < 0.001).  
For MRP5, no statistical difference was found between genital tract tissues, colorectal tissue, and 
liver. For MRP7, the ectocervical level was significantly higher than the colon (p = 0.05) and 
liver (p < 0.01), but there was no difference between other pairs of tissue types. For ENT1, the 
endocervical level was significantly higher than the liver level (p < 0.05) and vaginal level (p = 
0.05), while there was no significant difference between any other pair of tissue types. 
 
For each transporter, the GAPDH-normalized mRNA levels in human cervicovaginal and 
colorectal tissues were divided by the average of GAPDH-normalized transporter level in human 
liver, and the results were shown in the table embedded in Figure 2.3. It should be noticed that 
healthy human liver has low level of MRP4 gene expression, although the expression can be 
profoundly up-regulated by the treatment of toxicants.
195,196
 Therefore, cervicovaginal and 
colorectal tissue MRP4 was expressed at moderate level compared to GAPDH (>1/1000 of 
GAPDH), but when normalizing these levels to the MRP4 level in healthy liver, high ratios 
could be obtained. The function of MRP4 in cervicovaginal and colorectal tissues cannot be 
assumed from these high ratios, and should be experimentally confirmed.  
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Figure 2.4 Effect of menopause on the mRNA expression of transporters in human 
ectocervix. 
GAPDH-normalized transporter expression levels were compared between premenopausal and 
postmenopausal human ectocervix tissues. Tissues were collected from 12 patients (6 
premenopausal and 6 postmenopausal women). For each transporter tested, the GAPDH-
normalized transporter levels from the 6 donors in the postmenopausal group were compared 
with the average of GAPDH-normalized transporter levels in the premenopausal group. The 
postmenopausal/premenopausal ratios (mean ± standard deviation) were plotted above. 
 
 
The effect of menopause on transporter mRNA expression was examined by comparing 
transporter levels in pre- and postmenopausal human ectocervix (Figure 2.4). Although MRP5 
level was approximately 8-fold higher in postmenopausal tissues, no significant difference was 
found for MRP5 or another transporter examined, due to large inter-individual variability in 
MRP5 mRNA levels. 
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2.3.3 Real-time RT-PCR examination of mRNA levels of a select panel of transporters in 
pigtailed macaque cervicovaginal and colorectal tissues 
The same panel of transporters was examined in pigtailed macaque tissues. In macaques, the six 
transporters were also moderately to highly expressed in endocervix, ectocervix, vagina, and 
colorectum compared to macaque liver levels (Figure 2.5). OAT1 and OAT3 were also examined 
in macaque tissues but were not detectable by real-time RT-PCR. For each of the transporters 
examined in macaque, there was no significant difference in transporter mRNA level among 
endocervix, ectocervix and vagina, colorectum, nor was there any significant difference between 
these tissues and positive control tissue (liver), although the MRP4, MRP5 and MRP7 levels in 
these tissues were several times higher than the corresponding liver levels (Figure 2.5). For each 
transporter, the GAPDH-normalized mRNA levels in macaque cervicovaginal and colorectal 
tissues were divided by the average of GAPDH-normalized transporter level in macaque liver, 
and the results were shown in the table embedded in Figure 2.5. 
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Figure 2.5 Real-time RT-PCR analysis of a select panel of transporters in macaque 
cervicovaginal and colorectal tissues 
The expression in endocervix, ectocervix, vagina, colorectum and liver were examined in tissues 
from 3 macaques. For each macaque, all the 5 kinds of tissues were collected. A small piece (50-
200 mg) cut from each tissue sample was used for RNA extraction and RT-PCR analysis. The 
threshold cycle numbers (Ct) of transporters and Gapdh of each sample were measured in 
triplicate, and the average Ct was used to reflect the Ct of transporter or Gapdh in this sample. 
The Gapdh-normalized transporter levels (generated using 2
-ΔCt
 method) in different tissues were 
plotted in the figure shown above. The Gapdh-normalized transporter expression levels in genital 
tract and colorectal tissues relative to the Gapdh-normalized transporter expression levels in 
macaque liver were summarized in the table. The data shown represent mean ± standard 
deviation of all samples in a given group.  
 
Overall, P-gp, BCRP, MRP4,5,7 and ENT1 were moderately to highly expressed at the mRNA 
level in the lower genital tract and colorectal tissues of humans and macaques, compared to 
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macaque Gapdh in corresponding tissues (between 1/1000 and 1/10 of GAPDH level), and 
compared to the transporter levels in macaque liver. Oat1, Oat3, and Oct2 were not detectable in 
all kinds of macaque tissues tested (data not shown). The cervicovaginal and colorectal 
expression patterns of these transporters were generally comparable between human and 
macaque (Figures 2.3 and 2.5). 
 
2.3.4 Real-time RT-PCR examination of mRNA levels of a select panel of transporters in rabbit 
cervicovaginal and colorectal tissues 
 
Figure 2.6 Real-time RT-PCR analysis of a select panel of transporters in rabbit 
cervicovaginal and colorectal tissues. 
The expression in uterus, cervix, vagina, colorectum and liver were examined in tissues from 3-7 
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rabbits (uterus, cervix and liver were collected from 3 rabbits; colorectum was collected from 6 
rabbits; vagina was collected from 7 rabbits). For each rabbit, all the 5 kinds of tissues were 
collected. For vagina, colorectum and liver, a small piece (50-200 mg) cut from each tissue 
sample was used for RNA extraction and RT-PCR analysis. For uterus and cervix, whole tissue 
samples were used for analysis. Rabbit endocervix and ectocervix were difficult to distinguish, 
therefore the rabbit genital tract part connecting vagina and uterine horns was obtained to 
represent the whole cervix. The uterine horn adjacent to cervix was obtained to represent the 
tissue similar to endocervix. The threshold cycle numbers (Ct) of transporters and Gapdh of each 
sample were measured in triplicate, and the average Ct was used to reflect the Ct of transporter 
or Gapdh in this sample. The Gapdh-normalized transporter levels (generated using 2
-ΔCt
 method) 
in different tissues were plotted in the figure shown above. the Gapdh-normalized transporter 
expression levels in genital tract and colorectal tissues relative to the Gapdh-normalized 
transporter expression levels in rabbit liver were summarized in the table. The data shown 
represent mean ± standard deviation of all samples in a given group.  
 
The New Zealand White rabbit is widely used to evaluate the safety of vaginally or rectally 
administered microbicides.
197
 Since the safety/toxicity of drug products depends on drug 
pharmacokinetics in the tissues, it is necessary to examine transporter expression pattern in rabbit 
tissues in comparison to human. The anatomy of rabbit lower genital tract is quite different from 
that of human and macaque. In human and macaque, the endocervix is lined with single-layer 
epithelium, while the ectocervix and vaginal tissues are lined with stratified, squamous epithelial 
cells. However, in rabbit genital tract, the upper and lower genital tracts are lined with single-
layer columnar epithelium, and the endocervix and ectocervix were not readily distinguishable. 
Therefore, rabbit uterus close to the lower genital tract was used in rabbit tissue characterization, 
to represent the most distal region that can be reached by male ejaculation in rabbit genital tract.   
 
The expression of 5 efflux transporters (P-gp, Bcrp, Mrp4, 5, 7) most relevant to antiretroviral 
drugs were examined in rabbit tissues. In rabbits, the five transporters were also moderately to 
highly expressed in uterus, cervix, vagina, and colorectum compared to rabbit Gapdh in 
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corresponding tissues, and compared to rabbit liver transporter levels (Figure 2.6). OAT1 and 
OAT3 were also examined in these tissues but were not detectable by real-time RT-PCR. 
 
For each transporter, the Gapdh-normalized mRNA levels in rabbit cervicovaginal and colorectal 
tissues were divided by the average of Gapdh-normalized transporter level in rabbit liver, and the 
results were shown in the table embedded in Figure 2.6. Overall, the liver-normalized transporter 
mRNA levels in rabbit genital tract and colorectum appear to be lower than those normalized 
levels in human and macaque. For P-gp, the mRNA level in rabbit uterus, cervix and vagina 
were significantly lower than liver level. For BCRP, the cervix, vagina and colorectum levels 
were significantly lower than the liver level.  
 
2.3.5 Real-time RT-PCR examination of mRNA levels of a select panel of transporters in 
mouse tissues 
The mRNA levels of P-gp, Bcrp, Mrp4, 5, 7, Oat1 and Oat3 were also examined in Swiss 
Webster mice undergoing natural estrous cycling, or treated with PMSG/Depo-Provera for 
estrous stage synchronization.  
 
As shown in Figure 2.7, the stages of mouse estrous cycle could be clearly identified by 
observing mouse vaginal smears under a regular bright light microscope. Small nucleated 
epithelial cells constituted the major cell type in the smear from proestrus stage. Extensive 
amount of anucleated cornified epithelial cells could be readily observed in the smear collected 
at estrus stage. Three types of cells, leukocytes, cornified, and nucleated epithelial cells could be 
found in the smear collected at metestrus stage. A lot of leukocytes could be observed as the 
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predominant cell type in the smear collected at the diestrus stage. The vaginal smear collected 
from PMSG-treated mice was very similar to the smear collected at natural estrus stage. The 
smear collected from Depo-Provera treated mice was very similar to the smear collected at 
natural diestrus stage.  
 
Figure 2.7 Vaginal cytology of mice undergoing natural estrous cycling or synchronized 
with PMSG/Depo-Provera.  
At different stages of mouse estrus cycle, or after the synchronization with PMSG or Depo-
Provera, vaginal smear samples were collected using 20 µL of saline. Five µL of the smear was 
spread on a glass slide and observed using bright light microscope. Magnification, 20 × for all 
pictures. The pictures shown are representative of the vaginal smear observations from more than 
3 mice. 
 
The effects of estrous cycle and exogenous treatments on cervicovaginal tissue morphology were 
demonstrated in Figure 2.8. During natural estrous cycle, the endocervical epithelium was a 
single-layer columnar cells at both estrus and diestrus stages. However, the thickness of 
ectocervical and vaginal epithelia underwent cyclic changes during the natural cycle. The 
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epithelial layers of these two tissue segments were obviously thinner at diestrus compared to 
estrus stage. This effect is due to the cyclic change of estrogens and progesterone during the 
estrous cycle. Estrogens increase the epithelial thickness while progesterone exerts the opposite 
effects.  
 
After PMSG treatment, the epithelial layers of mouse endocervix, ectocervix and vagina were 
markedly thickened, and the cornified epithelial cells can be observed on the superficial 
epithelial layers. This is in line with PMSG’s effect of stimulating estrogen production. On the 
contrary, the epithelium of mouse tissues became much thinner after Depo-Provera treatment, 
which was similar to that observed at natural diestrus stage (Figure 2.8). 
 
 
Figure 2.8 The morphology of mouse cervicovaginal tissues undergoing natural estrous 
cycling or synchronized with PMSG/Depo-Provera. 
The tissues were collected and fixed in 10% neutral buffered formalin for no less than 24 hours, 
and subjected to H & E staining. For the tissue samples with thin epithelium, blue arrows were 
used to indicate the position of epithelium. Magnification, 20 × for all pictures. Pictures shown 
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were representative of tissues collected from at least 3 mice. 
 
These vaginal cytology and tissue histology results were in line with published reports on mouse 
estrous cycle, and demonstrated that the synchronization protocols utilized in this study were 
successful in synchronizing mice into estrus and diestrus stages.  
 
The effects of estrous cycle, PMSG and Depo-Provera on the mRNA levels of 5 efflux 
transporters, including Abcb1a/Abcb1b (P-gp), Abcg2 (Bcrp), Abcc4 (Mrp4), Abcc5 (Mrp5), 
Abcc10 (Mrp7) were demonstrated from Figures 2.9 to 2.13. The effects were tissue- and 
transporter-dependent, however, in mouse female genital tract, some general tendencies appeared 
to exist. The mRNA levels of transporters tended to be highest at diestrus stage and lowest at the 
estrus stage, during the natural cycle. The PMSG treatment generally decreased transporter levels, 
while Depo-Provera generally increased transporter mRNA levels compared to the stages during 
natural cycle. For example, in mouse uterus, endocervix and ectocervix, the mRNA levels of 
Abcc4 (Mrp4) (Figure 2.11) were higher at diestrus stage compared to estrus. PMSG and Depo-
Provera synchronization significantly altered Abcc4 level compared to the natural estrous cycle. 
Abcc4 levels in uterus, endocervix and ectocervix were significantly decreased after PMSG 
synchronization, compared to the estrus and diestrus stages of the natural cycle. On the contrary, 
after Depo-Provera synchronization, Abcc4 levels in mouse uterus, endocervix and ectocervix 
were significantly higher than both stages of the natural cycle, and Abcc4 level in mouse vagina 
was significantly higher than the estrus stage of the natural cycle. 
 
PMSG treatment significantly decreased Abcc4 level in uterus, endocervix and ectocervix, 
compared to either stage during the natural cycle. On the contrary, Depo-Provera treatment 
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significantly increased Mrp4 levels in all the four segments of mouse genital tract compared to 
the levels during natural estrous cycle (Figure 2.11). 
 
Figure 2.9 Effect of estrus cycle or exogenous hormone/contraceptive on the mRNA 
expression of P-gp in mouse tissues.  
P-gp mRNA level was examined in mouse tissues collected under the following 4 conditions: 
estrus and diestrus stages during the natural estrous cycle, synchronized estrus after PMSG 
treatment, and synchronized diestrus after Depo-Provera treatment. Mouse P-gp consists of two 
isoforms, Abcb1a and Abcb1b. Therefore, the mRNA levels of both isoforms were shown to 
reflect mouse P-gp expression. The expression in endocervix, ectocervix, vagina, uterus, 
colorectum and liver were examined in tissues from 3-5 mice. For each mouse, all the 6 kinds of 
tissues were collected. For mouse uterus and liver, small pieces (30-50 mg) cut from tissue 
samples were used for RNA extraction and RT-PCR analysis. For mouse endocervix, ectocervix, 
vagina and colorectum, whole tissue samples were used for analysis. The threshold cycle 
numbers (Ct) of transporters and Gapdh of each sample were measured in triplicate, and the 
average Ct was used to reflect the Ct of transporter or Gapdh in this sample. The Gapdh-
normalized transporter levels (generated using 2
-ΔCt
 method) in different tissues were plotted in 
the figure shown above. The data shown represent mean ± standard deviation of all samples in a 
given group. Statistical comparison of transporter levels between the 4 conditions was conducted 
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using one way analysis of variance (ANOVA). * p<0.05; ** p<0.01, *** p<0.001. 
 
 
Figure 2.10 Effect of estrus cycle or exogenous hormone/contraceptive on the mRNA 
expression of Bcrp in mouse tissues.  
Bcrp mRNA level was examined in mouse tissues collected under 4 conditions as described in 
Figure 2.09. Tissue collection and data analysis were performed in the same way as described in 
Figure 2.09. Data shown represent mean ± standard deviation of all samples in a given group. * 
p<0.05. 
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Figure 2.11 Effect of estrus cycle or exogenous hormone/contraceptive on the mRNA 
expression of Mrp4 in mouse tissues.  
Mrp4 mRNA level was examined in mouse tissues collected under 4 conditions as described in 
Figure 2.09. Tissue collection and data analysis were performed in the same way as described in 
Figure 2.09. Data shown represent mean ± standard deviation of all samples in a given group. * 
p<0.05; ** p<0.01. 
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Figure 2.12 Effect of estrus cycle or exogenous hormone/contraceptive on the mRNA 
expression of Mrp5 in mouse tissues. 
Mrp5 mRNA level was examined in mouse tissues collected under 4 conditions as described in 
Figure 2.09. Tissue collection and data analysis were performed in the same way as described in 
Figure 2.09. Data shown represent mean ± standard deviation of all samples in a given group. * 
p<0.05; ** p<0.01. 
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Figure 2.13 Effect of estrus cycle or exogenous hormone/contraceptive on the mRNA 
expression of Mrp7 in mouse tissues.  
Mrp7 mRNA level was examined in mouse tissues collected under 4 conditions as described in 
Figure 2.09. Tissue collection and data analysis were performed in the same way as described in 
Figure 2.09. Data shown represent mean ± standard deviation of all samples in a given group. * 
p<0.05. 
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2.3.6 Real-time RT-PCR examination of mRNA levels of a select panel of transporters in cell 
lines derived from human cervicovaginal tissues and immune system 
 
 
 
Figure 2.14 Real-time RT-PCR analysis of a select panel of transporters in cell lines 
derived from human cervicovaginal tissues and T cells. 
Three epithelial cell lines derived from human endocervix (End1/E6E7), ectocervix (Ect1/E6E7) 
and vagina (VK2/E6E7), and a T cell line (PM1) were cultured under basal conditions as 
described in Materials and Methods above. Cells were collected when 60-90% confluency was 
reached for the epithelial cells, or good growing condition was maintained for the PM1 cells. The 
collected cells were then subjected to RNA extraction and RT-PCR, and GAPDH-normalized 
transporter mRNA levels were plotted. Data represent mean ± SD generated from at least three 
wells (End1/E6E7, Ect1/E6E7, VK2/E6E7) or three flasks (PM1).  
 
The same panel of efflux transporters were tested in cell lines derived from human endocervical 
epithelium (End1/E6E7), ectocervical epithelium (Ect1/E6E7), vaginal epithelium (VK2/E6E7), 
and human T cells (PM1). P-gp was not detectable in all the four cell lines, BCRP, MRP4, 
MRP5, and MRP7 can be detected in all the cell lines but their expression levels were lower 
compared to the tissue levels found in human and animal models. There is no significant 
difference in transporter level between different epithelial cell lines. In addition, when comparing 
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transporter levels between cervicovaginal epithelial cell lines and the PM1 T cell line, MRP7 
was expressed at much lower level in PM1 cells. OAT1 and OAT3 were not detectable in all the 
cell lines, which is consistent with the observations that these two uptake transporters could be 
detected by RT-PCR in the cervicovaginal tissues of human, macaque, rabbit and mouse. 
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Figure 2.15 Effect of contraceptives and inflammation-related cytokines on the transporter 
mRNA expression in cervicovaginal and T cell lines.  
Two epithelial cell lines (End1/E6E7, VK2/E6E7)  were grown on plate, and a T cell line (PM1) 
was grown in flask. Cells were treated with contraceptives (MPA, P4), or cytokines (IL1β or IL8), 
or vehicle solution used to dissolve contraceptives/cytokines, for 48 hours. Then, cells were 
collected and subjected to RT-PCR analysis of the mRNA levels of BCRP, MRP4, MRP5, and 
MRP7. For each treatment, data were generated from 3-5 wells or flasks. For each transporter 
examined, the GAPDH-normalized transporter levels (generated using the 2
-ΔCt
 method ) in 
contraceptive- and cytokine-treated cells were compared to the average GAPDH-normalized 
transporter level in vehicle-treated cells. These fold changes relative to vehicle-treated controls 
were expressed as mean ± SD. P-gp was not detectable in End1/E6E7, VK2/E6E7, and PM1 cell 
lines, under all treatments. MPA, medroxyprogesterone acetate, the active pharmaceutical 
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ingredient of Depo-Provera. P4, Progesterone. *, p<0.05 compared to the vehicle-treated control.  
 
To evaluate the effect of contraceptives and cytokines on transporter mRNA expression in 
cervicovaginal tissue and immune cells, the End1/E6E7, VK2/E6E7, and PM1 cells were 
incubated with MPA, P4, IL1β, or IL8 for 48 hours (Since there is no difference between 
End1/E6E7, Ect1/E6E7 and VK2/E6E7 in transporter mRNA levels, only End1/E6E7 and 
VK2/E6E7 were tested in this study to represent the single-layer columnar epithelial cells and 
multi-layer squamous epithelial cells, respectively). The impacts of these treatments were 
dependent on the type of cell and type of transporter, as shown in Figure 2.15. The general 
tendency is that the four factors appeared to regulate epithelial cell lines (End1/E6E7, VK2/E6E7) 
and immune cell line toward different directions.  
 
2.3.7 Multi-species comparison in mRNA levels of highly expressed and most relevant 
transporters  
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Figure 2.16 Multi-species comparison in mRNA levels of select transporters. 
 
The Gapdh-normalized transporter mRNA levels in animal tissues and cell lines were normalized 
to the GAPDH-normalized transporter mRNA levels in corresponding human tissues, and the 
ratios were expressed using different colors indicating different degrees of similarity. Grey color, 
5 fold lower or higher than the human tissue level; light blue and light red, 5-15 fold lower or 
higher; dark blue and dark red, more than 15 fold lower or higher. Human data were shown in 
Figure 2.4. Pigtailed macaque data were shown in Figure 2.5. New Zealand White rabbit data 
were shown in Figure 2.6. The mouse data used here for comparison was from Depo-Provera 
synchronized mice, as shown in Figures 2.9 to 2.13. This synchronized mouse model is used by 
researchers in the field of vaginal microbicides to evaluate the safety of vaginal products.
198-200
 
Mouse P-gp transporter consists of two functional isoforms, Abcb1a and Abcb1b. Therefore, the 
average level of each isoform was compared to average human P-gp level, and the results of both 
isoforms were listed together to indicate the similarity in P-gp levels between mouse and human. 
The three cell lines used for comparison are derived from the epithelial cells of human 
86 
 
endocervix (End1/E6E7), ectocervix (Ect1/E6E7), and vagina (VK2/E6E7). 
 
 
The transporter mRNA levels (using GAPDH as internal control) were compared across different 
species/models. The purpose of this comparison is to inform model selection for future studies of 
transporter function, judging from the mRNA expression data. It might be not practical to find a 
model that has identical expression pattern of multiple transporters, but such comparisons will 
help the researchers make informed decision and will help correlating 
pharmacokinetic/pharmacodynamics data between human subjects and preclinical models. 
As shown in Figure 2.16, pigtailed macaque appeared to be the model with highest similarity to 
human, in terms of cervicovaginal and colorectal transporter expression pattern. Rabbit Mrp4 
levels was more than 15-fold higher than human levels, but the difference for other transporters 
is within ± 5 fold. The levels of P-gp, BCRP, Mrp4 and Mrp5 in Depo-Provera synchronized 
mouse tissues were similar to human’s in certain tissue segments, but the difference in Mrp7 was 
higher than 15 fold for all mouse tissues examined. When comparing the three cervicovaginal 
epithelial cell lines to corresponding human tissues, the differences were larger than 15 fold for 
P-gp and BCRP, but the differences were within ± 5 fold for MRP4, 5, 7, except that MRP4 level 
in End1/E6E7 cells was more than 5 times lower than the MRP4 level in human endocervical 
tissue. The absence of OAT1 and OAT3 in all the tissues and cells examined suggested that these 
two uptake transporters were not likely to play a functional role in drug pharmacokinetics in the 
cervicovaginal and colorectal tissues. 
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2.3.8 Real-time RT-PCR examination of mRNA levels of nuclear receptors (NRs) in human, 
macaque, and mouse tissues 
The mRNA levels of 23 NRs were examined in the cervicovaginal and colorectal tissues of 
human, macaque, and Depo-Provera-synchronized mice (Figures 2.17 to 2.19). The purpose of 
this examination was to provide clues for the mechanism study of transporter regulation, and to 
evaluate the utility of different preclinical models in the study of NR-mediated regulation in 
cervicovaginal and colorectal tracts. The determination of the panel of NRs was based on their 
reported interactions with drug transporters in other tissues such as liver. 
 
 The GAPDH-normalized NR mRNA levels were used to compare the expression of each NR 
across different tissues, and between different NRs in the same type of tissue. Since liver has 
abundant expression of many NRs, the GAPDH-normalized levels were further divided by the 
average of liver levels in each species, and results were shown in the tables associated with 
Figures 2.17 to 2.19.  
 
In human endocervix, ectocervix, and vagina, many NRs were found to express at moderate to 
high levels. These NRs included  VDR, PPAR-α, PPAR-β, PPAR-γ, ER-α, PR, AR, GR, MR, 
RAR-α, RAR-β, RAR-γ, RXR-α, RXR-β, RXR-γ, ROR-α, ROR-β, Nrf2, and AhR. The mRNA 
levels of these NRs were above 1/1000 of GPADH levels in corresponding tissues. The NRs with 
highest GAPDH-normalized mRNA levels (around 1/10 GAPDH level or higher) were ER-α, PR, 
AR, GR, Nrf2, and AhR, all of which could respond to sex steroid hormones or oxidative stress. 
On the contrary, PXR, CAR, ER-β and RAR-γ were expressed at low levels (<1/1000 of 
GAPDH level) in human cervicovaginal tissues. The levels of VDR, PPAR-γ, MR, RAR-β, 
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RAR-γ, ROR-β appeared to differ between endocervix, ectocervix, and vagina. RAR-β in 
endocervix was significantly higher than that in ectocervix and vagina (p <0.001). No significant 
difference was observed for other NRs between the three segments of human female lower 
genital tract. The moderately and highly expressed NRs in lower genital tract may play a role in 
regulating the mRNA expression of transporters and other downstream genes in human 
cervicovaginal tissues. In addition, the difference in expression levels between endocervix, 
ectocervix and vagina may lead to differential regulation by the same NR in different segments 
of lower genital tract 
 
In human colorectal tissue, the expression profile of many NRs was found to be comparable to 
that of cervicovaginal tissues, but some NRs demonstrated differential expression levels. Similar 
to cervicovaginal tissues, VDR, PPAR-α, PPAR-β, PPAR-γ, AR, GR, MR, RAR-α, RAR-β, 
RAR-γ, RXR-α, RXR-β, ROR-α, Nrf2, and AhR were above 1/1000 of GAPDH level. However, 
ER-α, PR, RXR-γ, ROR-β, ROR-γ were found be express at levels lower than 1/1000 of GAPDH 
although they displayed high expression in human cervicovaginal tissues. In addition, PXR and 
ER-β were expressed at levels higher than 1/1000 of GPADH in human colorectal tissue, which 
was another difference from the cervicovaginal tissues. Judging from the GAPDH-normalized 
levels, the most highly expressed NRs were MR and Nrf2, and the least expressed NRs were 
CAR and ROR-γ, in human colorectal tissue. With respect to the statistical difference between 
colorectal tissue and cervicovaginal tissues, PXR, VDR, PPAR-γ, and MR levels in colorectal 
tissue was significantly higher than that in cervicovaginal tissues (p <0.05, p <0.001, p <0.001, p 
<0.05, respectively); On the other hand, ER-α and PR, RAR-β, ROR-β levels in colorectal tissue 
was significantly lower than their levels of endocervix (p <0.01, p <0.01, p <0.01, p <0.05, 
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respectively), RAR-γ level in colorectal tissue was significantly lower than that in human 
ectocervix (p <0.01), AR level in colorectal tissue was significantly lower than its levels in 
endocervix and ectocervix (p <0.01). The moderately and highly expressed NRs in human 
colorectal tissue may play a role in regulating the mRNA expression of transporters and other 
downstream genes in this tissue In addition, the difference in expression levels between 
colorectal and cervicovaginal tissues may lead to differential regulation by the same NR 
activator between these tissue sites. 
 
Human liver has abundant expression of many NRs, and cervicovaginal and colorectal tissues 
displayed comparable or even higher levels for some of the NRs highly expressed in liver. 
Judging from the GAPDH-normalized mRNA levels, PXR, CAR, PPAR-α, PPAR-β, PPAR-γ, 
ER-α, AR, GR, MR, RAR-α, RAR-β, RXR-α, RXR-β, ROR-α, Nrf2, and AhR were expressed at 
levels higher than 1/1000 of GAPDH. CAR and Nrf2 levels were found to be highest (around 
1/10 of GAPDH). These NRs can be activated by therapeutic drugs (e.g. PXR), hormones (e.g. 
ER-α), nutrients (e.g. RAR-α), and oxidative stress (e.g. Nrf2). As shown in the table associated 
with Figure 2.17, some of the NRs that showed moderate to high expression in human liver 
demonstrated comparable (p > 0.05) or even higher (p < 0.05) levels in cervicovaginal and/or 
colorectal tissues, including PXR (colorectal tissue, p > 0.05), PPAR-α (colorectal tissue, p > 
0.05), PPAR-β (ectocervix, p < 0.01; colorectal tissue, p < 0.05), PPAR-γ (colorectal tissue, p < 
0.001), ER-α (endocervix, p < 0.001; ectocervix, p < 0.05), AR (endocervix, p < 0.05), MR 
(colorectal tissue, p < 0.001), RAR-α (endocervix and ectocervix, p < 0.001; colorectal tissue, p 
< 0.05), RAR-β (endocervix, p < 0.001), RXR-β (endocervix, p < 0.01), and AhR (ectocervix, p 
< 0.001). To summarize, a number of NRs that had moderate to high expression in human liver 
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displayed comparable or higher expression levels in human cervicovaginal and colorectal tissues. 
This implicated that these NRs may play a role in regulating their downstream genes in 
cervicovaginal and colorectal tissues. 
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Figure 2.17 Real-time RT-PCR analysis of nuclear receptors (NRs) in human 
cervicovaginal and colorectal tissues.  
The NR mRNA expression in human endocervix, ectocervix, vagina, sigmoid colon and liver 
were examined in tissues from 4-6 donors (Endocervix, 4 donors; ectocervix, 6 donors; vagina, 5 
donors; sigmoid colon, 5 donors; liver, 6 donors). The GAPDH-normalized NR levels (generated 
using 2
-ΔCt
 method) in different tissues were plotted in the figure shown above. the GAPDH-
normalized NR levels in genital tract and colorectal tissues relative to the GAPDH-normalized 
NR levels in human liver were summarized in the table. The data shown represent mean ± 
standard deviation. N/A, the NR cannot be detected in liver, so that the normalization of 
cervicovaginal/colorectal level to liver level cannot be performed. 
 
 
The mRNA expression profile of NRs in macaque cervicovaginal and colorectal tissues were 
generally similar to that of corresponding human tissues Figure 2.18. The NRs that can interact 
with steroid hormones were expressed at high levels compared to macaque liver and colorectum. 
Similarly, the xenobiotic-binding NRs such as PXR was almost undetectable in macaque 
cervicovaginal tissues but was expressed in macaque colorectum at the levels similar to liver. 
 
In macaque endocervix, ectocervix, and vagina, many NRs were found to express at moderate to 
high levels. VDR, PPAR-α, PPAR-β, PPAR-γ, ER-α, PR, AR, GR, MR, RAR-α, RAR-β, RAR-γ, 
RXR-α, RXR-β, RXR-γ, ROR-α, ROR-β, Nrf2, and AhR were found to express at levels above 
1/1000 of macaque Gapdh. The moderate to high expression of these NRs was similar to the 
expression pattern of these NRs in human tissues (Figure 2.17). Similar to human tissues, ER-α, 
PR, AR, GR, Nrf2, and AhR were among the most highly expressed NRs in macaque 
cervicovaginal tissues. PXR, CAR, ER-β and RAR-γ were expressed at low level (<1/1000 of 
Gapdh level) in human cervicovaginal tissues. For these NRs, the levels CAR in macaque 
cervicovaginal tissues were undetectable, but the levels of PXR, ER-β, and RAR-γ were 
positively detected and even higher than 1/1000 of Gapdh (Figure 2.18). The levels of PXR, 
PPAR-γ, ER-β, GR, MR, RXR-γ, ROR-β, ROR-γ, Nrf2, and AhR appeared to differ between 
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endocervix, ectocervix, and vagina. However, no statistical difference has been observed for 
these NRs between the three segments of macaque cervicovaginal tract, possibly due to limited 
number of macaque tissues used in this study (n=3 for each kind of tissue). The moderately and 
highly expressed NRs in macaque cervicovaginal tissues could respond to therapeutic drugs (e.g. 
PXR), steroid hormones (e.g. ER-α), nutrients (e.g. RAR-α), and oxidative stress (e.g. Nrf2). 
Although the absolute levels of these NRs are not identical to those in human cervicovaginal 
tissues, the NR expression pattern was generally comparable between macaque and human 
cervicovaginal tissues. 
 
In macaque colorectal tissue, the expression profile of many NRs was found to be comparable to 
that of human colorectal tissue. The moderately to highly expressed NRs in human tissue, 
including PXR, VDR, PPAR-α, PPAR-β, PPAR-γ, AR, GR, MR, RAR-α, RAR-β, RXR-α, 
RXR-β, ROR-α, Nrf2, and AhR, were also found to be expressed at moderate to high levels in 
macaque colorectal tissue (1/1000 to 1/10 of Gapdh, Figure 2.18). ER-β and RAR-γ were 
expressed at slightly lower levels compared to human colorectal tissue, but were still around 
1/1000 of Gapdh. The lowly expressed or undetectable NRs (<1/1000 of Gapdh) in human 
colorectal tissue, including ER-α, PR, RXR-γ, ROR-β, ROR-γ, were expressed at low levels in 
macaque colorectal tissue. Compared to macaque cervicovaginal tissues; the colorectal PPAR-γ 
level was significantly higher than its ectocervical level (p <0.05); the colorectal ER-α level was 
significantly lower than its endocervical (p <0.05) and ectocervical (p <0.05) levels; the 
colorectal MR level was significantly higher than its endocervical (p <0.05) and ectocervical (p 
<0.05) levels. Overall, the expression pattern of NRs in macaque colorectal tissue was generally 
similar to that of human colorectal tissue.   
93 
 
 
Similar to human liver, the macaque liver also demonstrated abundant expression of many NRs. 
In addition, macaque cervicovaginal and colorectal tissues displayed comparable or even higher 
levels for some of the NRs highly expressed in macaque liver. Judging from the Gapdh-
normalized mRNA levels, PXR, PPAR-α, PPAR-β, ER-α, AR, GR, MR, RAR-α, RAR-β, RXR-
α, RXR-β, ROR-α, ROR-β, Nrf2, and AhR were expressed at levels higher than 1/1000 of Gapdh 
in macaque liver. The Gapdh-normalized NR levels in macaque cervicovaginal and colorectal 
tissues were divided by their levels in macaque liver, and the ratios were shown in the table 
associated with Figure 2.18 for comparison. Some of the NRs that showed moderate to high 
expression in macaque liver demonstrated comparable (p > 0.05) or even higher (p < 0.05) levels 
in cervicovaginal and/or colorectal tissues, including PPAR-β (colorectal tissue, p < 0.01), MR 
(colorectal tissue, p < 0.01). The cervicovaginal or colorectal tissues levels of several other NRs 
such as Nrf2 and AhR also appeared to be higher than their levels in liver, however the statistical 
significance was not achieved, probably due to limited number of tissues used in this study (n=3 
for each type of tissue). To summarize, a number of NRs that had moderate to high level of 
mRNA expression in macaque liver demonstrated comparable or higher levels in macaque 
cervicovaginal and colorectal tissues. This was similar to the comparison between human tissues 
(Figure 2.17), and implicated that multiple NRs may play a functional role in regulating 
downstream genes in macaque cervicovaginal and colorectal tissues. 
 
  
 
94 
 
 
 
Figure 2.18 Real-time RT-PCR analysis of nuclear receptors (NRs) in macaque 
cervicovaginal and colorectal tissues.  
The NR mRNA expression in macaque endocervix, ectocervix, vagina, colorectum and liver 
were examined in tissues collected from 3 macaques. For each macaque, all the 5 kinds of tissues 
were collected. The Gapdh-normalized NR levels (generated using 2
-ΔCt
 method) in different 
tissues were plotted in the figure shown above. The Gapdh-normalized NR levels in genital tract 
and colorectal tissues relative to the Gapdh-normalized NR levels in macaque liver were 
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summarized in the table. The data shown represent mean ± standard deviation. 
 
The NR expression profile in mouse cervicovaginal and colorectal tissues were generally 
comparable to that in human and macaque tissues (Figure 2.19). The hormone-binding NRs were 
expressed at much higher level in mouse cervix and vagina compared to mouse colorectum or 
liver; while the xenobiotic binding NRs such as PXR was expressed at much higher level in 
mouse colorectum compared to cervicovaginal tissues. 
 
In the examination of NR expression in mouse cervicovaginal tissues, the endocervix and 
ectocervix were combined for RNA extraction and real-time RT-PCR (Figure 2.19). In mouse 
cervix and vagina, many NRs were found to express at moderate to high levels (>1/1000 of 
mouse Gapdh level), including VDR, PPAR-α, PPAR-β, PPAR-γ, ER-α, AR, GR, MR, RAR-β, 
RAR-γ, RXR-α, ROR-α, ROR-β, ROR-γ, Nrf2, and AhR. On the other hand, a few NRs such as 
PXR, CAR, and ER-β were found to be expressed at low levels or undetectable (<1/1000 of 
mouse Gapdh). This expression pattern of NRs is similar to that in human cervicovaginal tissues 
(Figure 2.17). Differences in NR expression between mouse cervix and vagina have been 
observed. RAR-β and Nrf2 levels in mouse cervix were significantly higher than those in vagina 
(p <0.05 and p <0.01, respectively); AhR level in mouse cervix was significantly lower than that 
in mouse vagina (p <0.05). Although the absolute mRNA levels of NRs in mouse cervix and 
vagina were not identical to those in human cervicovaginal tissues, the pattern of expression was 
generally comparable between mouse and human cervicovaginal tissues. 
 
In mouse colorectum, the expression profile of many NRs was found to be comparable to that of 
human colorectal tissue. The moderately to highly expressed NRs in human tissue, including 
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PXR, VDR, PPAR-α, PPAR-β, PPAR-γ, GR, MR, RAR-β, RAR-γ, RXR-α, Nrf2, and AhR were 
also found to be expressed at moderate to high levels in mouse colorectum (1/1000 to 1/10 of 
Gapdh, Figure 2.19). ER-α and ROR-γ were expressed at low levels (<1/1000 of human GAPDH) 
in human colorectum tissue, but was above 1/1000 of mouse Gapdh level in mouse colorectum. 
Compared to mouse cervix and vagina, mouse colorectal levels of VDR, PPAR-β, ER-β, and MR 
were significantly higher than their levels in mouse cervix (p <0.001 for all NRs) and vagina (p 
<0.001 for all NRs); colorectal levels of RAR-α was significantly higher than its level in mouse 
vagina (p <0.05); colorectal levels of RAR-β and RAR-γ were significantly lower than their 
levels in mouse cervix (p <0.05 and p <0.01, respectively); colorectal levels of Nrf2 and AhR 
were significantly lower than their levels in mouse cervix (p <0.001 and p <0.01, respectively) 
and vagina (p <0.01 and p <0.001, respectively). Mouse colorectal PXR level appeared to be 
much higher than that in mouse cervix and vagina, however statistical significance was not 
achieved. The pattern of NR expression in mouse colorectum was generally similar to that in 
human colorectal tissue. 
 
Similar to human liver, mouse liver also demonstrated abundant expression of many NRs. In 
addition, mouse cervicovaginal and colorectal tissues displayed comparable or even higher levels 
for some of the NRs highly expressed in mouse liver. The mouse Gapdh-normalized mRNA 
levels of PXR, CAR, PPAR-α, PPAR-β, PPAR-γ, ER-α, GR, MR, RAR-β, RXR-α, ROR-γ, Nrf2, 
and AhR were expressed at levels higher than 1/1000 of Gapdh in mouse liver. Some of these 
NRs demonstrated comparable (p > 0.05) or even higher (p < 0.05) levels in cervicovaginal 
and/or colorectal tissues, including PXR (colorectum, p > 0.05), PPAR-β (colorectum, p < 0.001), 
MR (colorectum, p < 0.001), Nrf2 (cervix, p < 0.001; vagina, p < 0.001; colorectum, p < 0.05), 
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AhR (cervix, p < 0.05; vagina, p < 0.001). Overall, a number of NRs that had moderate to high 
levels of mRNA expression in mouse liver demonstrated comparable or higher levels in mouse 
cervicovaginal and colorectal tissues. This was similar to the comparison between human tissues 
(Figure 2.17), and implicated a functional role of NRs in mouse cervicovaginal and colorectal 
tissues. 
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Figure 2.19 Real-time RT-PCR analysis of nuclear receptors (NRs) in cervicovaginal and 
colorectal tissues of Depo-Provera synchronized mice.  
The NR mRNA expression in mouse cervix (containing both endocervix and ectocervix), vagina, 
colorectum and liver were examined in tissues collected from 3 mice receiving Depo-Provera 
synchronization. For each mouse, all the 4 kinds of tissues were collected. The Gapdh-
normalized NR levels (generated using 2
-ΔCt
 method) in different tissues were plotted in the 
figure shown above. The Gapdh-normalized NR levels in genital tract and colorectal tissues 
relative to the Gapdh-normalized NR levels in mouse liver were summarized in the table. The 
data shown represent mean ± standard deviation. N/A, the NR cannot be detected in liver, so that 
the normalization of cervicovaginal/colorectal level to liver level cannot be performed.  
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2.4 Discussion and Conclusion 
There is an urgent need to identify critical determinants of cervicovaginal tissue drug 
pharmacokinetics and pharmacodynamics (PK/PD) to optimize PrEP strategies.
42,201,202
 Efflux 
transporters and uptake transporters have been reported to pump out or uptake many 
antiretroviral drugs.
49,60,86
 If these transporters are present and functional in the cervicovaginal 
tissues, they will likely affect the distribution of topically or orally administered drugs to the sites 
of HIV-1 transmission. Our previous study and the current study in this chapter have examined 
the mRNA expression of transporters and enzymes in human lower genital tract (ectocervix and 
vagina) using conventional RT-PCR.
201
 While a number of efflux transporters (P-gp, BCRP, 
MRP4, MRP5, MRP7) were found to be expressed at moderate to high levels compared to liver, 
only a limited number of uptake transporters such as ENT1 were found to be positively 
expressed in both epithelium and stroma of ectocervix and vagina.
201
 OAT1 and OAT3, the 
major uptake transporters for tenofovir, were not detectable by RT-PCR in these tissues.
201
  
 
The comparison in mRNA expression patterns of cervicovaginal and colorectal tissue 
transporters between human, animal models, and the comparison between human tissues and cell 
lines have implications on the utilization of the animal and cell models in PrEP testing and 
functionality study of cervicovaginal transporters. Non-human primates are considered as the 
most clinically relevant animal model to study STI transmission and prevention. The rabbit 
model has been recommended by FDA for topical (vaginal and rectal) PrEP product safety 
testing. The wild-type mouse model utilized in our study is also used in safety evaluations as a 
convenient in vivo model.
198,203,204
 It has been shown that the toxicity profile of a number of 
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microbicide candidates in progesterone synchronized mice correlated well with clinical trial 
results.
199,200,205
 In addition, the End1/E6E7, Ect1/E6E7, and VK2/E6E7 cell lines as well as the 
PM1 T cell line have been widely used in microbicide safety or efficacy evaluations. Since the 
drug efficacy and toxicity are dependent on drug level in the recipient tissues, the comparisons 
between human and models have provided useful information regarding the validity of those 
models especially when the test drug is a substrate of the highly expressed transporters. 
Additionally, the interspecies comparisons have provided clues for the selection of preclinical 
models for future functional characterization of cervicovaginal/colorectal tissue transporters. 
However, it should be noted that mRNA levels do not necessarily correlate with protein 
expression and activity. Functional studies will be necessary to confirm the observed interspecies 
differences in transporter mRNA levels between human and the preclinical models used in PrEP 
product evaluation. Mrp4 transporter mRNA level in rabbit cervix and vagina were found to be 
much higher than that in corresponding human tissues. However, rabbit vagina is lined with 
single-layer epithelium, which is different from the multi-layer epithelia of human vagina and 
ectocervix. This anatomical difference renders the permeability across rabbit vaginal epithelium 
higher than that of human vaginal and ectocervical tissues. Even if the Mrp4-mediated efflux 
activity in rabbit tissues is higher, the overall uptake and tissue exposure of Mrp4 substrates (e.g. 
tenofovir) may still be comparable between humans and rabbits. Therefore, current data on rabbit 
transporter mRNA levels is not against the FDA recommended use of rabbit model in the 
screening of topical PrEP products.   
 
The conventional and real-time RT-PCR studies reported in this chapter were not without 
limitations, and strategies have been employed to address the shortcomings. Some primers used 
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in the PCR did not span the boundary of exons, rendering the risk of amplification from genomic 
DNA, and in turn may result in false positive results. To address this, DNase was utilized in the 
preparation of RNA samples for real-time RT-PCR, in order to remove the residual genomic 
DNA contamination. In addition, in some of the real-time RT-PCR analysis, the size of the PCR 
products was not confirmed by DNA electrophoresis. Although melt curve analysis following the 
amplification suggested the formation of single PCR product, it was possible that a non-specific 
amplification occurred instead of the target-specific amplification, so that the melt curve analysis 
still showed single amplification product during PCR. If this was the case, then positive detection 
of some transporters may just be false positive results. This limitation was resolved by 
examining the protein expression and/or transport function of the transporters with positive 
mRNA results. A third shortcoming of this study is associated with the difficulty in obtaining 
tissues from humans and non-human primates. A limited number of human cervicovaginal 
tissues was used in PCR experiments, and some experiments lack the most appropriate positive 
control tissues. For example, OAT1 and OAT 3 are highly expressed in kidney,
119
 but human 
kidney could not be obtained for our study as positive control. The positive control used for all 
transporters in our study was human liver, but the OAT1 and OAT3 mRNA expression is known 
to be minimal in this tissue. Thus, using liver as positive control for these transporters could not 
eliminate the possibility that the OATs were expressed at high level in cervicovaginal and 
colorectal tissues but primers were inefficient to detect the expression. This concern has been 
addressed by similar findings reported by other groups using better control tissues. Nicol et al. 
also reported negative real-time RT-PCR detection of OAT1 and OAT3 in human endocervix, 
vagina, and colorectal tissue. In this study, human kidney was used as positive control, and high 
levels of OAT1 and OAT3 could be detected in the kidney.
206
 The utilization of DNase, later 
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examination of protein expression of select transporters, and similar findings reported from other 
groups have enhanced the validity of our mRNA results described in this chapter.  
 
Efflux transporters have become the focus of our study that aims to identify critical determinants 
of drug PK/PD, due to a number of reasons. First, efflux transporters displayed higher expression 
levels than many uptake transporters and drug metabolizing enzymes. The majority of CYP 
isoforms, such as CYP3A4, were not detectable or were expressed at much lower levels 
compared to the liver, as identified in our previous studies.
201
 The relatively high mRNA levels 
of efflux transporters suggest that they may be more important regulators than uptake 
transporters or CYP enzymes in drug exposure in the cervicovaginal tissues. In addition to 
relatively high expression levels, extensive studies have tested the feasibility of inhibiting efflux 
transporters to increase drug exposure in tissues.
47,49,59,207,208
 The mostly tested approach is co-
administration of transporter inhibitors.
42, 43
 Another promising approach is to encapsulate the 
drug into lipid nanoparticles so that the drug will enter the cell via alternative routes and the 
transporter efflux could be minimized.
208
  There are a number of inhibitors and formulation 
strategies to utilize to modulate an efflux transporter in the scenario of PrEP. Many antiretroviral 
drugs are inhibitors of efflux transporters, such as protease inhibitors being potent P-gp inhibitors. 
In addition, there have been a lot of studies exploring nanoparticle formulations with diverse 
physicochemical properties for the incorporation of antiretroviral drugs. Compared to efflux 
transporters, there is much less information on the strategies available to enhance the uptake 
transporter function and get more drug molecules into the cell. Therefore, the relatively high 
expression levels of P-gp, BCRP, MRP4, 5, 7 in cervicovaginal tissues, the high relevance of 
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these transporters to antiretroviral drugs, and the availability of multiple approaches to overcome 
the efflux activity led us to focus on these efflux transporters in follow-up studies. 
 
Based on the mRNA expression profile of the transporters examined, a number of antiretroviral 
drugs could potentially be affected by the positively expressed transporters. Based on the 
Biopharmaceutics Classification System (BCS) discussed in Chapter 1, three classes (Class 2, 3, 
4) of antiretroviral drugs could be potentially affected by efflux transporters positively detected 
in cervicovaginal and colorectal tissues. Among the drugs from these three classes, nevirapine 
(MRP7), atazanavir (P-gp), ritonavir (P-gp), amprenavir (P-gp),  lopinavir (P-gp),  saquinavir (P-
gp),  darunavir (P-gp), indinavir (P-gp), tipranavir (P-gp), nelfinavir (P-gp) and raltegravir (P-gp) 
are from BCS Class 2; maraviroc (P-gp), lamivudine (BCRP), tenofovir DF (P-gp), tenofovir 
(MRP4, MRP7), didanosine (BCRP) are from BCS Class 3. Abacavir (P-gp, BCRP, MRP4), 
stavudine (BCRP, MRP5) and zidovudine (BCRP, MRP4) are substrates of transporters 
positively expressed in cervicovaginal and colorectal tissues, but their PK is not likely to be 
significantly affected because they belong to BCS Class 1. Etravirine belong to BCS Class 4, but 
the role of transporters in its PK is not clear because no transporter has been identified to 
transport this drug. Antiretroviral drugs from two classes (Class 3 and 4) are potentially affected 
by uptake transporters. In this dissertation, only ENT1 out of the tested uptake transporters 
showed cervicovaginal and colorectal expression level higher than liver. Among the drugs from 
these two classes, the only drug that can be transported by ENT1 is didanosine, which belongs to 
BCS Class 3. To summarize, based on the transporter expression profile revealed in by this study, 
16 approved antiretroviral drugs are potentially affected by efflux transporters positively 
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expressed in cervicovaginal/colorectal tissues including P-gp, BCRP, MRP4, and MRP7; only 1 
drug may be affected by the positively expressed uptake transporter ENT1. 
 
In previous PrEP clinical and non-human primate studies, several factors have been suggested to 
increase the vulnerability to HIV sexual transmission and decrease the effectiveness of 
antiretroviral-based PrEP drug products. Two major factors were found to be 
hormones/hormonal contraceptive, and reproductive tract inflammation.
209-212
 Macaques with 
progesterone implants displayed increased infection rate than non-administered macaques.
211
 
Contraceptives have shown varying effects on HIV infection.
212
 Depo-Provera is the most widely 
used contraceptive in sub-Saharan Africa where the rate of HIV sexual transmission remains 
highest. African women who used Depo-Provera had significantly elevated HIV acquisition rate 
compared to those who used another contraceptive norethisterone enanthate (NET-EN).
212
 In 
addition to hormones and contraceptives, human participants with bacterial vaginosis 
demonstrated increased rate of HIV sexual transmission compared to those with healthy 
reproductive tract.
209,210
 The mechanism underlying the increased infection has been suggested to 
involve increased amount of submucosal immune cells and increased HIV receptor abundance on 
immune cell surface, when Depo-Provera and proinflammatory cytokines were present.
213
 
However, the effect of Depo-Provera and proinflammatory cytokines on tissue drug levels have 
not been examined. If Depo-Provera and BV-associated cytokines could alter transporter levels 
and decrease drug exposure in tissues and cells relevant to HIV transmission, then the 
effectiveness of PrEP drug products may be worsened in the participants who use Depo-Provera 
or have genital tract bacterial vaginosis.  
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It has been reported that hormones and proinflammatory cytokines could alter the expression and 
activity of drug transporters,
214-217
 therefore the effect of these factors on transporter expression 
in transmission-related tissues and cells is worth exploring. Ideally, to study the effect of 
contraceptives, tissues should be collected from human or macaque subjects with and without 
contraceptive use; to test the effect of reproductive tissue inflammation, tissues should be 
collected from humans with and without ongoing inflammation such as bacterial vaginosis. 
However, due to the difficulty of collecting human and non-human primate tissues, only limited 
number of tissues were collected from humans and macaques, without knowing the information 
of menstrual cycle, hormone/contraceptive use, and inflammation status. Therefore, the effect of 
menstrual cycle and exogenous hormones/contraceptives/inflammation was tested in cell lines 
and mice. To test the effect of menstrual cycle, tissues were collected from mice at different 
stages of natural estrous cycle. To test the effect of hormones and contraceptives, cell lines were 
treated with MPA (active ingredient of Depo-Provera) and progesterone, and mice were treated 
with PMSG and Depo-Provera. To test the effect of inflammation, cell lines were treated with 
IL1β and IL8 solution, since these two cytokines were found to be significantly elevated in 
women with bacterial vaginosis, and presumably contribute to the inflammation status.
185-187
  
 
In the mouse model, menstrual (estrous) cycle, PMSG, and Depo-Provera demonstrated 
regulatory effects on the expression of several efflux transporters in mouse cervicovaginal tissues, 
and the most prominent effects were observed on Abcb1a/Abcb1b (P-gp), Abcg2 (Bcrp) and 
Abcc4 (Mrp4). The impacts of these factors were found to be dependent on the type of 
transporter and type of tissue. The general tendency was that the mRNA expression of these 
transporters was higher at diestrus stage compared to the level at estrus stage, during the natural 
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estrous cycle. In addition, PMSG, the estrogen-stimulating hormone, decreased transporter 
expression compared to the transporter levels during natural cycle. On the contrary, Depo-
Provera synchronization increased transporter expression compared to the transporter levels 
during the natural cycle. If these effects could be observed in humans, the menstrual cycle and 
the use of estrogenic hormone drugs or Depo-Provera could potentially result in intra-individual 
and/or inter-individual variability in tissue drug exposure and PrEP effectiveness. For example, 
in mouse endocervix and ectocervix, Abcc4 (Mrp4) level was significantly elevated at diestrus 
stage during natural estrous cycle, and was markedly up-regulated by Depo-Provera treatment. If 
these changes at mRNA level correlate with transport activity, the tissue exposure of topically or 
systemically administered TFV may be reduced under the up-regulated conditions compared to 
the conditions with unchanged or down-regulated Abcc4 level.   
 
It would be tempting to understand the mechanisms underlying the observed transporter 
regulations by menstrual (estrous) cycle, PMSG, and Depo-Provera. With an understanding of 
these mechanisms we may be able to predict other untested factors that can regulate transporters 
in the tissues of our interest through the same mechanisms. Currently there are no published 
reports describing the effect of Depo-Provera, or its active pharmaceutical ingredient 
medroxyprogesterone acetate (MPA), on the expression of MRP4 transporter. Our results 
represent the first demonstration that mouse Mrp4 mRNA expression can be regulated by Depo-
Provera, in cervicovaginal tissues. The mechanism may involve the expression and activity of 
NRs in cervicovaginal tissues. MPA has been demonstrated to bind and activate multiple NRs.
218
 
While MPA does not bind significantly to the NRs for estrogen and mineralocorticoids (ER and 
MR), it is an agonist of progesterone receptor (PR), androgen receptor (AR), and glucocorticoid 
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receptor (GR).
218
 The approximate EC50 values were 0.01, 1, and 10 nM, for PR, AR and GR, 
respectively.
219
 AR activation has been reported to up-regulate MRP4 gene expression in normal 
human prostate cells, prostate cancer cell line, and tumor tissue collected from prostate cancer 
patients.
220
 After the binding of androgen, AR translocates into the nucleus, and binds the 
androgen response elements in the promoter region of ABCC4 (MRP4) gene to regulate MRP4 
expression in normal human prostate tissue and prostate cancer cells.
221-223
 The MRP4 
expression in prostate tumor tissue was found to be higher than that in normal prostate cells, due 
to increased androgen signaling.
223,224
 The treatment with bicalutamide, an AR antagonist, 
reduced MRP4 expression in LnCAP prostate cancer cell line.
223
 In addition, prostate cancer 
patients receiving androgen ablation therapy had lower level of MRP4 expression in the tumor 
tissue, compared to the uncastrated prostate cancer patients.
223
   
 
However, it should be noted that the effect of nuclear receptors is tissue-dependent.
225,226
 The 
effect of the AR agonist (androgen) on MRP4 expression observed in prostate tissue and cell 
lines does not necessarily predict the effect of the AR agonist Depo-Provera in cervicovaginal 
tissues. In addition to AR, Depo-Provera binds to PR with high affinity in vitro.
219
 However, 
currently there is no report demonstrating the role of PR in the regulation of MRP4 gene 
expression. In pregnant mice, liver Mrp4 mRNA expression was found to be elevated by 63% on 
gestational day 11, compared to the levels observed before pregnancy.
227
 This implicated that 
progesterone and/or PR may be involved in MRP4 regulation, however more studies will be 
needed to confirm the involvement of PR. In addition to AR and PR, CAR, VDR, PPAR-α, Nrf2, 
and AhR have been demonstrated to regulate MRP4 expression,
110,228,229
 but no interaction 
between these nuclear receptors and Depo-Provera have been reported. Based on this analysis, 
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more studies are warranted to confirm the role of AR and PR in the regulation of MRP4 in 
cervicovaginal tissues, and to investigate the involvement of other nuclear receptors in the Depo-
Provera induced expression changes of MRP4. 
 
In order to provide clues for the mechanism study of transporter regulation, and to evaluate the 
utility of different preclinical models in this kind of study, the mRNA expression of NRs was 
examined in the cervicovaginal and colorectal tissues of humans, macaques, and mice (Figures 
2.17 to 2.19). Multiple NRs were found to express at moderate to high levels in these tissues 
across different species. These positively expressed NRs can respond to steroid hormones (e.g. 
ER-α), nutrients (e.g. RAR-α), and oxidative stress (e.g. Nrf2). The xenobiotic sensors, such as 
PXR and CAR, were absent in cervicovaginal tissues across different species (except low 
expression of PXR in macaque endocervix). However, PXR level in colorectal tissue was found 
to be high, and was comparable to its level in liver, in all species tested. This indicated that 
transporters in cervicovaginal and colorectal tissues may be regulated by different set of NRs, 
and may respond differently to different environmental factors. The expression pattern of NRs in 
cervicovaginal and colorectal tissues was generally comparable between humans, macaques, and 
mice. If the mRNA expression of the tested NRs correlates with their activity in the tissues 
examined in this study, then the comparable expression pattern between different species 
suggested that macaques and mice could be used as research models in the studies involving 
cervicovaginal and colorectal tissue NRs. The expression profile of NRs has provided clues for 
future investigation of transporter regulation mechanisms. For example, AR is a potential 
mediator of Depo-Provera regulation of Mrp4 transporter, as discussed above. In cervicovaginal 
tissues of human and Depo-Provera synchronized mice, AR level was close to or above 1/100 of 
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GAPDH in these tissues. In human and mouse colorectal tissues, AR level was more than 10 fold 
lower than its level in cervicovaginal tissues. Future studies could focus on the role of AR, in the 
Depo-Provera induced Mrp4 up-regulation. This could be achieved with AR agonists and 
antagonists, and possibly with AR knockout mice. In addition, the differential expression of AR 
between cervicovaginal and colorectal tissues may underlie the differential effects of Depo-
Provera on Mrp4 expression between mouse cervicovaginal and colorectal tissues. Overall, the 
examination of NRs has provided useful information for the design of future mechanism studies 
and selection of animal models for these studies.  
 
In addition to the mouse model, the effect of Depo-Provera was also tested on the two epithelial 
cell lines derived from human endocervix (End1/E6E7) and vagina (VK2/E6E7). Cervicovaginal 
cell lines responded differently to this treatment (Figure 2.15 and Figures 2.9-2.13). Depo-
Provera did not alter the mRNA level of MRP4 in the three cell lines tested. However, it caused 
significant up-regulation of Mrp4 level in mouse cervicovaginal tissues. Several possibilities 
may explain the observed differences in the responsiveness to Depo-Provera. First, human and 
animal tissues are composed of multiple types of cells, and epithelial cells only constitute a small 
portion in the total amount of cells in cervicovaginal tissues. The observed effect in epithelial 
cell lines may not reflect the overall changes in the entire tissue. Another possibility is the 
difference in dose. The mice were administered with Depo-Provera (containing 3 mg of MPA) 
twice before tissue collection and expression analysis. The MPA concentration in the mice dosed 
with Depo-Provera remained unknown, but it was possible that MPA concentration available to 
mouse cervicovaginal tissues was different from the concentrations used to treat human epithelial 
cell lines (1 µM). The third possibility is that the regulation mechanism that Depo-Provera 
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activated in mouse tissues did not exist in human cervicovaginal epithelial cell lines. One 
possible mechanism that mediated the effect of Depo-Provera is nuclear receptor (NR) activation 
(discussed above). The interspecies difference in NR-mediated transporter regulation has been 
reported. Therefore, future studies will be needed to test the effect of Depo-Provera at different 
dosing levels, in more clinically relevant models, such as in the pigtailed macaques. Since many 
participants of PrEP clinical trials take Depo-Provera, the effect of this contraceptive on the 
cervicovaginal tissue transporters could be delineated by comparing the transporter expression 
and substrate drug PK data in Depo-Provera users with the data generated from other participants 
who do not take this contraceptive. If resources permit, this kind of clinical sample and data 
analysis will overcome the shortcomings of preclinical models, and generate the most clinically 
relevant information on Depo-Provera’s effect, and will be valuable for decision making as to 
whether to adjust the PrEP drug dose in Depo-Provera users. 
 
In addition to testing the effect of contraceptives/cytokines on transporter expression in 
cervicovaginal tissues, it is also important to comparatively examine the effect of these factors 
on transporter expression in HIV target immune cells. Since many antiretroviral drugs 
(nucleoside and non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase 
inhibitors) act on intracellular targets within tissue-associated immune cells, the intracellular 
concentration of these drugs is critical for efficacy. In this chapter, a T cell line (PM1) exhibited 
differential response to contraceptive ingredients (MPA, P4) and proinflammatory cytokines 
(IL1β, IL8), compared to the epithelial cell lines End1/E6E7 and VK2/E6E7. For example, MPA 
has no significant effect on BCRP expression in End1/E6E7 and VK2/E6E7 cells, but caused 
significant decrease in BCRP level in PM1 cells. It is possible that the observed differences 
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between epithelial cell lines and PM1 was due to differential patterns of transporter regulation, 
between these cell lines. Nuclear receptors are potential mediators of the effects of 
contraceptives (discussed above), and human immune cells appeared to have different expression 
profile for a number of NRs tested in this study.
230
 For example, PXR and CAR were 
undetectable in human cervicovaginal tissues (Figure 2.17), but it was found to positively 
express in CD4+ and CD8+ human T cells.
230
 Future studies will need to test whether the 
differential changes in transporter expression is related to differential regulation of substrate drug 
exposure in different types of cells, and whether the changes in transporter levels could lead to 
altered drug efficacy in immune cells. 
   
It should be noted that all the possible roles of cervicovaginal and colorectal tissue transporters 
are based on the assumption that positive mRNA levels correlate with efflux activity and 
significant role in drug pharmacokinetics. The mRNA expression of transporters does not 
necessarily correlate with their activity in microbicide absorption and disposition, and further 
work is needed to confirm the functional activity of the transporters that are moderately or highly 
expressed. Considering the number of transporters that showed high expression in cervicovaginal 
tissue, the information of protein localization, and mRNA/protein regulation will facilitate the 
prioritization and experimental design of the functional studies of cervicovaginal 
tissue/colorectal tissue/immune cell transporters. The information of the localization will help 
predict the specific role of transporters in microbicide pharmacokinetics.  
 
The transporters localized in the epithelium may be able to limit the lumen-to-tissue drug 
distribution and tissue-to-lumen drug efflux, and therefore may be relevant to the 
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pharmacokinetics of drugs administered via both vaginal and systemic routes. The transporters 
localized within the venous endothelium such as BCRP may exert unidirectional control on 
blood-to-tissue drug distribution while not affecting lumen-to-tissue drug penetration. In addition, 
the localization information will help rationally select the model to study the functionality of 
transporters.  
 
As mentioned above, a transporter could be located in different kinds of cells, such as epithelial 
cells and venous endothelial cells. If a transporter is exclusively located in one type of cell, e.g. 
endothelial cell, then the impact of transporters modulation on microbicide pharmacokinetics 
could be studied using primary or immortalized cell culture that reconstitutes the specific cell 
type in vitro. However, if a transporter is located in multiple cell types, then a clinically relevant 
animal model should be used to provide comprehensive understanding of the in vivo effect of 
transporter modulation on the cervicovaginal tissue exposure of substrates. This in vivo model 
must possess intact cervicovaginal tissues that are anatomically and physiologically comparable 
to the human female genital tract. Besides the protein localization, the understanding of the 
factors that can regulate the expression of transporters and activity in cervicovaginal tissues will 
also aid in the functional study. As reported in other tissues, the transporters which are highly 
expressed in vagina and cervix are subject to complex regulation mechanisms. One example is 
the effect of sex hormone on the expression and activity of transporters
217
 Since sex hormones 
are deposited in the lower genital tract and their concentrations can be affected by various factors 
(race, age, menstrual stage, contraception choice),
231
 it is possible that the expression and activity 
of transporters will change in different scenarios, causing inter- and intra-individual variability in 
cervicovaginal drug concentration and efficacy. It is therefore prudent to identify the scenarios 
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that transporters have differential expression/activity compared to the basal status, and 
understand whether this will result in a difference in the pharmacokinetic profile and efficacy of 
administered drugs that target the lower genital tract. 
 
In conclusion, the studies in this chapter have provided a systematic evaluation of the expression 
profile of transporters in the cervicovaginal and colorectal tissues of human and PrEP animal 
models, as well as in the cell lines derived from human cervicovaginal tissues and immune 
system. In addition, this study has examined the effects of pathophysiological factors (PrEP 
relevant factors), including menstrual/estrous cycle, exogenous 
hormones/contraceptives/inflammatory cytokines, on the mRNA levels of transporters in 
transmission-related tissues and immune cells. The information generated from this study will 
facilitate the understanding of the role of transporters in PrEP drug pharmacokinetics, and will 
likely contribute to the development of novel strategies aimed for achieving adequate tissue 
levels of PrEP drug products. This study also provides critical information regarding rational 
experimental design and data interpretation, for animal and cell line models utilized in PrEP drug 
screening and future in vivo functional study of cervicovaginal/colorectal transporters. 
Nevertheless, this study is not without limitations. The mRNA level does not necessarily 
correlate with protein level and transport/enzyme activity. Future studies are warranted to 
examine the protein localization and regulation of the most important transporters in tissues, and 
to examine the functionality of the highly expressed transporters in antiretroviral drug PK/PD.  
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3 PROTEIN LOCALIZATION OF SELECT TRANSPORTERS IN 
CERVICOVAGINAL AND COLORECTAL TISSUES OF HUMAN AND 
ANIMAL MODELS 
 
3.1 Introduction 
In Chapter 2, the mRNA expression of drug transporters has been examined in tissues and cells 
relevant to HIV-1 sexual transmission. However, the mRNA levels do not necessarily correlate 
with transporter activity, and further work is needed to confirm the functional activity of the 
transporters and enzymes that are moderately or highly expressed.  
 
The information on transporter protein localization will help rationalize the experimental design 
in the studies of transporter function. Transporters located in the epithelium presumably limit the 
lumen-to-tissue drug distribution and tissue-to-lumen drug efflux, and therefore may be a 
relevant factor in the pharmacokinetic profile of drugs administered via both vaginal and 
systemic routes. Transporters localized within the venous endothelium may affect the tissue-to-
blood drainage of the substrate drugs already distributed into tissue. Given this potential impact 
on pharmacokinetics (PK), examination of transporter localizations is required information for 
appropriate experimental design and accurate interpretation of pharmacokinetic data obtained 
from different physiologic compartments. 
 
Female users of the PrEP products have varying levels of sex steroid hormones (e.g. estrogens 
and progesterone) during their menstrual cycle. In addition, they frequently use contraceptives to 
avoid unwanted pregnancy. The information of transporter protein localization, under the 
influence of menstrual cycle, sex steroid hormones and hormonal contraceptives will enhance 
our understanding on the dynamics of transporter expression in PrEP participants. In addition, 
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the examination of the effect of these factors on transporter protein abundance and localization 
will help identify the scenario in which a transporter has the highest expression level and would 
most likely play a role in drug pharmacokinetics. This information will in turn guide the 
experimental design and prioritization of transporter function studies. As reported in other tissues, 
the transporters which are highly expressed in the vagina and cervix are subject to complex 
regulation mechanisms. One example is the effect of sex steroid hormones on the expression and 
activity of transporters. Since sex steroid hormones are deposited in the lower genital tract and 
their concentrations can be affected by various factors (race, age, menstrual stage, contraception 
choice), it is possible that the transporter expression and activity will change in different 
scenarios, causing inter- and intra-individual variability in cervicovaginal drug concentration and 
efficacy. It is therefore prudent to identify the scenarios that transporters have differential 
expression/activity compared to the basal status, and understand whether transporter modulation 
under this condition could result in improved tissue exposure of substrate drugs. 
 
The studies described in this chapter aimed to examine the protein localization of drug 
transporters in the tissues associated with or relevant to HIV-1 sexual transmission, in human 
and animal models utilized in PrEP testing. P-gp, BCRP, and MRP4 were found to be 
moderately to highly expressed in cervicovaginal and colorectal tissues of human, macaque, and 
mice. Among other positively detected transporters, these three efflux transporters potentially 
affect the pharmacokinetics/pharmacodynamics (PK/PD) of largest number of antiretroviral 
drugs, as discussed in Chapter 1 and 2, and should be listed as priorities in further investigations 
of cervicovaginal and colorectal tissue transporters. Therefore, in this chapter, the protein 
localization of these three efflux transporters was examined in the endocervix, ectocervix, vagina, 
116 
 
and colorectal tissue of human, pigtailed macaque, and Swiss Webster mice, using 
immunohistochemical (IHC) staining. To examine the effect of menopause, the protein 
localizations of P-gp, BCRP and MRP4 were compared between human premenopausal and 
postmenopausal ectocervix. In order to evaluate the effect of menstrual cycle, exogenous 
hormones and contraceptives, the protein localizations of P-gp, Bcrp and Mrp4 were examined in 
mouse tissues collected at different estrous cycle stages and after the treatment of PMSG/Depo-
Provera. The information revealed from this chapter confirms the mRNA results described in 
Chapter 2 at the protein level, and provides critical information on the experimental design and 
model selection of transporter function studies in next chapter.   
 
3.2 Materials and Methods 
3.2.1 Collection of human and animal tissues 
The procurement of human, macaque, and mouse tissues were described in Chapter 2. Tissues 
were fixed in 10% neutral buffered formalin (10% NBF) for no less than 24 hours. The rabbit 
tissues were not stained due to the lack of appropriate primary antibodies for rabbit transporter 
detection.  
 
3.2.2 Immunohistochemical staining 
Immunohistochemical staining was conducted by the Research Histology Service of the 
University of Pittsburgh. Human, macaque, and mouse tissues (endocervix, ectocervix, vagina, 
and sigmoid colon/colorectum) were fixed in 10% neutral-buffered formalin for over 24 hours 
and embedded in paraffin. Five µm sections were made and de-paraffinized using xylene. 
Antigen retrieval was performed by steaming the slides in the pH9 retrieval buffer (Dako) for 40 
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minutes. The slides were treated with 3% H2O2 for 8 minutes, followed by blocking in 
Avidin/Biotin block solution (Vector) for 15 minutes and blocking in non-serum protein block 
for 10 min.  
 
Primary antibodies (Table 3.1) purchased from Santa Cruz Biotechnology Inc. were applied to 
slides with overnight incubation at 4 °C. After washing with phosphate buffered saline solution 
containing Tween 20 (PBST), biotinylated secondary antibodies (Table 3.2) purchased from 
Vector Inc. were applied to the slides and incubated at room temperature for 30 min.  
 
Table 3.1 Information of primary and secondary antibodies. 
 
Transporter 
Primary antibody  Biotinylated secondary antibody  
(1: 200 IgG) 
Human and macaque 
samples 
Mouse samples 
 Human and macaque 
samples 
Mouse samples 
P-gp H-241 (1:15) H-241 (1:15)  goat anti-rabbit goat anti-rabbit 
BCRP BXP-21 (1:20) BXP-53 (1:25)  horse anti-mouse Goat anti-rat 
MRP4 F6 (1:50) M4I-80 (1:15)  horse anti-mouse Rabbit anti-Rat 
 
After the incubation with secondary antibodies, the slides were washed with PBST. ABC Elite 
reagents (Vector) were applied afterwards and slides were incubated for 30 minutes, followed by 
AEC chromogen (Skytec) incubation for color development. The slides were then counterstained 
with Hematoxylin and mounted with Crystal Mount (Sigma). In the negative control staining for 
a transporter protein in a given tissue, the non-immunized IgG purified from the species in which 
the primary antibody was raised was used instead of the primary antibody. 
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3.3 Results 
3.3.1 Protein localization of P-gp in human and macaque cervicovaginal tissues 
For P-gp staining in human tissues, the sigmoid colon was stained as a positive control tissue, 
since abundant P-gp protein expression has been reported for this tissue.
139
 The apical membrane 
of the columnar epithelial cells of sigmoid colon was stained strongly positive, while the colonic 
vascular endothelial cells were not stained (Figure 3.1). This is in line with published studies and 
validated the IHC staining procedure in our experiments. 
 
As discussed above, since multiple cell types may control the drug absorption and disposition in 
a given tissue, the columnar epithelial cells, stratified squamous epithelial cells, as well as 
vascular endothelial cells along the cervicovaginal tract were examined for their staining of 
transporter proteins. In endocervix, ectocervix and vagina, the epithelial cells facing the 
cervicovaginal lumen as well as the endothelial cells of the blood and lymphatic vessels running 
through the stromal tissue were stained positive (Figure 3.1). Among the epithelial cells of the 
three kinds of genital tract tissues, the stratified squamous epithelial cells in ectocervical tissue 
showed most intensive staining. In ectocervix, the basal layer of the ectocervical epithelium, 
which is composed of single layer of columnar cells, showed even more intense staining 
compared to the uppermost layers. Notably, the uppermost layers predominantly displayed 
plasma membrane staining for P-gp, while the basal layer of the epithelium displayed cytosol 
staining. This difference was possibly due to more abundant P-gp distribution in subcellular 
organelles in the basal layer epithelial cells, as reported in other cell types.
232,233
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The staining of the endocervical and vaginal epithelial cells appeared to be weaker than that of 
ectocervical epithelial cells (Figure 3.1). In addition, the difference in staining signal intensity 
between the uppermost and basal epithelial layers in human vagina was less evident than the 
difference observed in ectocervix. However, the staining of the stromal vascular endothelial cells 
in human endocervix and vagina was as strong as it was in ectocervix. The positive staining of P-
gp in human lower genital tract and colorectal tissue corresponded to their moderate to high level 
mRNA expression revealed in Chapter 2.  
 
In macaque tissues, the P-gp staining patterns were generally similar to those of human tissues 
(Figure 3.1). However, differences had been observed between the two species. In the epithelial 
cells of macaque ectocervix and vagina, the staining signal was found in the cytoplasm rather 
than preferentially distributed on the plasma membrane. Moreover, there was no clear difference 
in signal intensity between different layers of the epithelium, in macaque ectocervix and vagina. 
The similarity between human and macaque in P-gp staining was consistent with the similarity in 
mRNA expression between these two species. The staining results for human and macaque P-gp 
were summarized in Table 3.2.  
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Figure 3.1 Localization of P-gp protein in human and macaque cervicovaginal tissues.  
Human and macaque tissues were fixed in 10% neutral buffered formalin (NBF) for no less than 
24 hours, and embedded, processed, and stained for P-gp as described in Materials and Methods 
of this chapter. For endocervix, ectocervix and vagina, a representative picture from at least 3 
tissue samples was shown above; for colorectal tissue, the staining of one tissue sample was 
shown above. Color development was with AEC, and red color indicates positive detection. A-D: 
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endocervix, ectocervix, vagina and sigmoid colon of women. E-H: endocervix, ectocervix, 
vagina and colorectum of pigtailed macaques. Black arrows: epithelial cells; white arrows: 
vascular endothelial cells. Magnification, 40 × for A and E, 10 × for B, C, D, F, G, H. 
 
 
3.3.2 Protein localization of BCRP in human and macaque cervicovaginal tissues 
For BCRP staining in human tissues, the epithelial cells of human sigmoid colon exhibited 
strong positive signal, while the staining of vascular endothelial cells was not observed in the 
colon (Figure 3.2). For the genital tract tissues, the staining was not observed in the plasma 
membrane of epithelial cells. However, positive staining signal was found in the nucleus of a 
subset of ectocervical and vaginal epithelial cells.  
 
Intense staining was observed for the vascular endothelial cells within the stromal tissue of 
endocervix, ectocervix and vagina (Figure 3.2). Notably, strongly positive staining of blood 
vessels running through the epithelial layers of human ectocervix and vagina could be observed, 
which clearly distinguished these vessels from surrounding epithelial cells.  
 
In macaque tissues, the BCRP staining patterns were generally similar to those of human tissues 
(Figure 3.2). However, differences were observed between the two species. The nucleus staining 
was not observed in the epithelial cells of macaque ectocervix and vagina. In addition, the 
epithelial cells of macaque colorectum appeared to have weaker staining compared to their 
human counterparts, while the staining of vascular endothelial cells was more obvious compared 
to those cells in human colon. The strong staining signal of BCRP in human and macaque genital 
tract tissues was in line with the high mRNA level of BCRP in these tissues, as described in 
Chapter 2. The staining results for human and macaque BCRP were summarized in Table 3.2. 
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Figure 3.2 Localization of BCRP protein in human and macaque cervicovaginal tissues.  
Human and macaque tissues were fixed in 10% neutral buffered formalin (NBF) for no less than 
24 hours, and embedded, processed, and stained for BCRP as described in Materials and 
Methods of this chapter. For endocervix, ectocervix and vagina, a representative picture from at 
least 3 tissue samples was shown above; for colorectal tissue, the staining of one tissue sample 
was shown above. Color development was with AEC, and red color indicates positive detection. 
A-D: endocervix, ectocervix, vagina and sigmoid colon of women. E-H: endocervix, ectocervix, 
vagina and colorectum of pigtailed macaques. The insets of B and C are enlarged epithelial areas 
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that contain intensely stained intraepithelial blood vessels and the positively stained epithelial 
nuclei. Black arrows: epithelial cells; white arrows: vascular endothelial cells. Magnification, 40 
× for A and E, 10 × for B, C, D, F, G, H.) 
 
3.3.3 Protein localization of MRP4 in human and macaque cervicovaginal tissues 
For MRP4 staining in human tissues, the columnar epithelial cells of colorectum gave a 
moderately positive signal, while no staining was found in the vascular endothelial cells of the 
colon tissue (Figure 3.3).  
 
Among genital tract tissues, the most intense staining was observed on the basolateral membrane 
of the columnar epithelial cells in endocervix. However, no staining signal can be readily 
observed in the vascular endothelial cells of endocervix (Figure 3.3). Compared to endocervix, 
the staining of ectocervical and vaginal epithelial cells appeared to be weaker. The staining of 
vascular endothelial cells in ectocervix and vagina appeared to be more obvious than that in 
endocervix (Figure 3.3).  
 
In macaque tissues, the MRP4 staining of the columnar epithelial cells in macaque colorectum 
appeared to be less evident, while the vascular endothelial cells displayed stronger staining, 
compared to those cells in human sigmoid colon (Figure 3.3). In macaque endocervix, the 
staining pattern was identical to that of human endocervix. In macaque ectocervix and vagina, 
the cytoplasmic staining was the major staining pattern for MRP4, and no positive staining on 
the plasma membrane could be observed.  
 
In human ectocervix, vagina and colorectum, the MRP4 staining appeared weaker than the signal 
of P-gp and BCRP, which was in line with the lower mRNA level of MRP4 in these tissues. The 
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stronger MRP4 staining signal in human endocervix and ectocervix compared to vagina was 
consistent with several fold higher MRP4 mRNA levels in endocervix and ectocervix, as 
demonstrated in Chapter 2. In addition, the similarity between human and macaque in MRP4 
staining corresponded to the similarity in mRNA levels (Chapter 2). The staining results for 
human and macaque MRP4 were summarized in Table 3.2. 
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Figure 3.3 Localization of MRP4 protein in human and macaque cervicovaginal tissues.  
Human and macaque tissues were fixed in 10% neutral buffered formalin (NBF) for no less than 
24 hours, and embedded, processed, and stained for MRP4 as described in Materials and 
Methods of this chapter. For endocervix, ectocervix and vagina, a representative picture from at 
least 3 tissue samples was shown above; for colorectal tissue, the staining of one tissue sample 
was shown above. Color development was with AEC, and red color indicates positive detection. 
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A-D: endocervix, ectocervix, vagina and sigmoid colon of women. E-H: endocervix, ectocervix, 
vagina and colorectum of pigtailed macaques. Black arrows: epithelial cells; white arrows: 
vascular endothelial cells. Magnification: 20 × for A, 40 × for E, 10 × for B, C, D, F, G, H. 
 
Table 3.2 Summary of the immunohistochemical staining results of P-gp, MRP4 and BCRP 
in human and macaque tissues.  
 
Tissue type Cell type 
P-gp  MRP4  BCRP 
Human Macaque  Human Macaque  Human Macaque 
Endocervix 
Columnar epithelial cells ● ●  ●● ●●  ○ ○ 
Vascular endothelial cells ●● ●● 
 
○ ○ 
 
●● ●● 
Ectocervix 
Squamous epithelial cells ●● ● 
 
● ● 
 
● ○ 
Vascular endothelial cells ●● ●●  ● ●  ●● ●● 
Vagina 
Squamous epithelial cells ● ●  ● ●  ● ○ 
Vascular endothelial cells ●● ●● 
 
● ● 
 
●● ●● 
Sigmoid 
colon 
(human) or 
Colorectum 
(macaque) 
Columnar epithelial cells ●● ●●  ● ●  ●● ● 
Vascular endothelial cells ○ ○ 
 
○ ● 
 
○ ● 
 
○, not detected; ●, positively stained; ●●, strongly positive. 
 
3.3.4 The effect of menopause on transporter protein localization in human ectocervix 
To evaluate the effect of menopause on transporter protein abundance and localization in 
cervicovaginal tissues, IHC staining of P-gp, BCRP and MRP4 was performed on 
postmenopausal human ectocervix (Figure 3.4). Compared to the premenopausal tissues, the P-
gp, BCRP and MRP4 protein expression appeared to be weaker and more diffuse in the epithelial 
layers. The condensation of transporter protein in the basal epithelial layers, which were seen for 
all the three transporters in premenopausal ectocervix, was not observed in postmenopausal 
tissues. However, the vasculatures remained densely stained for all the three transporters, 
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especially in the stromal part of tissues. Notably, there were more blood vessels running through 
the epithelium could be observed in postmenopausal ectocervix, compared to the premenopausal 
tissues.    
 
Figure 3.4 The effect of menopause on protein expression of P-gp, BCRP and MRP4 in 
human ectocervix. 
Human postmenopausal ectocervical tissues were fixed in 10% neutral buffered formalin for no 
less than 24 hours, and embedded, processed, and stained for P-gp, BCRP and MRP4, as 
described in Materials and Methods of this chapter. For each transporter, 3 tissue samples (from 
3 donors) were stained, and representative pictures were shown above. The staining of 
premenopausal ectocervix tissues for P-gp, BCRP, and MRP4 are shown in Figures 3.1, 3.2, and 
3.3, respectively. Color development was with AEC, and red color indicates positive staining. 
Two magnifications were employed, 10 × for the first row to depict the overall staining pattern in 
both epithelium and stroma, and 20 × for the second row to focus on the staining of vascular wall 
of blood vessels running through the epithelial layers (white arrows). 
 
3.3.5 Protein localization of P-gp in cervicovaginal tissues of naturally cycling and 
synchronized mice  
During the natural estrous cycle, P-gp protein was distributed in both epithelium and stroma, in 
the three segments of female mouse genital tract (Figure 3.4). There was no marked difference in 
P-gp protein abundance and localization pattern. Compared to the natural estrous cycle, PMSG 
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treatment did not exert obvious effect  on protein abundance or localization. Depo-Provera 
treatment did not affect P-gp protein in vagina. However, Depo-Provera increased the P-gp 
protein density in stroma and reduce P-gp density in epithelia of both endocervix and ectocervix 
(Figure 3.4).  
 
Figure 3.5 The effect of estrous cycle, PMSG and Depo-Provera on protein expression of P-
gp (Abcb1a and Abcb1b) in mouse cervicovaginal tissues. 
Tissues were collected from mice euthanized under the following 4 conditions: estrus and 
diestrus stages during the natural estrous cycle, synchronized estrus after PMSG treatment, 
synchronized diestrus after Depo-Provera treatment. Tissues were fixed in 10% neutral buffered 
formalin for no less than 24 hours, and embedded, processed, and stained for P-gp (antibody 
recognizes both mouse Abcb1a and Abcb1b), as described in Materials and Methods of this 
chapter. The majority of pictures shown are representative of the staining results from more than 
3 mice. Color development was with AEC, and red color indicates positive staining. Black 
arrows indicate the position of epithelial cells, and blue arrows denote the positively stained 
vascular endothelial cells. Magnification, 20 × for all pictures. 
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3.3.6 Protein localization of Bcrp in cervicovaginal tissues of naturally cycling and 
synchronized mice 
During the natural estrous cycle, Bcrp protein was primarily localized in the vessel wall of the 
stromal part of mouse endocervix and ectocervix (Figure 3.6). The epithelium of mouse vagina 
was also positively stained. There was no obvious difference in Bcrp protein abundance and 
localization between the two stages of natural estrous cycle, in all the three segments of mouse 
lower genital tract. Compared to the natural cycle, pregnant mare's serum gonadotropin (PMSG) 
synchronization did not seem to cause a significant change in endocervix and ectocervix, while 
Depo-Provera appeared to increase the protein density in these two tissues, especially in the 
stromal part. In addition, PMSG and Depo-Provera synchronization appeared to decrease Bcrp 
protein density in vaginal epithelium, compared to natural estrous stages. 
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Figure 3.6 The effect of estrous cycle, PMSG and Depo-Provera on protein expression of 
Bcrp in mouse cervicovaginal tissues. 
Mouse tissues were fixed in 10% neutral buffered formalin for no less than 24 hours, and 
embedded, processed, and stained for Bcrp, as described in Materials and Methods of this 
chapter. The majority of pictures shown are representative of the staining results from more than 
3 mice. Color development was with AEC, and red color indicates positive staining. Black 
arrows indicate the position of epithelial cells, and blue arrows denote the positively stained 
vascular endothelial cells. Magnification, 20 × for all pictures. 
 
3.3.7 Protein localization of Mrp4 in cervicovaginal tissues of naturally cycling and 
synchronized mice 
During the natural estrous cycle, Mrp4 protein in mouse endocervix and ectocervix was 
primarily found at the diestrus stage, while the staining at estrus stage was not readily observed. 
Weak staining of Mrp4 protein was found in epithelium and stroma in mouse vagina at both 
estrus and diestrus stages. Compared to the natural estrous cycle, PMSG treatment decreased the 
epithelial and stromal abundance of Mrp4 protein in mouse endocervix, ectocervix and vagina. 
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Depo-Provera treatment markedly increased Mrp4 density in the epithelial layers, while 
decreased Mrp4 density in the stromal part, in all three tissue segments, compared to the natural 
estrous cycle.    
 
Figure 3.7 The effect of estrous cycle, PMSG and Depo-Provera on protein expression of 
Mrp4 in mouse cervicovaginal tissues. 
Mouse tissues were fixed in 10% neutral buffered formalin for no less than 24 hours, and 
embedded, processed, and stained for Mrp4, as described in Materials and Methods of this 
chapter. The majority of pictures shown are representative of the staining results from more than 
3 mice. Color development was with AEC, and red color indicates positive staining. Black 
arrows indicate the position of epithelial cells, and blue arrows denote the positively stained 
vascular endothelial cells. Magnification, 20 × for all pictures. 
 
3.4 Discussion and Conclusion 
The protein expression examined in this chapter confirmed the transporter mRNA results 
presented in Chapter 2. Although IHC staining is not a quantitative approach for the 
132 
 
measurement of protein level, the results here address the limitations of the RT-PCR approach 
adopted in Chapter 2.  
 
The IHC staining results once again confirmed the positive mRNA expression of three most 
important efflux transporters, at protein level. P-gp, BCRP, and MRP4 were positively detected 
at mRNA level, in the cervicovaginal and colorectal tissues of humans, macaques, rabbits, and 
mice. The cervicovaginal levels were moderate or high compared to the levels in colorectal 
tissue and liver. In this chapter, the positive protein expression of these transporters in human, 
macaque, and mouse tissues was demonstrated using IHC staining. In addition, the protein 
abundance of P-gp, Bcrp, and Mrp4 in mouse cervicovaginal tissues generally correlated well 
with their mRNA levels under the influence of estrous cycle, PMSG, and Depo-Provera, as 
reported in Chapter 2.   
 
The IHC staining of transporters presented provides valuable information on transporter 
localization, which cannot be revealed by RT-PCR. For example, the transporter mRNA levels 
did not significantly differ between pre- and postmenopausal human ectocervix (Chapter 2), 
however the differences at protein level has been found for P-gp, BCRP, and MRP4. Although 
the protein expression on stromal vessel walls remained unchanged for these three transporters 
(Figure 3.4), the protein expression appeared to be more diffuse in the epithelial layers in 
postmenopausal tissues. In addition, the IHC staining of mouse P-gp demonstrated that Depo-
Provera treatment not only increased P-gp protein density in mouse endocervix and ectocervix, 
but also decreased the epithelial P-gp abundance in these two tissues (Figure 3.5).  
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However, it should be noted that positive mRNA and protein expression of cervicovaginal 
transporters do not necessarily predict their significant role in antiretroviral drug 
pharmacokinetics. In addition, the differential expression patterns of cervicovaginal transporters, 
under different conditions (menstrual cycle, exogenous hormones and hormonal contraceptives), 
do not necessarily result in differential levels of transporter activity. Post-translational 
modifications represent an additional mechanism of transporter regulation, sometimes resulting 
in the transport activity inconsistent with the protein expression level. Therefore, it is crucial to 
examine the function of the positively expressed transporters in cervicovaginal and colorectal 
tissue exposure of substrate drugs. 
 
The region-specific characterization of transporter protein localization could inform the 
experimental design of studies on transporter function. The transporters examined in this study 
are localized in multiple cell types, including columnar (glandular) epithelial cells, squamous 
epithelial cells, and vascular endothelial cells. This suggests that each transporter may affect 
various aspects of substrate absorption and disposition. For topically (vaginally) administered 
drugs, the efflux transporters located on the luminal (columnar and squamous) epithelial cells 
provides a mechanism that can directly limit drug penetration into tissue, which could be similar 
to that observed for the enterocytes lining the small intestine.
49
 As the columnar (glandular) 
epithelial cells are responsible for the secretion of mucosal fluid, the transporters located in this 
type of cell likely will affect the secretion of absorbed drugs from tissue to the mucosal fluid. 
The transporters located on the venous/lymphatic endothelium may have a role in the 
blood/lymphatic drainage from tissue to systemic blood/lymph circulation. For orally 
administered drugs, the transporters on the venous/lymphatic endothelium may limit the 
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distribution from blood/lymph to cervicovaginal tissues, and the transporters on glandular 
epithelial cells may function to efflux the drug from tissue to lumen. Therefore, when conducting 
studies to investigate transporter function in tissue drug distribution, its role in both topically 
(vaginally or rectally) and systemically administered drugs should be examined. 
 
Drug absorption and disposition in the cervicovaginal and colorectal tissues is a complex process, 
which can be affected by a number of factors, including mucus secretion, systemic blood 
perfusion and drainage, as well as the regional blood flow between tissues.
234
 Therefore, when 
studying a transporter’s role in PrEP drug pharmacokinetics, it is critical to understand its 
comprehensive role in controlling drug exposure in the entire tissue and not just its function in a 
specific type of cell. When utilizing in vitro models to study transporter function, it is necessary 
to employ multiple cell lines corresponding to the multiple cell types that carry transporter 
protein in female genital tract. When utilizing animal models for functional characterization, it is 
prudent to ensure that the animal’s genital tract is anatomically similar to human tissues, and 
patterns of transporter expression and localization are comparable to those patterns in human.  
 
In this study, pigtailed macaques showed comparable expression and localization patterns of 
cervicovaginal P-gp, MRP4 and BCRP as compared to humans. Macaque is considered to be a 
biologically relevant model for PrEP efficacy assessment.
198,235,236
 The similarity in transporter 
expression between humans and macaques also confirmed the utility of macaque model in 
microbicide efficacy and/or safety testing, especially when the three efflux transporters will 
affect the absorption and disposition of the tested drug.  
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Depo-Provera synchronized Swiss Webster mouse model has been used by researchers to 
evaluate the safety of vaginally administered PrEP products (microbicides).
199,200
 Although the 
mRNA and protein expression of transporters in the Swiss Webster mice were not identical to 
those in human tissues, the mouse model is comparable to human in certain aspects. For example, 
the Depo-Provera synchronize mice showed strongly positive expression of Mrp4 in the 
epithelium of endocervix, which is similar to MRP4 expression pattern in human endocervix. In 
addition, the complexities of transporter-mediated drug distribution in tissues require an in vivo 
model for comprehensive understanding of transporter function, and the mouse model represents 
a convenient platform for proof-of-concept studies of transporter function in vivo. Future studies 
are warranted to examine the transporter expression in the cervicovaginal and colorectal tissues 
of humanized mice with transplanted human liver and lymphocytes,
237
 thus both 
pharmacokinetics and efficacy studies can be conducted in the mouse model. 
 
In conclusion, the studies presented in this chapter have characterized protein expression of three 
most relevant efflux transporters in the lower genital tract of humans, pigtailed macaques, and 
mice. The results have confirmed positive transporter expression in cervicovaginal tissues at 
protein level. In addition, these studies have confirmed the effect of menstrual (estrous) cycle, 
PMSG, and Depo-Provera on transporter protein abundance and localization, in cervicovaginal 
tissues. The comparison between human and animal/cell models in transporter protein expression 
provides critical information regarding the utility of these models to study cervicovaginal tissue 
transporter function. These results will inform the experimental design and data interpretation of 
future studies of transporter function.   
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4 FUNCTIONAL ROLE OF MRP4 TRANSPORTER IN THE 
DISTRIBUTION OF TENOFOVIR INTO MOUSE CERVICOVAGINAL 
AND COLORECTAL TISSUES 
 
4.1 Introduction 
Previous chapters have revealed the positive expression of several efflux transporters in the 
cervicovaginal and colorectal tissues of human and animal models, at mRNA and protein levels. 
The next required step is to investigate whether these transporters are functional in the tissue 
distribution of antiretroviral drugs. The information generated from such functional 
characterizations will enhance the understanding on critical determinants of drug exposure in 
those tissues relevant to HIV-1 sexual transmission, and facilitate PrEP optimization in multiple 
aspects.  
 
Tenofovir (TFV) is an extensively investigated drug in both oral and topical PrEP.
10,238
 It is a 
nucleotide reverse transcriptase and prevents HIV-1 infection by interfering with the reverse 
transcription of viral RNA in host immune cells. In oral PrEP, it has been tested in the prodrug 
form TFV disoproxil fumarate (TDF), in combination with emtricitabine. The combination 
regimen Truvada has been approved by the FDA for the prevention of HIV-1 sexual transmission 
between serodiscordant couples (one partner in the couple is HIV-1 positive while the other 
partner is negative). In the development of vaginal microbicides, it has been tested in dosage 
forms including gel, ring, and tablet. A 1% TFV gel showed effectiveness in reducing the HIV-1 
acquisition rate by 39% in a Phase 2b trial.
13
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Strategies are being actively pursued to enhance the effectiveness of antiretroviral-based PrEP 
products for HIV-1 prevention,
12
 and long-acting dosage forms are undergoing development. 
Although the utilization of long-acting products could avoid the low adherence issue observed in 
PrEP clinical trials,
12
 challenges remain for the successful development of PrEP products. The 
effective in vivo drug concentration for HIV-1 prevention remains unknown,
239
 and multiple 
barriers exist toward achieving sufficient drug exposure in the tissue-associated immune cells, 
even with topically applied microbicides.
33
 Therefore, it is urgent to understand critical 
physiologic determinants of TFV exposure in cervicovaginal and colorectal tissues, to inform the 
development of novel strategies that can achieve maximally tolerated drug exposure and further 
enhance PrEP effectiveness. MRP4 and MRP7 efflux TFV, and MRP4 is the major efflux 
transporter.
84,113
 OAT1 and OAT3 are major uptake transporters for TFV.
86,113
 As demonstrated 
in Chapters 2 and 3, MRP4 and MRP7 were expressed at moderate to high levels, while OAT1 
and OAT3 were not detectable, in human cervicovaginal and colorectal tissues. The IHC staining 
revealed that MRP4 protein was localized in the epithelial cells of human endocervix and 
colorectal tissue, and in the epithelial and vascular endothelial cells in human ectocervix and 
vagina. Based on these results, it is highly possible that MRP4 plays a role in TFV distribution 
into the cervicovaginal and colorectal tissues, and this should be examined in transporter 
function studies.  
 
Although previous chapters have revealed the positive mRNA and protein expression of multiple 
transporters including MRP4, its in vivo role remains largely unknown. Functional studies are 
necessary to confirm the in vivo role of cervicovaginal and colorectal tissue transporters in 
controlling local tissue distribution of TFV. Even if the positively expressed MRP4 possesses 
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activity, it does not necessarily exert a significant impact on the pharmacokinetics of TFV in 
every tissue where positive expression was seen. TFV entry and retention in a given tissue is 
determined by multiple factors, including the passive transcellular and paracellular permeability 
of TFV, blood flow between tissues and systemic compartment, abundance and viscosity of 
cervicovaginal fluid, and binding to tissue proteins. Therefore, the study of the role of MRP4 in 
TFV distribution is warranted to confirm MRP4 function in the tissues with positive expression.  
 
Based on the characterization of MRP4 mRNA and protein expression in the tissues of human 
and animal models, the Depo-Provera synchronized mouse was selected for the study of Mrp4 
function in cervicovaginal and colorectal tissues. This model has been previously utilized by 
some researchers to evaluate the safety of vaginal microbicides, and has shown good correlation 
with the clinical results for several microbicide candidates.
199,200
 The Mrp4 expression in mouse 
cervicovaginal and colorectal tissues were tested at two different stages of the natural estrous 
cycle, and under the synchronization by PMSG or Depo-Provera, which were described in 
Chapters 2 and 3. The mRNA and protein expression of cervicovaginal tissue Mrp4 was highest 
after Depo-Provera synchronization, compared to the mice undergoing natural cycling or 
synchronized by PMSG, suggesting the Mrp4 function may be most prominent under this 
condition. Efflux transporters, epithelial layer, intercellular tight junction proteins constitute the 
major component of the physiologic barrier against drug distribution from vaginal lumen to 
tissue and plasma. After Depo-Provera treatment, the cervicovaginal epithelium was evidently 
thinned, and it has been reported that tight junction protein abundance may be decreased after the 
treatment of progesterone-based agents. Under this condition, the role of Mrp4 transporter may 
become more evident in the overall permeation barrier function. In addition, the effect of co-
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administration of Mrp4 inhibitor on substrate drug penetration may be most evident under this 
condition. This does not only apply to the vaginal administration, but may also be true in the 
systemic administration of substrate drugs, since the drug distribution from blood to 
cervicovaginal tissue and fluids also needs to go through the similar set of tissue barriers. 
 
Although the expression level and protein localization of Mrp4 in mouse tissues were not 
identical to those in human tissues, the mouse model represents a convenient in vivo model for 
proof-of-concept studies of transporter function. In this chapter, the function of the Mrp4 
transporter in the cervicovaginal tissue distribution of vaginally and systemically administered 
TFV is determined. In vaginal dosing studies, Depo-Provera synchronized mice were 
administered with vaginal gel containing TFV, with or without the Mrp4 inhibitor MK571. In 
systemic dosing studies, the mice were administered intraperitoneally with TFV solution, with or 
without MK571. The TFV concentrations in cervicovaginal lavage (CVL), cervicovaginal tissues 
and colorectum, as well as plasma were measured to delineate the effect of Mrp4 inhibition on 
TFV distribution in these three compartments. The results obtained from this study will provide 
direct evidence of Mrp4’s role in TFV distribution into mucosal tissues relevant to HIV-1 sexual 
transmission. 
 
4.2 Materials and Methods 
4.2.1 Preparation of vaginal gels and drug/chemical solutions for mouse administration 
3
H-TFV was purchased from Moravek Biochemicals and Radiochemicals Inc.. Two batches of 
3
H-TFV stock were used, and the specific activity of the stock solution was either 13.3 Ci/mmol 
or 8.8 Ci/mmol. The radioactivity of the stock solution (EtOH:H2O = 1:1) was 1 mCi/mL for 
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both batches. For vaginal gel administration, 20 µL of gel was administered intravaginally to 
each mouse, using a 1 mL disposable syringe (BD Biosciences) sequentially capped with a 200 
µL pipette tip and a 10 µL tip, as shown in Figure 4.1 below. 
 
Figure 4.1 The syringe used for gel administration into mouse vagina. 
 
For mouse vaginal administration, 2.7% universal placebo gel (pH4.4) was used as a base to mix 
with TFV and/or MK571. Two kinds of gel were formulated for the pharmacokinetic (PK) study, 
and three kinds of gel were formulated for the safety study. For each kind of gel listed in Table 
4.1 below, at least 500 µL was prepared, and the amount of each ingredient was shown in the 
table. Gel administration in the mouse model is described in the next section (4.2.2) of this 
chapter.  
Table 4.1 Preparation of gels for mouse PK and safety evaluations via the vaginal route 
 
Ingredients 
Amount added (µL)  
PK study 
 
Safety study 
TFV 
gel 
(TFV+MK571) 
gel 
 
TFV 
gel 
(TFV+MK571) 
gel 
4% N-9 gel 
3
H-TFV stock (8.8 Ci/mmol, 1 mCi/mL) 25 25 
 
0 0 0 
0.5% TFV solution (non-radiolabeled) 7.8 7.8  
9.4 9.4 0 
7.5 mg/mL MK571 saline solution 18 0 
 
0 18 0 
Saline (0.9% NaCl) 0 18 
 
0 0 0 
Nonoxynol-9 (N-9) 0 0 
 
0 0 20 
2.7% universal placebo gel 449 449 
 
490 472 480 
Total volume (µL) 499.8 499.8 
 
499.4 499.4 500 
Twenty µL of gel was administered to each mouse. 
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The components of the universal placebo gel used to formulate the gel products in mouse studies 
were shown in Table 4.2 below. Sorbic acid was added into water and mixed until fully dissolved. 
Sodium chloride was added, and pH was determined. If the pH was different from the target 
pH4.4, then 1M NaOH or HCl was added to adjust the pH. Hydroxyethyl cellulose was then 
slowly added to the solution with a mixer, and water is added to adjust the final total weight after 
all the ingredients were fully dissolved.  
 
Table 4.2 Preparation of universal placebo gel 
 
Ingredient Amount added to make 100 g gel 
Sorbic acid 0.1 
Sodium chloride 0.85 
Hydroxyethyl cellulose 250 HX 2.7 
Sodium hydroxide 18% As needed 
MilliQ water Supplement to 100 
Total weight (g) 100 
 
4.2.2 Mouse administration and sample collection 
All animal procedures were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee (IACUC). Female Swiss Webster mice (6 weeks old, around 23 g body 
weight) synchronized with Depo-Provera were used for all experiments in this chapter. To 
synchronize the mice into diestrus stage, mice were subcutaneously (SC) injected twice with 
Depo-Provera (Pfizer Inc.), on Day 1 and Day 5, at the dose of 3 mg per mouse. Synchronized 
diestrus stage was reached on Day 8, and all the pharmacokinetic experiments were performed 
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on this day. The diestrus stage of mouse estrous cycle was confirmed when vaginal smears were 
found to contain predominantly leukocytes, as described in Chapter 2.  
 
To study the functional role of Mrp4 transporter in the PK of vaginally administered TFV, 
synchronized mice were divided into 3 groups. The gels used in these experiments are listed in 
Table 4.1 above. Group 1 mice were dosed intraperitoneally (IP) with 100 µL of saline, followed 
by 20 µL of TFV gel dosed 30 min later vaginally; Group 2 mice were dosed IP with 100 µL of 
saline containing 7.5 mg/mL MK571, followed by 20 µL of TFV gel dosed 30 min later 
vaginally; Group 3 mice were dosed IP with 100 µL of saline, followed by 20 µL of 
(TFV+MK571) gel dosed 30 min later vaginally. The determination of TFV dosing level in mice 
was based on the measured TFV concentration in human cervicovaginal tissues several days post 
gel administration in the pharmacokinetic studies of 1% TFV gel.
21
 The purpose of selecting this 
dose is to mimic the situation in which the tissue drug concentration is dramatically decreased 
from the initial level, and increasing drug exposure would most likely enhance microbicide 
effectiveness. The selection of MK571 dose was based on published animal studies with this 
inhibitor. In these studies, MK571 dose ranged from 1 to 100 mg/kg, and MK571 was 
administered through oral or intravenous routes.
240-242
 In this chapter, 0.75 mg MK571 was 
administered IP to each mouse weighed around 23 g (32.6 mg/kg). This is an intermediate dose 
that was supposed to result in adequate levels in cervicovaginal and colorectal tissues for 
transporter inhibition, without causing obvious toxicity. Five minutes prior to vaginal gel dosing, 
mice were injected IP with 100 µL of saline containing 10 mg/mL ketamine HCl (Henry Schein 
Animal Health) and 20 mg/mL xylazine (Sigma-Aldrich), to sedate the mice and facilitate 
vaginal gel administration. The dosed mice were euthanized with CO2 followed by cervical 
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dislocation, at 0.5 h and 1 h post gel administration, for all the three groups. The euthanized mice 
were immediately subject to the collection of cervicovaginal lavage (CVL). CVL was obtained 
through 8 sequential vaginal washes with 25 µL of saline (200 µL in total), using a 200 µL 
pipette tip with blunt-end. Around 0.25 cm of the sharp end of the tip was cut using a scissor to 
account for the high viscosity of the lavage. Blood was collected from inferior vena cava (IVC) 
and heart, using 1 mL disposable syringe capped with heparinized 25G needles. The collected 
blood was centrifuged at 5000 rpm for 5 min (Eppendorf MiniSpin Plus), and 100 µL of the 
supernatant was collected as plasma samples for further analysis. Mouse tissues including uterus, 
endocervix, ectocervix, vagina, colorectum, and kidney were collected using a surgical scissor. 
The harvested tissues were rinsed with saline, and the surface water was gently absorbed using 
gauzes. The tissues were then put into 1.5 mL tubes, and the weight of a tissue sample (mg) was 
obtained by subtracting the weight of the empty tube from the weight of the tube with the tissue. 
 
To study the functional role of Mrp4 transporter in the PK of IP administered TFV, synchronized 
mice were divided into two groups. Group 1 mice were IP administered with 100 µL of saline, 
followed by IP injection of 100 µL of 
3
H-TFV saline solution (0.94 × 10
-5
 mmol/mL, 125 
µCi/mL) 15 min later. Group 2 mice were IP administered MK571-containing saline (7.5 
mg/mL), followed by the same 
3
H-TFV solution in Group 1. The determination of TFV dosing 
level in mice was based on the measured TFV concentration in human cervicovaginal tissues 
several days post the administration of Truvada (oral tenofovir disoproxil fumarate in 
combination with emtricitabine) in oral PrEP pharmacokinetic studies.
21
 The purpose of selecting 
this dose is to mimic the situation in which the tissue drug concentration is dramatically 
decreased from the maximal level, and increasing drug exposure would most likely enhance 
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microbicide effectiveness. Mice were euthanized 1.5 h after TFV administration. CVL was 
collected using 60 µL of saline (20 µL saline per wash × 3 times). Blood and tissues were 
collected as described above for the gel-dosed mice. 
 
To evaluate the safety of MK571 application, in both vaginal and IP routes, mice were 
administered with non-radioactive TFV gels or solutions, with or without MK571 co-
administration. The molar quantity of TFV of the gels and solutions used in these safety 
evaluations was kept same as in the PK experiments, as detailed in Table 4.2 above. For the 
vaginal route, mice were administered with 1) 100 µL IP administered saline followed by 20 µL 
TFV gel; 2) 100 µL IP administered MK571 solution followed by TFV gel; 3) 100 µL IP 
administered saline followed by (TFV+MK571) gel; 4) 100 µL IP administered saline followed 
by 20 µL of N-9 gel (4%), as a positive control. The mice were euthanized at 1 h for the vaginal 
dosing group, or at 1.5 h for the IP dosing group. The uterus, endocervix, ectocervix, vagina and 
colorectum were collected in the same way as in the PK experiments described above, and fixed 
in 10% neutral buffered formalin (10% NBF) until further processing for histological staining.  
 
4.2.3 Measurement of radioactivity in mouse samples 
The CVL (200 or 60 µL), plasma (100 µL), and tissue (5-50 mg) samples were transferred to 
scintillation vials. Five hundred µL of Solvable
TM
 tissue lysis buffer (Perkin Elmer) was added 
into the vials containing the CVL, plasma, or tissues. The vials were then incubated overnight in 
a 50°C water bath to completely dissolve the tissues. Following this incubation period, the 
sample vials were taken out and added with 100 µL of H2O2 (Fisher Scientific) was added to 
each sample and incubated at 50°C for 1 hour. The purpose of adding H2O2 was to decolorize the 
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samples in order to eliminate the influence of sample color on subsequent scintillation counting, 
and 1 hour of 50°C incubation was to completely remove the remaining H2O2 which would also 
affect the activity of scintillation cocktail. The complete removal of H2O2 was reflected by the 
absence of air bubbles arising from the H2O2-added vials. After H2O2 treatment, the vials were 
removed from the water bath and cooled to room temperature, followed by the addition of 2.5 
mL of ScintiSafe™ Plus cocktail (Fisher Scientific). The vials were vortexed, and placed in a 
scintillation counter (Perkin Elmer) for the measurement of radioactivity of the 
CVL/plasma/tissue samples. 
 
4.2.4 Histological evaluation 
Hematoxylin & eosin (H & E) staining was performed as previously described,
243
 on the genital 
and colorectal tissues of the mice receiving vaginal gel or IP solution administrations. Briefly, 
the fixed tissues were embedded into paraffin. The staining was performed on 5 m sections. 
Pictures were taken using a Zeiss (Genna, Germany) Axioskop 40 microscope with AxioVision 
Software. 
 
4.2.5 Measurement of permeability of gel-released TFV across artificial membranes 
To evaluate the potential impact of the incorporation of the Mrp4 inhibitor MK571 on TFV 
release from the formulated gels, the permeability studies were performed using a Franz Cell 
system as previously described.
243
 The 7 mm Franz Cells (Permegear Inc. Hellerstown, PA) were 
water-jacketed and the temperature was maintained at 37 ± 0.5C throughout the experiment. 
The receptor chamber was filled with 5.0 mL PBS (pH 7.4) solution and continuously stirred. 
The Spectra/Mesh nylon filters (Spectrum Inc.) were sandwiched between donor chamber and 
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receptor chamber, which yielded a diffusion area of 0.385 cm
2
. These nylon filters were used as 
inert membranes which allow the permeation of small molecules but restrict the permeation of 
gel matrix. The excessive PBS in the donor chamber was absorbed by cotton tips. The study was 
initiated by adding 100 µL of TFV gel with or without MK571 into the donor chamber using a 1 
mL disposable syringe. Aliquots of 200 µL were removed from the receptor compartment for 
radioactivity analysis at 1, 15, 30, 45, 60, 120, 180, 240, 300, 360 min after the addition of the 
gel to the donor chamber. Fresh PBS (pH 7.4) was immediately supplemented to maintain 
receptor volume and sink conditions. Radioactivity was measured using a Wallac 1409 DSA 
Liquid Scintillation Counter (Perkin Elmer Life Sciences, Inc., Boston, MA). The amount of 
TFV was calculated based on the CPM reading. The cumulative amount of TFV in the receptor 
compartment, as a percentage of the initial TFV amount in the donor compartment, was plotted 
over time to reflect the permeation profile of TFV through the inert membranes. Apparent 
permeability coefficient, Papp, was calculated as: Papp  (cm·s
-1
), where dQ/dt was 
the slope of the curve of Q (amount in fmol) versus t (time in minutes), A was the surface area 
(cm
2
) of the inert membrane exposed to the gels, and Cd is the initial amount of TFV in the 
donor compartment. 
 
4.2.6 Data analysis and statistical methods 
The CPM (count per minute) values generated from the scintillation counter were converted to 
DPM (decay per minute) using the following equation: DPM =  . The 
radioactivity (µCi) of samples was calculated based on Radioactivity (µCi) = DPM / (2.22 × 10
6
). 
The molar concentrations of 
3
H-TFV in CVL, plasma, or tissue samples (fmol/µL or fmol/mg 
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tissue) = CPM/counting efficiency/(2.22 × 10
6
)/specific activity × 10
6
. Data were presented as 
mean ± standard deviation. 
 
For vaginal substrate (TFV) administration: Cplasma, CCVL, and Ctissue were compared between the 
three groups using one way analysis of variance (ANOVA) with Bonferroni post hoc test. For IP 
substrate administration: the following were compared between the two groups: 1) CCVL, Cplasma 
and Ctissue, 2) CCVL/Cplasma and Ctissue/Cplasma. The differences were compared using Student’s t-
test. P<0.05 was considered statistically significant, and p<0.01 was considered as very 
significant.  
 
 
4.3 Results 
 
4.3.1 The effect of MK571 co-administration on the tissue distribution of vaginally 
administered TFV 
The co-administration of MRP transporter inhibitor (MK571) significantly increased the TFV 
concentration in endocervix, ectocervix and vagina, by up to several fold at the examined time 
points post vaginal administration of TFV gel. However, the concentrations in plasma, uterus, 
and colorectum were only slightly increased by the MK571 co-administration (Figure 4.2). 
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Figure 4.2 The effect of MK571 on tissue distribution of vaginally administered TFV 
The effect of MRP transporter inhibitor MK571 on TFV distribution was tested using vaginal 
gels containing 
3
H-TFV, with or without the administration of MK571. Mice were euthanized 0.5 
h and 1.0 h post TFV gel administration, CVL, plasma, and tissue samples were collected and 
radioactivity was measured in a scintillation counter. TFV molar concentrations in these samples 
were plotted for the two time points tested. Red columns, mice were administered IP with saline, 
followed by vaginal administration of TFV gel; blue columns, mice were administered IP with 
MK571 solution, followed by vaginal administration of TFV gel; green columns, mice were 
administered IP with saline, followed by vaginal administration of (TFV+MK571) gel. Data 
represent mean ± SD. In the group dosed with (TFV+MK571) gel and euthanized at 1.0 h, 4 
mice were used. For other groups, 7-13 mice were used. *p<0.05; **, p<0.01. 
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The incorporation of MK571 into the TFV gel exerted time-dependent effects on TFV 
distribution. At 0.5 h post gel administration, the TFV concentration in mouse vaginal tissue was 
significantly higher in the MK571 group. The TFV concentration was slightly increased in 
plasma, uterus, ectocervix and colorectum, however no statistical significance was observed. The 
TFV concentration in CVL and endocervix remained unchanged with the addition of MK571 
(Figure 4.2). At 1.0 h, the TFV concentration in colorectum was significantly increased, while its 
CVL concentration was significantly decreased. There was also a decrease in the TFV 
concentration in endocervix, ectocervix and vagina, but the differences were not statistically 
significant. The TFV concentration in plasma and uterus remained unchanged with the 
incorporation of MK571 into the TFV gel (Figure 4.2). 
 
4.3.2 The effect of MK571 incorporation on the release kinetics and permeability of gel-
formulated TFV 
To examine whether the differential TFV PK profiles of the two kinds of TFV gels were related 
to the release kinetics of TFV, the Franz Cell permeability experiments were conducted. As 
shown in Figure 4.4. Compared to the gel containing TFV alone, the incorporation of MK571 
into the gel did not have any impact on the in vitro release profile of TFV. The percentages of the 
cumulative amount released by 30 min and 60 min, which were the two time points employed in 
the PK experiments described above, were very similar between the two kinds of TFV gels. The 
permeability coefficient Papp, as calculated from the time-dependent TFV concentration 
appearing in the acceptor chamber of the Franz Cell apparatus, was almost identical for both 
kinds of gels. 
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Figure 4.3 The effect of MK571 incorporation on the release of TFV from formulated gels. 
Gels with or without MK571 incorporation were applied to the donor chamber of Franz Cell 
Apparatus, and the TFV concentration in acceptor chamber medium (PBS) was measured to 
generate the kinetics of TFV release from the gels. Papp, permeability coefficient. Results 
represent mean ± SD from 3 gels in each group.  
 
 
4.3.3 The effect of vaginal MK571 co-administration on tissue morphology 
To evaluate the safety of the co-administration of MK571, H & E staining was performed to 
examine the morphology of female mouse genital and colorectal tissues after the vaginal 
administration of TFV gels with or without MK571. N-9 gel was used as a positive control due 
to its reported damage to the morphology of mouse cervicovaginal tissues.  
 
As shown in Figure 4.4 below, there was no difference in the morphology of tissues, between the 
mice administered with TFV gels, TFV gel with IP administration of MK571, or the combined 
(TFV+MK571) gel. After Depo-Provera synchronization, the epithelia in uterus, endocervix, and 
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ectocervix became single-layer columnar cells, but the intactness of this single layer was 
maintained. The vaginal epithelia still contained several layers after synchronization, while the 
colorectal epithelium did not appear to be affected by Depo-Provera. The administration of TFV-
and MK571-containing gels and solutions did not cause any discernable damage to the genital 
and colorectal tracts of female mice (Figure 4.4). On the contrary, the 4% N-9 gel negatively 
affected the morphological intactness of the epithelia of endocervix, ectocervix, and vagina. 
Detachment of columnar and squamous epithelial cells from the basal lamina could be readily 
observed in significant portion of the epithelium-lining regions of these tissues (Figure 4.5). 
These results demonstrated that the topical application of MK571 did not negatively affect the 
intact epithelia of the mouse cervicovaginal tissues, which are important natural barriers against 
sexually transmitted infectious pathogens.
33
 In addition, the differential effect of gel-
administered MK571 on TFV tissue distribution, compared to the MK571 administered IP, was 
unlikely due to the altered epithelial intactness upon local administration of MK571. 
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Figure 4.4 H & E staining of mouse cervicovaginal tissues after vaginal administration of 
gels containing TFV or N-9.  
The tissues were collected from mice receiving vaginal gel administrations with IP co-
administration of saline and MK571. The gel containing 4% nonoxynol (N-9) was used as 
positive control since N-9 is a well known disruptor of cervicovaginal epithelial layers. The 
tissues were rinsed to remove blood or viscous fluid on the surface, fixed in 10% neutral buffered 
formalin for more than 24 h, and subjected to H & E staining. Red circles highlight the epithelial 
layers to observe. Magnification is 20 × for all pictures. 
 
4.3.4 The effect of MK571 IP co-administration on the tissue distribution of IP administered 
TFV 
To examine the functional role of Mrp4 transporter in the cervicovaginal/colorectal tissue 
distribution of systemically administered TFV, mice were given TFV solution through IP route, 
153 
 
with or without MK571 co-administration via the same route 15 min prior to TFV dosing. The 
TFV concentrations in the three compartments, i.e. cervicovaginal fluid, tissues, and plasma 
were measured 1.5 h post TFV administration.  
 
As shown in Figure 4.6, compared to its plasma concentration, TFV was preferentially 
distributed into cervicovaginal tissues and fluid after IP administration. MK571 increased TFV 
concentration in CVL and vagina (p=0.04), while slightly decreased TFV plasma concentration 
(-13%). 
 
The vagina/plasma (p=0.03) and colorectum/plasma (p=0.006)  ratios were significantly 
increased by MK571 co-administration, suggesting that the observed increase in vagina and 
colorectum tissue concentrations found after MK571 application was due to Mrp4 transporter 
inhibition, thus providing evidence for the functional role of Mrp4 transporter in limiting TFV 
distribution from blood to these tissues. MK571 significantly increased kidney/plasma ratio by 
33% (p=0.002), consistent with published report that the MRP4 transporter limiting kidney tissue 
TFV accumulation.
84
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Figure 4.5 Function of Mrp4 transporter in the tissue distribution of systemically 
administered TFV.  
The effect of MRP transporter inhibitor MK571 on TFV distribution was tested. Mice were IP 
administered with saline (red columns) or MK571 (blue columns), followed by IP administration 
of 
3
H-TFV saline solution 15 min later. Mice were euthanized 1.5 h post TFV solution 
administration. CVL, plasma, and tissue samples were collected and radioactivity was measured 
in a scintillation counter. TFV molar concentrations in these samples were plotted above. Data 
represent mean ± SD from 12-13 mice. *p<0.05; **, p<0.01. 
 
 
4.3.5 The effect of intraperitoneal TFV and MK571 administration on tissue morphology 
To examine whether the IP co-administration of MK571 solution had any impact on the 
morphology of genital and colorectal tissues, H & E staining was performed on these tissues 
after the dosing of TFV and TFV+MK571 solutions. As shown in Figure 4.7, neither TFV alone 
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nor the combination with MK571 exerted any effect on tissue morphology and epithelial 
intactness. N-9 treated tissues were used as positive control and shown in Figure 4.5. TFV 
solution with or without MK571 did not exert any discernable negative impact on the intactness 
of cervicovaginal tissues, suggesting that the effect of MK571 on TFV distribution was unlikely 
due to altered passive permeability which is often a result of compromised tissue intactness. 
 
Figure 4.6 H & E staining of mouse cervicovaginal tissues after IP administration of TFV 
solutions with or without MK571.  
The tissues were collected from mice receiving IP TFV solution, with IP co-administration of 
saline and MK571. The tissues were rinsed to remove blood or viscous fluid on the surface, fixed 
in 10% neutral buffered formalin for more than 24 h, and subjected to H & E staining. Red 
circles highlight the epithelial layers to observe. Magnification is 20 × for all pictures. 
156 
 
4.4 Discussion and Conclusion 
The studies conducted in this chapter have provided proof of concept that the Mrp4 plays a role 
in TFV tissue distribution, and the co-administration of MRP inhibitor MK571 could alter the 
TFV distribution, in a mouse model utilized for vaginal microbicide safety evaluation. TFV is a 
substrate of two efflux transporters (MRP4, MRP7) and two uptake transporters (OAT1, OAT3). 
As examined by real-time RT-PCR, OAT1 and OAT3 were found to be undetectable in 
cervicovaginal and colorectal tissues of human and mice. The GAPDH-normalized mRNA levels 
of MRP7 were at least 100 fold lower than the Mrp4 level, in the endocervix, ectocervix and 
vagina of the Depo-Provera synchronized mice (Figure 2.11). The Mrp7 mRNA level in mouse 
colorectum was more than 10 fold lower than the Mrp4 level (Figure 2.11). Based on the 
expression levels, Mrp4 is most likely to be the major efflux transporter for TFV, in the 
cervicovaginal and colorectal tissues of the synchronized mouse model. In addition, the observed 
effects of MK571 on TFV distribution into cervicovaginal and colorectal tissues were most 
likely due to the inhibition of Mrp4 transporter in these tissues. 
 
The distribution of TFV in mouse tissues after vaginal administration resembled clinical 
pharmacokinetics of TFV vaginal gel products, in several aspects. First, mouse vagina 
concentration of TFV was the highest in all segments of mouse lower genital tract, followed by 
ectocervix and endocervix, and mouse plasma concentration of TFV was about 100 fold lower 
compared to the vaginal tissue concentration. This was in line with the clinical observation that 
vaginal tissue TFV concentration was the highest in human female lower genital tract after gel 
administration, and human plasma level of TFV was much lower than the tissue level.
21,244
 
Secondly, mouse colorectum TFV concentration was much lower than the vaginal tissue 
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concentration but was about 20 fold higher than the plasma concentration. This was similar to the 
observation that human and macaque colorectal tissue TFV level was lower than vaginal tissue 
drug level but was much higher than the blood level of TFV after vaginal gel 
administration.
244,245
 Third, mouse kidney TFV concentration was 10-25 fold higher compared to 
plasma concentration, at 0.5 and 1.0 h after TFV gel administration (Figure 4.2). This is in line 
with the observation that MRP4 expression in kidney is high, and MRP4 facilitates the efflux of 
TFV from kidney cells into urine.
84
  
 
The tissue distribution pattern of TFV after IP administration was also comparable to the clinical 
pharmacokinetics of orally administered tenofovir disoproxil fumarate (TDF). TDF is a prodrug 
of TFV, and could be converted to TFV and TFV diphosphate metabolites in the body. Although 
the TFV solution used in the current study is different from TDF, the preferential distribution of 
TFV into mouse cervicovaginal fluid after IP administration resembled the similar pattern 
observed after oral TDF administration in humans. At 1.5 h post TFV administration, the average 
TFV concentration in CVL samples was around 4.11 fmol/µL, which was 5 times higher than 
plasma concentration. CVL concentration was calculated by dividing the TFV quantity in CVL 
to 60 µL, which was the volume of saline used to collect the cervicovaginal lavage. The actual 
fluid volume in mouse vaginal lumen was actually much lower than 60 µL, and TFV 
concentration in the cervicovaginal fluid should be much higher than the calculated 4.11 fmol/µL. 
The average TFV concentrations in mouse uterus, endocervix, ectocervix, and vagina were 1.49, 
1.33, 1.17, and 1.32 fmol per mg of tissue, respectively, which were not very different from 
plasma concentration (0.89 fmol/µL). This is in line with the clinical observation that TFV 
concentration in vaginal tissue did not differ from its blood concentration, and the vaginal fluid 
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TFV concentration was much higher than blood after oral administration of TDF or Truvada 
(TDF combined with emtricitabine).
21,244
  
 
For both administration routes (vaginal and IP dosing), wide variability of TFV concentration in 
female genital tract could be observed between individual mice, at all the time points post 
administration (0.5 and 1.0 h post vaginal dosing, 1.5 h post IP dosing). Notably, the variability 
in female mouse reproductive tract was much wider than the variability in mouse plasma and 
other internal organs such as kidney (Figures 4.2 and 4.4). Similarly, high degree of intra- and 
inter-subject variability was also observed in human and non-human primate studies of TFV and 
other antiretroviral drugs such as the viral entry inhibitor maraviroc.
21,41-43,114,244,246-249
 This is 
probably due to the complexity of drug disposition in female genital tract. In the vagina, 
ectocervix, and endocervix, many factors, such as the epithelial layer thickness, tight junction 
abundance, vaginal fluid level, transporters and metabolizing enzymes could potentially affect 
TFV distribution across vaginal lumen, cervicovaginal tissues, and plasma.
12,33,34
 These 
physiologic determinants are regulated by various factors such as hormone status, age, and have 
large variability between individuals. Therefore, it is not surprising to observe a high level of 
variability in TFV concentration in the CVL samples and in the lower female genital tract tissues.   
 
In this chapter, the effect of MK571 on TFV concentration was not comparable between 
different segments of the mouse female genital tract (FGT). In addition, the MK571 exerted 
differential effects on TFV distribution, when MK571 was co-administered via different routes. 
The IP co-administration of MK571 solution increased TFV concentration up to 3 fold in 
endocervix, ectocervix, and vagina, on at least one time point (0.5 or 1.0 h) post TFV 
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administration. However, the vaginal co-administration of MK571 in the form of gel only 
resulted in an 80% increase in vaginal tissue TFV concentration at 0.5 h post TFV administration. 
There was no significant difference in other cervicovaginal tissues and in plasma, but the TFV 
concentration in CVL at 1.0 h was significantly decreased. It appeared that TFV penetration 
through the vaginal tissue is greater, when MK571 was given vaginally, resulting in increased 
TFV concentration in the vaginal tissue at early time point (0.5 h), and decreased TFV content 
remaining in the gel at later time point (1.0 h), but not in other tissues.  
 
One possibility underlying these differential effects of MK571 could be that the incorporation of 
MK571 into the TFV gel altered TFV release kinetics. However, the release profile of TFV was 
not altered by MK571 incorporation, as examined using Franz Cell apparatus which is the 
standard USP method of testing the drug release from semisolid dosage forms. The two dosing 
routes of MK571 did not cause differential impacts on epithelial morphology, compared to the 
groups dosed with the universal placebo gel or dosed with TFV gel containing no MK571. 
Therefore, the differential effects of MK571 were not caused by the differences in TFV release 
or epithelial integrity, when MK571 was dosed via different routes.  
 
Another possible explanation for these differential effects is that different dosing routes of 
MK571 resulted in differential levels of MK571 in the tissues examined. When MK571 was 
given IP, it can be distributed into different segments of the lower female genital tract, to similar 
degrees due to relatively high blood perfusion into reproductive tissues. However, in the scenario 
of vaginal administration, the primary site of MK571 absorption is vagina, and the MK571 
exposure in ectocervix and endocervix was much lower, resulting in a more obvious effect of 
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MK571 in the vaginal tissue but not in ectocervix and endocervix. If this is the case, the changes 
in TFV concentration in mouse vagina, CVL and plasma samples can be explained accordingly. 
It is possible that when MK571 was given intravaginally in the form of gel, it facilitated TFV 
entry into vaginal tissue, and increased the TFV concentration in vaginal tissue and plasma at 
early time point (0.5 h). Since TFV penetrated more quickly, less TFV gel remained in the 
vaginal lumen at the later time point (1.0 h), resulting in reduced amount of TFV in the CVL 
samples at the 1.0 h time point, and reduced vaginal tissue concentration at 1.0 h. Therefore, the 
experiments using IP administered MK571 provided the proof of concept for Mrp4 function in 
the tissue distribution of vaginally administered TFV, however the feasibility of incorporating a 
transporter inhibitor to increase the tissue distribution of gel-released TFV will need further  
testing using MK571 at higher concentrations. 
 
Several future studies will be needed to address the potential issues associated with MK571 
concentration in mouse tissues. Ideally, MK571 concentration should be measured to link the 
observed changes in TFV PK to the inhibitory effect of MK571. However, due to the lack of a 
validated method of quantifying MK571 tissue concentration, MK571 concentration was not 
measured in the tissues where it was supposed to exert inhibitory effect. IC50 values of MK571 
for the MRP4 transporter were reported to be at µM level.
250,251
 In order for a chemical inhibitor 
to be effective in reversing tissue efflux transporters, the tissue concentration of this inhibitor 
should be at least several fold higher than its in vitro IC50. The time course of MK571 
concentration in target tissues should also be considered when selecting the time points of in vivo 
sample collection. Based on previously published in vivo studies which used MK571 to study 
Mrp4 transporter in tissues including mucosal tissues such as mouse lung,
240-242
 we suspected 
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that the MK571 concentration in our study was sufficient at early time points (0.5 and 1.0 h in 
the vaginal TFV dosing experiments, 1.5 h in the IP TFV dosing experiments). Future studies 
will need to address this shortcoming. These studies could include the development of an 
analytical method for MK571 quantification, and measurement of its tissue concentration after 
the IP or vaginal co-administration to mice. In addition, the effect of MK571 dose on TFV PK 
could be explored to provide more evidence on the functional role of Mrp4 in TFV tissue 
exposure. If the observed changes in TFV distribution was indeed due to MK571 inhibition on 
Mrp4, then the dose-dependent effect of MK571 may be observed. Moreover, different strategies 
of transporter inhibition could be incorporated into future studies to confirm the role of Mrp4 in 
TFV PK. Nonsteroidal anti-inflammatory drugs, such as ibuprofen, are also potent inhibitors of 
MRP4 transporter.
89,90
 Abcc4 (Mrp4) knockout mice may also be employed to eliminate all the 
issues with chemical transporter inhibitors. Overall, these future studies will address the issues 
associated with the tissue concentration of MK571 and other chemical inhibitors, and will 
validate the findings on Mrp4 function described in this chapter. 
 
In addition, future studies are warranted to further evaluate the functional role of Mrp4 in TFV 
exposure in cervicovaginal and colorectal tissues. First, The experiments conducted in this 
chapter have examined Mrp4 function in TFV distribution into three physiologic compartments 
(CVL, tissues, plasma), at 1 or 2 selected time points after TFV administration. However, since 
the area under concentration-time curve (AUC) is a more accurate measurement of drug 
exposure, more time points need be tested in future studies, in order to understand the role of 
Mrp4 in the AUC of TFV in tissues and fluids relevant to HIV-1 transmission. Secondly, Future 
pharmacokinetic studies with more doses of substrates will provide more detailed information of 
162 
 
the Mrp4 transporter function in cervicovaginal tissues. In this chapter, one dose was tested, 
which was below the TFV dose used in clinical testing in order to avoid the possible saturation 
of Mrp4 transporter. Higher doses will need to be tested to account for the possible saturation of 
efflux transporters by the substrate drug.  
 
Moreover, the Mrp4 expression level changes in response to mouse estrous cycle, the estrogen-
stimulating hormone PMSG, and Depo-Provera. The role of Mrp4 in tissue TFV distribution 
may be different under these physiologic/pharmacologic conditions. Therefore, Future PK 
studies under these conditions will provide a comprehensive picture of Mrp4 function and 
inhibitor effectiveness in the context that mimics clinical use of PrEP drugs.  
 
An additional focus of future PK studies will be to examine the time course of metabolite 
formation and disposition within the three physiologic compartments (cervicovaginal fluid, 
cervicovaginal tissues, and blood). In this chapter, the 
3
H-labeled TFV was used as Mrp4 
substrate, the measured radioactivity reflected the total drug amount in the samples, and the 
concentration of TFV metabolites remained unknown. Although the formation of TFV phosphate 
metabolites is negligible compared to the parent drug (<5% of TFV), the information of 
metabolite exposure in tissues is actually more important for estimating efficacy, because the 
TFV diphosphate metabolite (TFV-DP) is the only active form of TFV. Therefore, future studies 
could utilize non-radiolabeled TFV as substrate, and adopt established LC-MS/MS method to 
quantify both TFV and TFV-DP in administered mouse tissue samples.
252
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Although the mouse model represents a convenient in vivo tool for proof-of-concept studies, it is 
not without limitations. Future studies of transporter function using more biologically relevant 
models or the analyses of human data could address these limitations. Mouse transporters may 
differ from human counterparts with respect to the specificity and/or affinity to the substrate. In 
addition, some parts of mouse reproductive tract, such as the uterus, differs from human tissues 
in terms of morphology and physiology. These interspecies differences may cause potential 
issues to consider when using the mouse results to predict the function of transporters and 
feasibility of transporter inhibitors in humans studies. Macaques possess female reproductive 
tract and colorectal tissue with similar anatomy and philology to human counterparts. Therefore, 
compared to the mouse model, the macaque model is considered to be more biologically relevant, 
in PrEP research and other studies related to female genital tract and/or colorectal tissues. In 
addition, macaques can be infected by simian immunodeficiency virus (SIV) or the chimeric 
SHIV generated from the combination of HIV and SIV, thus making them a good model for 
simultaneous evaluation of PK and efficacy of HIV PrEP drug products.
198,247,248
 The utilization 
of the macaque model in future functional study of cervicovaginal and colorectal transporters 
could reveal whether the observed changes in tissue drug concentration correlates with drug 
efficacy in HIV prevention. In addition to animal models, the analysis of human PK data and 
tissue samples obtained from previous PrEP clinical studies testing oral products and topical 
microbicides may provide direct evidence for the function of cervicovaginal tissue transporters in 
humans. Such evidence could be obtained by analyzing the correlations between the clinical PK 
data (substrate antiretroviral drug exposure in tissues relevant to HIV transmission) and 
transporter expression level or genotype. Such analyses may also provide information regarding 
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the regulation of transporter expression/activity in cervicovaginal and colorectal tissues under the 
influence of hormones, contraceptives, and inflammation.   
 
Lastly, the function of other highly expressed transporters also warrants further testing. As 
revealed by examinations conducted in Chapters 2 and 3, P-gp, BCRP, MRP5, and MRP7 are 
also highly expressed efflux transporters in human cervicovaginal and colorectal tissues. In 
mouse tissues, these transporters, except Mrp7, are also expressed at high levels. The IHC 
staining confirmed the critical localization of mouse P-gp (Abcb1a/Abcb1b) and Bcrp in the cell 
types that may control drug disposition in tissues (epithelial cells, vascular endothelial cells). The 
function of P-gp and BCRP could be the priority in the list of transporters to be tested in the 
functional studies, and the mouse model appeared to be the model of choice due to the high level 
of expression of these two transporters.  
 
In conclusion, the studies described in this chapter have provided preliminary evidence to 
demonstrate Mrp4 function in TFV distribution into cervicovaginal and colorectal tissues. The 
data also suggested that the co-administration of MRP inhibitor could alter TFV distribution, at 
least when the inhibitor is dosed at proper level via appropriate route. However, it should be 
noted that the adherence is the key to the drug exposure and efficacy for once daily PrEP 
products. The functional role of MRP4 transporter and the effectiveness of MRP4 inhibitor could 
be observed only when the adherence is kept at high level. In the CAPRISA 004 study, 
participants with vaginal fluid TFV concentration higher than 1000 ng/mL had more than 3 times 
lower HIV acquisition rate compared to the participants whose vaginal TFV concentration was 
lower than 1000 ng/mL (infection rate 3.7% versus 12.3%).
13,21
 Participants had highly variable 
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TFV concentration in vaginal fluid, from below the limit of detection (<1 ng/mL) to nearly 10
7
 
ng/mL. The major cause for this large inter-individual variability has been identified to be low 
adherence to the gel products, and the efficacy differed significantly among participants with 
different degrees of adherence.
13
 Seventy six percent of the 335 participants has TFV 
concentration below 1000 ng/mL. Only 12.5% of participants had fluid concentration between 
11-1000 ng/mL, and 63% of participants had fluid concentration below 10 ng/mL. In this study, 
TFV concentration in cervicovaginal tissues was increased by up to 3-4 fold, when MK571 was 
co-administered. If this tend can be observed in humans, and if the inhibitor approach could be 
used in the participants of the CAPRISA 004 PK study, then only a small number of participants 
with 11-1000 ng/mL vaginal concentration might be able to achieve the effective TFV 
concentration (1000 ng/mL) with the help of the inhibitor approach. Apparently, for the low-
adherent participants, the co-administration of MRP transporter inhibitor does not appear to be 
an effective approach to increase the effectiveness of gel products in those people who do not use 
the once-daily products. In these scenarios, the most effective strategy could be the utilization of 
sustained release formulations, such as the vaginal ring or long-acting injectable.
26,29-32,35,36,212
 
Once the problem of product adherence is resolved (by increasing patient adherence or changing 
the dosage form to long-acting injectables or intravaginal rings), the information on transporters 
may be utilized to interpret intra- and inter-individual variability in PK/PD, and the utilization of 
transporter inhibitors will likely enhance drug exposure and/or reduce the drug load of PrEP 
products.  
 
The information generated from this chapter, as well as future studies that would examine more 
time points, more drugs, and more transporters, will facilitate PrEP optimization in multiple 
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aspects. First, this information is useful for the optimization of PrEP drug candidates. If the 
transporters play a significant role in drug distribution into the cervicovaginal tissues, then non-
substrate drugs may be better candidates than transporter substrates, if all other attributes are 
similar. Alternatively the substrates could be chemically modified to remove transporter binding 
moieties while at the same time retain the antiviral activity. In addition, the information on 
transporter function will facilitate the optimization of PrEP product formulations and inform the 
design of combination PrEP products. Some antiretroviral drugs, such as protease inhibitors, are 
potent inhibitors of efflux transporters through competitive binding.
49
 Some pharmaceutical 
excipients, such as pluronic P85, polyethylene glycol (PEG) 300, and cyclodextrins (CDs) have 
been reported to inhibit ATP-binding cassette (ABC) transporters including P-gp, BCRP, and 
MRPs.
59
 The efflux activity of ABC transporters requires the intracellular availability of ATP, 
and certain degree of plasma membrane fluidity to conduct conformational changes during the 
efflux process. The transporter-inhibiting excipients could temporarily inhibit intracellular 
ATPase activity and decrease the cell membrane fluidity, thus reducing the intracellular ATP 
production and restricting the conformational change of transporters at plasma membrane.
59
 In 
addition to chemical inhibitors, nano-sized drug delivery systems have been reported to cross 
plasma membrane via routes different from free drug, and represent an alternative strategy to 
circumvent the membrane transporter-mediated efflux.
208
 Utilization of these strategies to 
overcome transporter efflux may increase drug exposure and efficacy in HIV-1 prevention. 
167 
 
 
5 DISCUSSION OF MAJOR FINDINGS AND FUTURE DIRECTIONS 
 
5.1 Major findings, implications, and limitations 
More than two million new HIV-1 infections occur each year, and there is an urgent need to 
curtail this global pandemic. Since a large portion of the new infections are due to poorly 
protected sexual intercourse, there is a great need for drug products that can effectively prevent 
the sexual transmission of HIV-1. Although antiretroviral-based topical and oral PrEP products 
have shown efficacy in some clinical trials, other studies have achieved inconsistent results, and 
strategies are needed to enhance the effectiveness of PrEP products. Since the antiretroviral drug 
exposure in the cervicovaginal and colorectal tissues is critical for PrEP effectiveness, and given 
that the efflux and uptake transporters are key regulators of tissue drug exposure, a greater 
understanding of the expression and function of drug transporters in tissues and cells relevant to 
HIV-1 sexual transmission is urgently needed. The studies presented provide critical information 
regarding the expression, regulation, and function of transporters in human cervicovaginal and 
colorectal tissues, as well as in the animal models and cell lines utilized in PrEP product 
screening. This information is valuable for the development of novel strategies that can increase 
tissue drug exposure, and will ultimately lead to the design of more effective drug products for 
HIV-1 prevention.  
 
The work conducted in this dissertation was based on the hypothesis that multiple efflux and 
uptake transporters are positively expressed in the cervicovaginal tissues and play a significant 
role in tissue drug exposure, which can be modulated by transporter inhibitors. The studies 
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conducted to address this hypothesis included examination of the mRNA and protein expression 
of multiple transporters in humans, animal models, and cell lines, under the influence of 
menstrual cycle, exogenous hormones/contraceptives, and proinflammatory cytokines, as well as 
the investigation of Mrp4 function in a mouse model. The major findings of the dissertation are 
summarized below. 
 
5.1.1 mRNA expression of multiple transporters in tissues and cells relevant to HIV-1 
transmission 
Previously published studies indicated that some efflux and uptake transporters were expressed 
in cervicovaginal and colorectal tissues, as well as in HIV-1 target immune cells. However, there 
was a lack of systematic characterization of transporter mRNA and protein expression in these 
tissues and cells, under the conditions commonly encountered by PrEP participants. These 
conditions included menstrual cycle, exogenous hormones, hormonal contraceptives, and local 
tissue inflammation. This information is important for understanding the dynamics of transporter 
expression in these tissue sites, and is needed for experimental design and data interpretation of 
further studies concerning cervicovaginal and colorectal transporters.  
 
To fill this knowledge gap, the studies conducted in Chapter 2 of this dissertation first examined 
the mRNA expression of  9 efflux transporters and 13 uptake transporters which are involved in 
the transport of antiretrovirals and other therapeutic drugs, using conventional RT-PCR. As 
hypothesized, 5 efflux transporters (P-gp, BCRP, MRP4, MRP5, MRP7) and 4 uptake 
transporters (OAT2, OCT2, ENT1, and OATP-D) were found to be moderately to highly 
expressed in the human ectocervix and vagina, compared to their levels in liver. 
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The real-time PCR was conducted to validate the positive mRNA expression of the efflux and 
uptake transporters most relevant to antiretroviral drugs (P-gp, BCRP, MRP4, 5, 7, OAT 2, 
OCT2, ENT1), in human cervicovaginal and colorectal tissues. P-gp, BCRP, MRP4, 5, 7, and 
ENT1 were found to be expressed in cervicovaginal and colorectal tissues at levels comparable 
to or higher than the liver. OAT2 and OCT2 were not detectable using real-time PCR in human 
tissues, presumably due to the difference in the processing method of extracted RNA. The 
genomic DNA was removed in real-time PCR experiments, while it was not removed during the 
conventional RT-PCR. The primers designed for these transporters could amplify from both 
genomic DNA and mRNA. Therefore, the positively expressed transporters in human 
cervicovaginal and colorectal tissues were P-gp, BCRP, MRP4, MRP5, MRP7, and ENT1.  
 
Based on the mRNA expression profile of the transporters examined, 16 antiretroviral drugs 
could potentially be affected by the positively expressed transporters, as discussed in Chapter 2 
in detail. Taking the Biopharmaceutics Classification System (BCS) into consideration, the 
antiretroviral drugs that are potentially affected by the positively expressed transporters in 
cervicovaginal and/or colorectal tract include nevirapine (MRP7), atazanavir (P-gp), ritonavir (P-
gp), amprenavir (P-gp),  lopinavir (P-gp),  saquinavir (P-gp),  darunavir (P-gp), indinavir (P-gp), 
tipranavir (P-gp), nelfinavir (P-gp) and raltegravir (P-gp), maraviroc (P-gp), lamivudine (BCRP), 
tenofovir DF (P-gp), tenofovir (MRP4, MRP7), didanosine (BCRP). The antiretroviral drugs that 
are potentially affected by positively expressed uptake transporter include didanosine (ENT1).  
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The mRNA expression of these transporters was also examined in the tissues of pigtailed 
macaques, rabbits, Depo-Provera synchronized mice, as well as three cervicovaginal epithelial 
cell lines (End1/E6E7, Ect1/E6E7, VK2/E6E7 derived from human endocervix, ectocervix, and 
vagina) and a T cell line (PM1). These animal models and cell lines are used for the efficacy 
and/or safety testing of PrEP products especially topical microbicides. The results have shown 
positive expression of the transporters being tested, in animal tissues and cell lines. The absence 
of OAT1 and OAT3 in all the tissues and cells examined suggested that these two uptake 
transporters were not likely to paly a functional role in drug pharmacokinetics in human 
cervicovaginal and colorectal tissues, as well as in the tissues and cell lines used in PrEP drug 
candidate evaluation. 
 
A multi-species comparison has been conducted to evaluate the similarity in the expression 
profile of P-gp, BCRP, MRPs4, 5, 7, between human tissues and animal tissues/cell models. The 
transporter mRNA expression of pigtailed macaque tissues is most similar to that of human 
tissues. The Mrp4 levels in rabbit cervicovaginal and colorectal tissues were more than 15-fold 
higher compared to human tissues, and caution will be needed when interpreting the drug 
concentration and safety data from the rabbit model. The human-rabbit differences for other 
transporters were within ± 5 fold. The difference in mRNA levels of P-gp, BCRP, Mrp4 and 
Mrp5 in mouse tissues were within ± 5 fold from those levels in human, but the level of Mrp7 in 
all mouse tissues was more than 15-fold higher than the Mrp7 level in corresponding human 
tissues. In the three cervicovaginal cell lines (End1/E6E7, Ect1/E6E7, VK2/E6E7), P-gp and 
BCRP mRNA levels were more than 15-fold lower than the levels in human endocervix, 
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ectocervix and vagina. The levels of MRP4, 5, and 7 were no more than 5-fold lower in the cell 
lines, compared to corresponding human tissues. 
 
Sex steroid hormones, hormonal contraceptives and proinflammatory cytokines have been 
demonstrated to influence transporter expression and activity in tissues such as liver. The female 
PrEP product users have cyclic changes of sex steroid hormones in the cervicovaginal tissues, 
and the hormone levels are significantly altered after menopause. In addition, a significant 
portion of users take hormonal contraceptives such as Depo-Provera (long-lasting injectable 
suspension of MPA), and have increased levels of proinflammatory cytokines such as IL1β and 
IL8 in the genital tract which is caused by bacterial or fungal vaginosis. Therefore, it is necessary 
to examine the effect of menstrual cycle, menopause, contraceptives, and proinflammatory 
cytokines on transporter expression in the cervicovaginal tissues. To address this, the effect of 
menopause was studied by comparing transporter mRNA levels in pre- and postmenopausal 
human ectocervix; the effects of MPA and P4, as well as IL1β and IL8 on efflux transporter 
mRNA expression were examined using End1/E6E7, VK2/E6E7, PM1 cell lines; the effects of 
menstrual cycle, PMSG, and Depo-Provera were examined in a mouse model. Five transporters, 
P-gp, BCRP, MRP4, 5, 7 were examined. In cell lines, the effects were found to depend on the 
type of transporter and type of cell. The contraceptives and cytokines appeared to regulate 
transporter mRNA expression toward opposite directions in different cells 
(End1/E6E7/VK2/E6E7 vs. PM1). In mice, the general tendency in cervicovaginal tissues was 
more obvious than in other tissue types: transporter mRNA levels were higher at diestrus stage 
compared to estrus stage, during the natural estrous cycle, which mimicked the secretory phase 
and proliferative phase in human menstrual cycle. In addition, the Depo-Provera treatment 
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resulted in significant up-regulation of the mRNA levels of several cervicovaginal transporters, 
compared to the natural estrous cycle, while PMSG induced the opposite effect by reducing 
mRNA levels. 
 
Understanding the mechanisms underlying the observed transporter regulation by hormones and 
cytokines in cervicovaginal and colorectal tissues is important for the prediction of other factors 
that can regulate transporters through similar mechanisms. Nuclear receptors (NRs) are 
transcriptional factors that mediate hormone- and cytokine-induced regulation of transporters. As 
the first step toward elucidating the transporter regulation mechanisms in cervicovaginal and 
colorectal tissues, the mRNA expression of 23 nuclear receptors (NRs) was examined in these 
tissues of humans, macaques, and mice. The real-time PCR showed abundant expression of NRs 
that can bind sex steroid hormones (e.g. ER-α, PR) or proinflammatory cytokines (e.g. Nrf2, 
AhR), while negligible expression of typical xenobiotic-sensing NRs (e.g. PXR). The expression 
profile of these NRs in macaques and mice showed similar tendency as compared to human, with 
absent or very low levels of PXR mRNA expression and high levels of hormone-responsive NRs. 
 
5.1.2 Protein expression of three efflux transporters in cervicovaginal and colorectal tissues 
Since mRNA levels do not necessarily correlate with protein expression, the protein abundance 
and localization of three efflux transporters (P-gp, BCRP, MRP4) were examined in the tissues 
of humans, macaques, and mice, using IHC staining.  
 
As described in Chapter 3, in human tissues, P-gp, BCRP, MRP4 were found to be positively 
expressed, in multiple cell types within the cervicovaginal tissues, including columnar epithelial 
cells, stratified squamous epithelial cells, and vascular endothelial cells. Transporter protein 
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abundance and localization depended on the type of transporter and type of tissue examined. 
Compared to the premenopausal human ectocervix, the postmenopausal ectocervical tissues 
appeared to have more diffuse staining of P-gp, BCRP and MRP4 in the epithelial cells, however 
the vascular wall in the epithelium and stroma region remained densely stained for all the three 
transporters. It is unclear whether the transporter activity in postmenopausal tissues will be 
different from that of premenopausal tissues, and whether this will affect drug exposure in the 
tissues. Compared to premenopausal human tissues, the transporter protein expression in 
macaque tissues were very similar.  
 
The protein abundance of the three transporters appeared to be in line with their mRNA levels, in 
mouse cervicovaginal tissues collected at two different stages of natural estrous cycle, or after 
synchronization using PMSG/Depo-Provera. Consistent with the tissue- and transporter-specific 
mRNA levels, each transporter was differentially expressed in mouse endocervix, ectocervix and 
vagina, at protein levels. The expression patterns of P-gp, BCRP, and MRP4 at mRNA and 
protein levels in Depo-Provera treated mice were generally comparable to those patterns in 
human tissues.  
 
5.1.3 Transporter function in tissue distribution of PrEP drugs 
Since tenofovir (TFV) has been extensively tested in vaginal and oral PrEP trials, as a single 
agent as well as in combination regimens, it is necessary to test the role of transporters in the 
distribution of TFV into tissues important for HIV-1 sexual transmission. MRP4 was found to be 
positively expressed in the cervicovaginal tissues at levels comparable to liver in human and 
animal models tested, and its expression level was markedly up-regulated during the use of 
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Depo-Provera, as demonstrated in the mouse model. Under the treatment of Depo-Provera, it is 
highly possible that MRP4 plays a significant role in TFV tissue distribution, since its expression 
is higher, while the epithelial thickness and tight junction abundance are reduced compared to 
untreated status. The Depo-Provera synchronized mice were used by some researchers to 
evaluate the safety of vaginally administered products for the prevention of sexually transmitted 
infections. Since a large percentage of PrEP participants take contraceptives, and Depo-Provera 
is the most widely used contraceptive in Sub-Saharan Africa where the rate of HIV-1 sexual 
transmission is highest, the study using this mouse model could enable better understanding of 
Mrp4 function in the cervicovaginal and colorectal tissues of PrEP participants who take Depo-
Provera. Based on these considerations, the role of Mrp4 transporter in cervicovaginal and 
colorectal distribution of TFV was studied in this model, in Chapter 4.  
 
When TFV was administered as a vaginal gel, the intraperitoneal (IP) co-administration of Mrp4 
inhibitor MK571 significantly increased TFV concentrations in mouse endocervix, ectocervix, 
and vagina, at one or both time points (0.5 h or 1.0 h) after TFV administration. The TFV 
concentrations in CVL, uterus, plasma, and colorectum were not significantly altered by MK571, 
at either time point tested.    
 
When MK571 was formulated into the TFV gel, it exerted time-dependent effect on tissue 
concentration of TFV. At 0.5 h, it significantly increased the vaginal tissue concentration and did 
not alter TFV concentration in other tissues or plasma. At 1.0 h, MK571 incorporation increased 
the colorectal tissue concentration, as well as the remaining TFV content in vaginal lumen, as 
reflected by the increased CVL concentration. The differential effects of MK571 on TFV 
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distribution were not due to the alteration in release kinetics of TFV from the two kinds of 
formulated gels, as demonstrated by the unchanged amount of TFV cumulative release at 0.5 and 
1.0 h, and unchanged TFV permeability coefficients. In addition, the differential effects of the 
gel-formulated MK571 was not likely caused by increased impact on epithelial intactness, as 
demonstrated by the unchanged morphology of cervicovaginal epithelia after IP or vaginal co-
administration of MK571. Another possibility underlying the differential effects of MK571 was 
the differential MK571 concentrations achieved when being dosed via different routes (vaginal 
vs. IP), as discussed in Chapter 4. This possibility warrants further testing using TFV gels with 
increased doses of MK571, to delineate the effect of topically applied transporter inhibitor on 
TFV tissue distribution. 
 
For the systemically (IP) administered TFV, the co-administration of MK571 (IP) resulted in a 
3.5-fold yet not significant increase in the TFV concentration in CVL. Further, MK571 
significantly increased the vagina/plasma and colorectum/plasma ratios, suggesting that the 
increase in vaginal and colorectal tissue concentrations was due to the inhibition of Mrp4 
transporter in local tissue sites not the increased TFV availability in blood.  
 
These proof-of-concept studies using TFV gel and TFV solution in Chapter 4 provide 
preliminary evidence of Mrp4 function in TFV distribution into cervicovaginal and colorectal 
tissues. In addition, these results demonstrate the feasibility of using Mrp4 inhibitor to increase 
TFV distribution into the cervicovaginal fluid, cervicovaginal tissues, or colorectum. However, it 
should be noted that the effect of Mrp4 inhibitor on TFV distribution appeared to depend on the 
route of TFV and inhibitor administration, and further testing is needed as proposed below.  
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5.1.4 Implications on antiretroviral-based HIV-1 prevention 
The results generated from the studies in this dissertation have wide implications for the 
development and optimization of drug products for HIV-1 prevention. First, the positive 
expression of multiple efflux transporters at mRNA and protein levels, suggest that these 
transporters may function to limit the distribution of their substrate drugs into female genital tract 
and colorectal tissues. Notably, the efflux transporters are expressed at relatively higher levels, 
compared to the uptake transporters and CYP enzymes, suggesting that the efflux transporters 
may be more important regulators of drug exposure in the cervicovaginal tissues, compared to 
uptake transporters and CYP enzymes. 
 
Secondly, the observation that MK571 co-administration could increase the cervicovaginal tissue 
drug exposure of both vaginally and systemically administered TFV suggested the Mrp4 
transporter was functional in cervicovaginal tissues. Although further studies are needed to 
validate the functional role of Mrp4 and other efflux transporters, these results serve as the proof 
of concept that TFV tissue distribution could be enhanced by pharmacologic inhibition of the 
Mrp4 transporter.  
 
In addition, the effect of estrous cycle, contraceptives, hormones, and inflammation-related 
cytokines on cervicovaginal/colorectal transporter expression suggested that the expression of 
transporters in these tissues can be variable under different pathophysiological conditions. 
Caution should be implemented when designing experiments and interpreting data when they 
involve drugs which are potential substrates of transporters present in cervicovaginal or 
colorectal tissues. Transporters present in these tissues may have varying degrees of contribution 
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to the overall pharmacokinetics of drugs, which is a potential source of inter-individual and intra-
individual variability in drug PK profile in those tissues. The expression profiling of 23 nuclear 
receptors in human, macaque and mouse tissues suggested that multiple NRs were potential 
mediators of the observed effects of hormones, contraceptives, and cytokines on transporter 
expression. In addition, the absence of PXR expression in cervicovaginal and colorectal tissues 
suggested that the PXR receptor is unlikely to be an important mediator of transcriptional 
regulation of cervicovaginal or colorectal transporters, and transporters in these tissues are 
unlikely to be regulated by many therapeutic drugs that can bind and activate PXR. 
 
Multi-species comparisons in transporter expression and localization have implications on the 
rational selection of research models, for the studies of transporter function and safety/efficacy 
evaluations of microbicide products. In addition, the comparisons have implications on the 
validity of models used in PrEP testing, especially when the tested drug is a substrate of one or 
more transporters highly expressed and functional in the tissues. 
 
5.1.5 Limitations 
The major limitations of the studies conducted in this dissertation are listed below: 
 
There are several limitations related to this study of transporter expression. In Chapter 2, when 
assessing the transporter expression in immune cells, those immune cells residing in the 
cervicovaginal and colorectal tissues are the primary target of HIV-1 particles. Although the 
transporter expression in blood-derived immune cells have been reported and the expression in a 
T cell line (PM1) has been characterized in this dissertation (Chapter 2), it remains unknown 
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whether the expression and activity of major transporters will be altered when the immune cells 
migrate into tissues. In Chapters 2 and 3, when testing the effect of hormones and contraceptives 
and inflammation, the effect of concentration remains unknown. In addition, when examining the 
transporter expression in colorectal tissues, it remains unknown whether the gender will affect 
the expression level and function. In this study, the colorectal tissue levels of transporters were 
examined only in female tissues but not in male tissues. However, men who have sex with men 
(MSM) are especially vulnerable to the transmission of HIV-1 through anal intercourse, and 
colorectal transporter expression needs to be evaluated for this subpopulation. 
 
In Chapter 4, the effect of MK571 on TFV distribution was studied at one (intraperitoneal TFV 
dosing) or two (vaginal TFV dosing) time points post TFV dosing. The results provide evidence 
for the effect of Mrp4 inhibition on TFV distribution at these time points. However, the area 
under the concentration-time curve (AUC) is a better indicator of drug exposure compared to 
single time point measurements. AUC data will enable a more comprehensive understanding of 
tissue drug exposure over the entire period of TFV product use. 
 
5.2 Proposed future studies 
Below is a list of proposed future studies, which could address the limitations discussed above 
and extend the studies to achieve further understanding of transporter expression, regulation and 
function in the tissues and cells relevant to HIV-1 sexual transmission. 
 
1. Examine the expression profile of transporters in the HIV-1 target immune cells associated 
with cervicovaginal and colorectal tissues. Due to the paucity of healthy human tissues, the 
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quantity of purified immune cells from tissues may be insufficient for subsequent studies which 
aim to examine their function. However, by comparing the expression levels between these 
tissue-associated cells and blood-derived primary immune cells (e.g. PBMCs) which have 
established function in antiretroviral transport, researchers may be able to estimate the functional 
role of the transporters in the immune cells residing in tissues.  
 
2. Further examine the effect of hormones, contraceptives and inflammation, at different 
concentrations. The concentration dependency will be examined, so that a more comprehensive 
understanding of the influence of these factors on transporter expression will be obtained. 
 
3. Examine the kinetics of tissue drug concentrations after topical and systemic dosing of the 
substrate drugs, and acquire tissue drug concentrations at more time points to obtain the AUC 
with and without the transporter inhibitors. In addition, more doses of the substrate drug and 
inhibitor need to be tested in future studies to under the effect of substrate and inhibitor 
concentrations on the feasibility of the inhibitor approach. Finally, the roles of other highly 
expressed efflux transporters, such as P-gp, Bcrp, in tissue drug exposure remain unknown and 
should be studied.  
 
4. Test the transporter function in colorectal tract. It has been shown that MRP4 transporter in 
Caco-2 cells could limit the apical-to-basolateral permeation of acyclovir, which is an MRP4 
substrate.
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 In addition to cell-based assays, in vivo experiments are also needed to confirm the 
function of colorectal tissue transporters in the whole tissue exposure of substrate drugs used in 
PrEP and AIDS treatment.  
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5. Finally, although the wild type mice is a convenient model to assess the role of transporters in 
antiretroviral PK, it cannot be infected by HIV-1, and the effect of transporter modulation on 
antiretroviral efficacy cannot be examined in the wild type mouse model. This limitation can be 
overcome by using the humanized mice transplanted with functional human lymphocytes. These 
humanized mice have emerged as powerful tools for the rapid screening of topical and oral PrEP 
products, and could enable the simultaneous examinations of the effects of transporter 
modulation on drug PK and PD, in the same model. 
 
5.3 Contribution to the fields of HIV prevention, treatment, and vaginal/colorectal drug 
delivery  
The studies conducted in this dissertation have systematically examined the expression of 
transporters and nuclear receptors, in humans as well as animal and cell models used in PrEP 
testing. In addition, these studies have demonstrated the function of the MRP4 transporter in 
mouse cervicovaginal tissues. The observed effects of menstrual (estrous) cycle, exogenous 
hormone/contraceptives/cytokines on transporter expression shows that these factors can 
influence transporter expression, and possibly efflux activity, in mucosal tissues and cells 
relevant to HIV-1 transmission. The comparisons between human, animal models, and cell lines 
provides critical information on the validity of application of those models, in microbicide 
product evaluations. In addition, these studies provide data to inform the rational selection of 
research models for future study of transporter function. The knowledge generated from the 
conducted studies has enhanced our understanding of the critical determinants of drug exposure 
in the tissues and cells important for HIV-1 sexual transmission, and will likely facilitate the 
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development of novel strategies that could increase the tissue drug exposure and effectiveness of 
PrEP products.  
 
In addition to the PrEP of HIV-1 sexual transmission, the findings generated from these studies 
also have implications for the treatment and eradication of HIV-1, in infected patients. Since 
antiretroviral drug exposure in cervicovaginal and colorectal tissues is inversely correlated with 
viral shedding in mucosal fluids, the information generated from this dissertation will facilitate 
the optimization of HAART effectiveness and eradication of HIV-1 particles in these tissue sites, 
and will in turn contribute to the research efforts toward AIDS cure, and will help reduce the 
HIV-1 transmission from the receptive sex partners to the insertive partners.  
 
Furthermore, the results from this dissertation also have wide implications on the prevention and 
treatment of many other diseases, such as reproductive tract cancer and other non-malignant 
diseases, in which the drug molecules need to reach the female genital tract or colorectal tissue to 
take effect. Overall, the research reported in this dissertation will facilitate the development and 
optimization of prevention or treatment strategies for a variety of female health issues and 
diseases. 
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APPENDIX 
 
Information of the human tissue donors and tissue usage. *, used in the specified experiment. 
Patient # Tissue type 
Age/Age 
range 
Gender 
RT-
PCR 
P-gp 
staining 
MRP4 
staining 
BCRP 
staining 
1 Endocervix 35-40 Female * * * * 
2 Endocervix 20-25 Female * * * * 
3 Endocervix 40-45 Female * * * * 
4 Endocervix 25-30 Female * 
   5 Endocervix 45-50 Female 
 
* * * 
        6 Ectocervix 40-45 Female * 
   7 Ectocervix 45-50 Female * 
   8 Ectocervix 35-40 Female * 
   9 Ectocervix 40-45 Female * 
   10 Ectocervix 45-50 Female * 
   11 Ectocervix 40-45 Female * 
   12 Ectocervix 35-40 Female * 
   13 Ectocervix 40-45 Female * 
   14 Ectocervix 45-50 Female 
 
* * * 
15 Ectocervix 35-40 Female 
 
* 
  16 Ectocervix 35-40 Female 
 
* * * 
17 Ectocervix 45-50 Female 
 
* * 
 18 Ectocervix 30-35 Female 
 
* * 
 19 Ectocervix 40-45 Female 
 
* * 
 20 Ectocervix 35-40 Female 
 
* * 
 21 Ectocervix 40-45 Female 
 
* 
  22 Ectocervix 40-45 Female 
 
* 
  5 Ectocervix 45-50 Female 
 
* * * 
        23 Vagina 40-45 Female * 
   24 Vagina 45-50 Female * 
   25 Vagina 45-50 Female * 
   26 Vagina 45-50 Female * * * * 
27 Vagina 45-50 Female * 
   28 Vagina 35-40 Female 
 
* * * 
29 Vagina 40-45 Female 
 
* * * 
5 Vagina 45-50 Female 
 
* * * 
        30 Liver 30 Female * 
   31 Liver 35 Female * 
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32 Liver 15 Female * 
   33 Liver 65 Male * 
   34 Liver 49 Female * 
   35 Liver 23 Male * 
   
        36 Sigmoid colon 70-79 Female * 
   37 Sigmoid colon 70-79 Female * 
   38 Sigmoid colon 40-49 Female * * * * 
39 Sigmoid colon 20-29 Female * 
   40 Sigmoid colon 50-59 Female * 
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